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ABSTRACT
Gonorrhea is the second most common sexually transmitted bacterial infection in
the United States, with nearly 600,000 cases reported in 2018 by the Centers for Disease
Control. Alarmingly, the causative agent Neisseria gonorrhoeae has developed resistance
to a number of antimicrobials over the last century. With limited options remaining, the CDC
now recommends dual therapy with ceftriaxone and azithromycin to decrease the likelihood
of resistance development. However, strains with combined cephalosporin and macrolide
resistance have now emerged, raising concerns of a post-antibiotic future in which
untreatable gonorrhea would impose enormous human and economic cost. The discovery
and development of novel antigonococcal agents is, therefore, necessary to avoid a public
health crisis.
The pharmacologic receptors for β-lactams are a group of transpeptidases known
as penicillin-binding proteins (PBP), which catalyze the cross-linkage of peptidoglycan, an
essential component of the bacterial cell wall that plays major roles in cell growth and
division. N. gonorrhoeae develops chromosomally mediated β-lactam resistance via
alterations of PBPs affecting drug affinity, specifically through the acquisition of mutations in
the penA gene encoding PBP2. Resistant strains harbor mosaic penA alleles encoding PBP2
variants containing around 60 amino acid changes compared to wild-type. In this work, we
examine inhibition of a mosaic form of N. gonorrhoeae PBP2 from the cephalosporinresistant strain H041, seeking to understand better which features of ligand structure
enhance or diminish PBP2 binding in order to develop more effective PBP2 inhibitors.
First, we report structure-activity relationships (SAR) for the cephalosporin class of
β-lactams against PBP2 from N. gonorrhoeae H041 with the goal of identifying or designing
cephalosporins effective against resistant strains. We find that structural features of the C7
acylamino side chain (R1) correlate highly with the second-order rate of PBP2H041

xvi

acylation, including increased size, modest lipophilicity, and two ring systems separated
by a single branch point. The C3 side chain (R2) makes lesser, but still important,
contributions to inhibition, with electronegative elements and planarity enhancing activity.
We also found that many of the features enhancing target inhibition (e.g., lipophilicity,
aromaticity) diminish antimicrobial activity against the H041 strain, perhaps due to
decreased accumulation in the periplasm. Finally, we identify cefoperazone as highly
active against PBP2H041 and similarly active against N. gonorrhoeae H041 both in vitro
and in vivo compared to ceftriaxone. Second, we report the in silico discovery of novel
noncovalent PBP2 inhibitors possessing a 1,1’-biphenyl system. Arylamide JEK-42 and
its isosteric sulfonamide derivative JMT-1 are capable of inhibiting PBP2 from both βlactam-susceptible and -resistant gonococcal strains. Their cross-inhibition of P.
aeruginosa PBP3, predicted binding modes showing interaction with highly conserved
residues, and structural similarities to bicyclic β-lactam scaffolds indicate their potential for
broader activity against class B PBPs. Using the structural similarities between JEK-42,
JMT-1, and bicyclic β-lactam scaffolds (i.e., penam, carbapenem, and cephem), a threepoint pharmacophore was generated that can be used to identify additional PBP-inhibitory
scaffolds. Third, we report the synthesis of 127 derivatives of JMT-1, showing specific
substitutions that enhance the inhibition of PBP2 derived from both β-lactam-susceptible
and -resistant strains. In keeping with the cephalosporin SAR, hydrophobic substitutions
enhance PBP2 inhibition, likely through increased van der Waals contact with the active
site, but they can also result in diminished antimicrobial activity. Together, our efforts yielded
10 compounds that show near full inhibition of PBP2 from susceptible and resistant strains,
as well as large zones of gonococcal growth inhibition in disc diffusion assays. These
studies lay the groundwork for the development of several structurally diverse
antigonococcal chemotypes, thereby increasing the probability of producing a successful
preclinical candidate.
xvii

CHAPTER 1: Introduction

1

1.1 Neisseria gonorrhoeae
1.1.a. Epidemiology and clinical features of gonococcal disease
Neisseria gonorrhoeae is a Gram negative diplococcus responsible for the sexually
transmitted infection (STI) gonorrhea. Gonorrhea is a global problem and, despite a sound
public health infrastructure, a growing issue in the United States. There are nearly 600,000
cases reported annually by the Centers for Disease Control (CDC)1 and 87 million cases
reported annually by the World Health Organization (WHO),2 and as with many infectious
diseases, the true number of cases is expected to be much higher due to asymptomatic
infection and underreporting. In the United States, overall rates of infection showed a
substantial decline until 2009, reaching a low of 98.1 cases per 100,000 person years; in
the last decade, however, an upward trend in infection rates has begun and persisted,
with 179.1 cases per 100,000 person years reported in 20181 (Figure 1.1). The highest
reported rates are seen among the following groups: adolescents and young adults, racial
minorities, men who have sex with men (MSM) and persons living in the southeastern
states1 (Figure 1.1). Symptomatic disease is generally associated with urethritis in men
and cervicitis in women, although rectal and pharyngeal gonorrhea are not uncommon.
Untreated, the infection can spread in an ascending pattern, resulting in epididymitis in
males and pelvic inflammatory disease (PID) in females. These complications can result
in serious sequelae, including infertility and ectopic pregnancy. Disseminated gonococcal
infections result most commonly in suppurative arthritis or tenosynovitis but can cause
more serious disease, such as endocarditis or meningitis.3-8 Importantly, gonococcal
infection results in mucosal disruption and can therefore increase the risk of both
transmitting and contracting human immunodeficiency virus (HIV).9,10
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Figure 1.1: Epidemiology of gonococcal disease in the United States. A. Reported incidence of
gonorrhea in the United States over the last 70 years. The absolute incidence is shown in black,
and the rate of change is shown in red. B. Incidence of gonorrhea stratified by age and sex. Data
are from 2018. C. Incidence of gonorrhea stratified by age and ethnicity. Data are from 2018. D.
Estimated incidence in gonorrhea stratified by sexual behavior. Values are modeled based on
interviews of a random sample of reported cases (n = 6,482 patients). Key: men who have sex with
men (MSM), men who have sex with women (MSW), women (W). E. Heat map of gonococcal
incidence by state. All data are from CDC infectious disease surveillance.
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1.1.b. Emerging antimicrobial resistance
Historically, gonorrhea was treated with sulfanilamide or penicillin, but due to
increased prevalence of resistant strains, the Centers for Disease Control & Prevention
(CDC) called for their withdrawal as recommended antibiotics for gonococcal infections
due to emerging resistance.11-20 With the subsequent withdrawal of spectinomycin,21-25
tetracyclines,26-30 and fluoroquinolones31-38 for the same reason, only third-generation
cephalosporins (e.g., ceftriaxone and cefixime) remained as CDC-recommended drugs of
choice in the United States39,40 (Figure 1.2). In the last two decades, strains of N.
gonorrhoeae with decreased susceptibility to extended-spectrum cephalosporins (ESCs)
have emerged, prompting concerns that gonococcal infections may soon become
untreatable using monotherapy.41-59 For this reason, treatment guidelines now recommend
dual therapy with ceftriaxone and azithromycin in the United States and Europe.60,61
Alarmingly, strains exhibiting high-level resistance to ESCs have now been isolated on
most continents (Asia, Australia, Europe, North America, and South America),62-87 and
macrolide resistance has become increasingly common.48,88-93 While combined ESC and
macrolide resistance is exceedingly rare, a few such cases have been reported.78-80 This
rapidly changing landscape of antimicrobial resistance indicates that the currently used
dual regimen will not provide a long-term solution for antigonococcal chemotherapy.94-98
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Figure 1.2: Timeline of treatment recommendations and resistance development in Neisseria gonorrhoeae. In the
immediately pre-antimicrobial era, options for the treatment of gonorrhea included urethral irrigation, potassium
permanganate, silver compounds, mercurochrome, and hyperthermia. Key: sulfonamides (Sulf), penicillin (Pen),
spectinomycin (Spec), tetracyclines (Tet), fluoroquinolones (Quin), cephalosporins (Ceph), macrolides (Mac),
decreased susceptibility (DS), resistance (R).

In addition to the human costs, STIs have a substantial impact on the national and
global economies. Diagnosis and treatment alone cost the United States healthcare
system $16B annually, with gonococcal infections contributing an estimated $162M in
direct costs.99 With the present surge of multidrug-resistant gonorrhea, disease
prevalence and severity are expected to rise due to treatment failure, augmenting the
economic burden of gonorrhea and its sequelae. To date, there have been no strains
exhibiting high resistance to ESCs isolated in the United States; however, with the recent
international transmission of a ESC-resistant clone from Asia to Canada,67 the arrival of
such a strain to the United States seems imminent. It is predicted that if antimicrobialresistant N. gonorrhoeae were to become established in North America, there will be 5.9
million new cases, an added cost of approximately $780M, over a seven-year period.100
1.2 β-Lactams and their biological targets
1.2.a. Penicillin-binding proteins as the molecular targets for β-lactam antibiotics
The pharmacologic receptors for β-lactams are a group of DD-transpeptidases
known as penicillin-binding proteins (PBPs), which catalyze the cross-linkage of
peptidoglycan via the formation of isopeptide bonds.101-103 Peptidoglycan is a mesh-like
polymeric macromolecule consisting of glycan strands of β-1,4-linked N-acetylmuramic
acid and N-acetylglucosamine covalently linked to L-alanyl-ɣ-D-glutamyl-L-diaminoacyl-Dalanine peptide chains via amidation of the muramic acid carboxyl group by the L-alanine
amino group104 (Figure 1.3). Cross-linkage of peptidoglycan units occurs when a unit of
endogenous pentapeptide substrate, L-alanyl-ɣ-D-glutamyl-L-diaminoacyl-D-alanyl-Dalanine, forms an isopeptide bond between the penultimate D-alanine and the side chain
amine of the diaminoacyl residue at the expense of the D-alanyl-D-alanine peptide bond,
a process catalyzed by the PBPs (Figure 1.4). Peptidoglycan is an essential component
of the bacterial cell wall and plays major roles in cell growth and division, as well as
protection from osmotic or tensile stress, and it has a natural turnover rate dictated by the
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processes of synthesis and autolysis.104,105 There are three classes of PBP: class A are
bifunctional enzymes, with transpeptidase and transglycosylase functionalities; class B
are monofunctional transpeptidases; and class C catalyze either carboxypeptidase or
endopeptidase reactions.102,103 Whereas PBPs of classes A and B are generally essential
for the survival of bacteria, class C can often be genetically deleted without significant
effects on cell growth or morphology.
The transpeptidase active site contains three conserved motifs: SxxK, SxN, and
KTG (where x denotes a variable residue)106 (Figure 1.5). The catalyzed reaction involves
three steps: Michaelis-Menten binding of peptide substrate, acylation, and deacylation. It
is proposed that the KTG lysine serves as an electrostatic anchor for the pentapeptide
carboxy terminus to allow initial recognition of the substrate.107-112 In N. gonorrhoeae
PBP2, there is evidence that the KTG threonine then rotates in response to carboxylate
binding, acting as a trigger that initiates the acylation reaction by allowing β3 strand
rotation for formation of the oxyanion hole.113 The SxxK lysine acts as a base, polarizing
the hydroxymethylene sidechain of the SxxK serine to form a pseudo-alkoxide nucleophile
that attacks the carbonyl carbon of the peptide substrate’s penultimate D-Ala.107-112 The
resulting substitution reaction goes through a tetrahedral intermediate stabilized by an
oxyanion hole made up of the backbone amides of the SxxK serine and a residue following
the KTG motif.114-117 Upon resolution of the tetrahedral intermediate, the terminal Dalanine is eliminated to form an activated L-alanyl-ɣ-D-glutamyl-L-diaminoacyl-D-alanyl
acyl enzyme, at which time the carbonyl carbon undergoes nucleophilic attack by the
diaminoacyl residue of an adjacent peptidoglycan strand.
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Figure 1.3: Structure of Gram negative peptidoglycan. On the left is a schematic depiction of the overall polymeric structure. On the
right is a detailed chemical drawing of a single unit. Key: N-acetylglucosamine (GlcNAc), N-acetylmuramic acid (MurNAc), mesodiaminopimelate (meso-DAP)
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Figure 1.4: Functions of PBPs and the mechanism of action of β-lactam antimicrobials.

Figure 1.5: Conserved active site motifs in the PBPs. The example shown is PBP2 of N.
gonorrhoeae.

β-lactam antibiotics mimic the D-Ala-D-Ala terminus of the peptidyl substrate.118-124
In the presence of a β-lactam, the serine nucleophile instead attacks the carbonyl carbon
of the cyclic amide, but upon resolution of the tetrahedral intermediate, the leaving group
remains tethered to the acyl-enzyme, blocking deacylation125-127 (Figure 1.4). The reaction
of β-lactams with PBPs is described by Equation 1, where E·S is the noncovalent
enzyme-lactam complex, E−S′ is the acyl-enzyme complex, and P is the hydrolyzed βlactam.
"!
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The second-order rate constant (k2/Ks) is a direct measure of the reactivity of a βlactam with a PBP, and these rate constants can exceed 106 M-1s-1 against PBPs of
susceptible strains.128 As described above, the rate of deacylation (k3) is slow, occurring
on the order of one reaction per hour.129-132
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Four PBPs are encoded by the genome of N. gonorrhoeae.133 PBP1 (class A),
and PBP2 (class B) are both essential and are potential targets for bactericidal activity;
however, because PBP2 is inhibited at tenfold lower penicillin concentrations than PBP1,
it is generally accepted to be the clinical target for susceptible strains. While PBP3 and
PBP4 (class C) are nonessential, deletion of both in one strain results in pleiomorphy and
slowed growth.111
1.2.b. Factors affecting β-lactam acylation of PBPs
As shown in Equation 1, there are two component steps to β-lactam acylation of
PBPs: formation of the precovalent enzyme-lactam complex (Ks) and reaction of the serine
nucleophile with the lactam ring to form the covalent acyl-enzyme (k2). The first step is
determined by factors affecting affinity of the β-lactam for the active site of the PBP,
including complementarity of size, shape, and charge; however, very little is known about
how these features contribute to the binding of β-lactams. Isothermal titration calorimetry
(ITC) and surface plasmon resonance (SPR) are not especially useful to this end, as they
can only report an apparent association constant (Ka) due to the overall reaction being
covalent. Mutation of the nucleophilic serine to alanine has been performed in our
laboratory, however, and in ITC studies of this modified system, we have shown that
affinity is important for acylation.134 Whereas Kd of ceftriaxone was measured to be 2.3 µM
against PBP2 derived from a fully susceptible strain of N. gonorrhoeae, no heat exchange
was seen upon titration of millimolar ceftriaxone into PBP2 derived from cephalosporinresistant strains. Previous studies have indicated that the common acylamino side chain
of many β-lactams may be an important driver of affinity against PBPs, but more rigorous
analyses were not done to determine which characteristics specifically enhance or hinder
acylation.135-139 In one instance, a high-affinity penicillin analogue was designed with a
specific acylamino group that rendered it orders of magnitude more active than other βlactams (k2/Ks = 1.5×107 M−1s-1).140,141 Finally, complex formation is largely dependent
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upon the active site architecture of the specific PBP being studied. Each bacterial species
has its own collection of PBPs, and beyond the conserved motifs, there is considerable
sequence variation. Resistant mutants arising from target modification complicate this
problem further.
In addition to side chains and overall topology of the molecule, another factor, the
Cohen parameter c, describes the precovalent complementarity of β-lactams in the PBP
active site.142,143 The Cohen parameter is defined as the distance between the carboxylate
carbon and the amide oxygen in bicyclic β-lactam systems (Figure 1.6). Lower Cohen
parameters are correlated with higher complementarity, likely due to a physical
requirement created by the distance between the carboxylate-binding residues and the
oxyanion hole created by the SxxK serine and a β3 residue following the KTG motif.

Figure 1.6: Illustrations of Woodward height and Cohen parameter for several classes of β-lactam
antimicrobials.
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The acylation reaction by β-lactams is determined by factors governing
nucleophilic attack of the lactam ring, including both target and ligand factors. Target
factors involve the electronic environment of the serine and how this environment affects
its ability to act as a nucleophile. From studies of the mechanistically analogous serine
protease chymotrypsin, as well as studies assigning protonation states to active site
lysines in several PBPs, it is widely accepted that the SxxK motif lysine polarizes the serine
hydroxyl group, forming an activated pseudo-alkoxide.107-112 The acid-base chemistry of
the SxxK serine and lysine has been shown to be key to this process and is influenced by
the local environment of the active site. For a Brønsted-Lowry acid or base to function
optimally in a catalytic cycle, its pKa must be near the effective pH at the reaction site so
that its protonation state can be readily restored.144-147 In the case of the conserved SxxK
residues of PBPs, there are three predominating factors influencing protonation states:
local electrostatics, the presence of an extensive hydrogen bonding network, and the Born
effect.148,149 The presence of additional nearby ionizable groups can influence the pKa of
an ionizable residue in accordance with the thermodynamic tendency away from
Coulombic repulsion.150 The presence of the KTG lysine adjacent the SxxK lysine in PBPs
will, therefore, decrease the pKa of both toward surrounding pH. The active site of PBPs
also contains an extensive hydrogen bonding network, including a direct SxxK serinelysine donor-acceptor pair. The favorable energy of this interaction results in an increase
in the acidity of the serine hydroxyl group due to the stabilization of its conjugate base.151
Finally, the Born effect prescribes that the ionized state of an acid or base exists more
readily in a hydrophilic environment – when buried in a protein, the pKa is perturbed to
favor the neutral species (i.e., the pKa of the SxxK lysine is decreased).152 In studies on
the pH dependence of E. coli PBP5 activity, these general principles have been supported
experimentally, with results showing that the SxxK lysine is in its free-base form at optimal
catalysis.108 Further, disruption of the residue’s pKa by substitution with arginine’s
13

guanidine side chain results in a 600-fold decrease in the second order rate constant for
penicillin binding.153
The preeminent ligand factor affecting β-lactam binding to PBPs is the activation
of the lactam ring itself to reaction with nucleophiles, a property determined by the p-orbital
character of the lactam nitrogen. In monocyclic 2-azetidinone systems, the amide system
is stabilized by resonance, decreasing the electrophilicity of the carbonyl group. In bicyclic
systems, however, the amide nitrogen is geometrically constrained to an sp3 hybridized
trigonal pyramidal geometry, decreasing this resonance effect.154-159 The result is that in
bicyclic systems, the lactam ring exhibits much higher intrinsic reactivity to nucleophiles.
The amount of nitrogen p-orbital character can be measured by the distance of the
nitrogen from the base of the trigonal pyramid defined by its three bond-pair substituents,
a parameter known as the Woodward height160-162 (Figure 1.6).
1.2.c. Major classes of β-lactam antimicrobials
Monobactams are the simplest class of β-lactam antimicrobials, possessing a
monocyclic 2-azetidinone system with an N-sulfonic acid moiety (Figure 1.7) the base
structure of which was first isolated from Chromobacterium violaceum.163-165 Due to their
monocyclic structure, they are the least activated of the β-lactam antimicrobials, and their
activity is thought to be a consequence predominantly of their ease of entry into PBP active
site. However, there is evidence to suggest that the electron-withdrawing inductive effect
of the N-sulfonic acid serves to disrupt amide resonance, albeit slightly, lending to partial
p-orbital character of the nitrogen’s hybrid orbitals.166 There is currently only one
monobactam in clinical use, aztreonam, which exhibits potent inhibition of Gram-negative
PBPs.167-170 It finds limited utility clinically, however, as it has no activity against Grampositive or anaerobic bacteria.
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Figure 1.7: Structures of major classes of β-lactams in clinical use.

Penams are a class of β-lactams possessing an azabicyclo[3.2.0]heptane ring
system, a carboxylic acid moiety at C3, and a sulfur atom at position one (Figure 1.7).
They exhibit a large Woodward height (h ~ 0.4 Å) due to strain imparted by 5-membered
ring fusion, and as such, exhibit good intrinsic reactivity to nucleophiles. Interestingly,
molecules of the penam class can exist in two distinct conformational states, one in which
the C3 carboxylate is in an equatorial position in relation to the ring system and one in
which it is axial171-187 (Figure 1.6). In the equatorial position, it contributes to a lower Cohen
distance (c ~ 3.9 Å) and, thus, a better fit to the geometric requirements of the PBP active
site. In the axial position, the structure is considered inactive (c ~ 4.3 Å). The existence of
two equally populated states related by rotation results in lowered activity compared with
lactams possessing constrained carboxylate α-carbons. The prototypic and most wellknown penam is penicillin G, or benzylpenicillin, discovered in cultures of Penicillium
chrysogenum in the 1920s.188

The other natural product penam is penicillin V, or

phenoxymethylpenicillin. In the absence of β-lactamases, the natural penicillins show
good Gram-positive activity but fail to inhibit the growth of many Gram-negative
organisms.189-193 A great deal of medicinal chemistry has been executed on the penam
scaffold to modulate the spectrum of this class, resulting in many structural subclasses.
The penicillinase-resistant penicillins (e.g., nafcillin, oxacillin, cloxacillin, dicloxacillin), as
the name implies, were introduced specifically to combat the acquisition of narrow15

spectrum β-lactamases and do not exhibit improved Gram-negative activity over the
natural product compounds;194-204 the aminopenicillins (e.g., ampicillin, amoxicillin) show
better Gram-negative activity but are generally outperformed by the natural penicillins
against Gram-positive organisms;205-207 the carboxypenicillins (e.g., carbenicillin,
ticarcillin) exhibit rather potent Gram-negative inhibition while retaining good Grampositive coverage;208-212 and the ureidopenicillins (e.g., piperacillin, mezlocillin, azlocillin)
show similar spectrum to the carboxypenicillins but generally possess increased potency
in comparison.208,209,211,213,214
Cephems are a class of β-lactams possessing an azabicyclo[4.2.0]oct-2-ene ring
system, a carboxylic acid moiety at C4, and a sulfur atom at position one (Figure 1.7)
These systems generally exhibit low Woodward heights (h ~ 0.3 Å) due to conformational
flexibility afforded by having a 6-membered ring fusion; however, there exists a
competitive enamine resonance, resulting from the delocalization of the nitrogen’s lone
electron pair into the π electron system of the dihydrothiazine ring, that contributes to
disrupted amide resonance.155,159,215 A unique feature of cephem-based compounds is
their chemistry at the C3 position, which can act as a leaving group upon ring opening due
to the aforementioned enamine resonance. The departure of a C3 leaving group results
in the formation of an exocyclic olefin that may enhance the thermodynamic stability of the
acyl enzyme complex, thereby decreasing regeneration of apoenzyme.216 Whether or not
it is a leaving group, C3 can participate in long range inductive effects with the β-lactam
amide moiety, and strongly electron withdrawing groups are postulated to enhance the
electrophilicity of the active carbonyl.159,217,218 A fixed, low Cohen parameter is
characteristic of the class due to sp2 hybridization of C4 (c ~ 3.2 Å) (Figure 1.6).
The

first

identified

cephem,

cephalosporin

C,

was

isolated

from

Acremonium chrysogenum and showed only marginal antimicrobial activity;219-225
however, its many semisynthetic derivatives have enjoyed great success as potent
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therapeutics. The cephalosporins are categorized into “generations” based on medicinal
chemistry and antimicrobial spectrum (Figure 1.8). First generation agents generally
possess an aromatic acylamino side chain at C7 and possess potent Gram-positive
activity.226-232 While second generation agents explore other aromatic acylamino groups
at C7, much of the variation found in this generation is from the replacement of the acetoxy
group with various nucleophiles (i.e., carbamates, heterocyclic mercaptans, and pyridines)
(Figure 1.8). Second generation agents largely exhibit broader spectrum than their earlier
counterparts, with some showing potent inhibition of Gram negatives with high intrinsic
resistance.233-240 Among the key findings of this iteration of cephalosporin design was the
alkoxyimino moiety, seen in cefuroxime, which confers resistance to degradation by serine
β-lactamases.241-243 This functional group became a mainstay in the design of third
generation agents, while the aryl group was modified to an aminothiazole, a change found
to enhance Gram negative activity (Figure 1.8). One notable outlier is cefoperazone,
which borrows its C7 acylamino group from the ureidopenicillin piperacillin. This group
exhibits not only further expanded spectrum compared to previous generations, but also
good stability to serine β-lactamases.244-259 In the fourth generation, various quaternary
nitrogen-containing C3 were examined to enhance passive transport through the Gram
negative outer membrane, decrease affinity for β-lactamases, and promote departure of
the leaving group.260-266 Fifth generation agents are specifically engineered to combat
various resistance problems while attempting to maintain spectrum.267-280 In general, these
compounds maintain the alkoxyimino group, exchange the aminothiazole for an
aminothiadiazole, and exhibit planarity in their C3 substituents.

17

18

Figure 1.8: Salient features of cephalosporin design by generation.

Carbapenems

are

a

class

of

bicyclic

β-lactams

possessing

an

azabicyclo[3.2.0]hept-2-ene ring system, a carboxylic acid moiety at C3, and a carbon
atom at position one (Figure 1.7). The carbapenems are thought to be the most
intrinsically active of known β-lactams – their rapid acylation of PBPs and potent
antimicrobial activity have been ascribed to a highly activated lactam ring system, as
shown by experiments examining the kinetics of base hydrolysis.156,162 Crystallographic
structures reveal a high Woodward coefficient (h ~ 0.5 Å) attributable to the geometric
constraints introduced by the unsaturation between C2 and C3 and the replacement of
sulfur with carbon at position one. Similar to the cephems, the carbapenems exhibit a fixed
Cohen distance due to an sp2 hybridized C3, but the bond angles imposed by a 5membered fused ring position the carboxylate slightly further from the lactam (c ~ 3.5 Å)
(Figure 1.6). The C6 R-hydroxyethyl side chain possessed by molecules of this class
represents a significant departure from penams and cephems, which generally exhibit
large and variable aminoacyl side chains at this position. Differences in activity and
spectrum among compounds of this class are, therefore, dictated almost exclusively by
the side chain at C2. Since the isolation of thienaymycin from Streptomyces cattleya in the
1970s,281,282 only four carbapenems have been approved for clinical use by the FDA:
imipenem, doripenem, meropenem, and ertapenem.283-286 Given their broad spectrum, as
well as their stability against β-lactamases afforded by their C6 R-hydroxyethyl side chain
and trans C5-C6 geometry,287-289 the carbapenems have found most of their clinical utility
as antimicrobials of last resort in infections with multidrug resistant organisms.
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1.3. β-lactams in the treatment of Neisseria gonorrhoeae
1.3.a. Overview of antimicrobial resistance
The discovery of penicillin and other compounds capable of inhibiting bacterial
growth revolutionized modern medicine and continues to shape its practice. These
therapies not only provided a means of pharmacologically managing conditions and
injuries that in the past killed or impaired many, but also provided avenues to prevent
infection post-operatively and in immunosuppressed patients, including those undergoing
solid organ transplant, those with advanced stage HIV / AIDS, and those receiving
myelotoxic cancer therapies. However, with increased and sometimes improper use of
antibiotics, resistance to these and other drugs has emerged in a number of common
pathogens, thereby limiting treatment options. Prominent examples include methicillin
resistant Staphylococcus aureus (MRSA),290 vancomycin resistant enterococcus (VRE),291
multidrug resistant nosocomial pathogens (Pseudomonas aeruginosa, Klebsiella
pneumonia, Stenotrophomonas maltophilia, etc.),292-294 and sexually transmitted infections
(Neisseria gonorrhoeae, Mycoplasma genitalium).295,296 In 2014, the WHO began to warn
of a post-antibiotic era, citing antimicrobial resistance as among the most dangerous
current threats to public health.297 With the increasing prevalence of strains resistant to
the existing armamentarium of antimicrobials, there is a great and manifest need for the
development of new drugs to treat these infections.
Antimicrobial resistance is classically ascribed to any combination of the following
processes: decreased accumulation at the site of action, drug inactivation by degradative
or modifying enzymes, overproduction of endogenous substrates, or target alteration by
either chromosomal or enzymatic means (Figure 1.9). While N. gonorrhoeae employs
multiple mechanisms in achieving β-lactam resistance, among its most powerful tools is
the modification of the penicillin-binding proteins.
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Figure 1.9: Mechanisms of β-lactam resistance in N. gonorrhoeae. Figure borrowed from Robert Nicholas, PhD, and
adapted.

1.3.b. Gonococcal β-lactam resistance not mediated by PBPs
Because peptidoglycan crosslinking occurs in the periplasmic space, β-lactams must
permeate the bacterial outer membrane to exert their cytotoxic effects. Hydrophilic small
molecules require aqueous channels known as porins to cross this barrier, and bacteria
have developed several mechanisms for restricting entry298 including global decreases in
porin expression,299-302 shifts in expression from one porin type to another of smaller
channel radius,303 and porin mutations resulting in impaired permeation through the
channel.304 In Neisseria gonorrhoeae, changes in antimicrobial permeability are mediated
in part by mutations in porB1B encoding the major outer membrane protein porin B1b,
known as the penB resistance determinant.305 These mutations are located at positions
120 and 121 on loop 3, which lies within the β-barrel in crystal structures of several porins
(including N. meningitidis porin B).304,305 It is hypothesized that these mutations perturb
the structure of the pore constriction, thereby disallowing entry of larger solutes; however,
penB is phenotypically silent in the absence of efflux overexpression.306 Changes to other
pore-forming elements may also diminish the periplasmic accumulation of β-lactams in N.
gonorrhoeae, such as point mutations to the pilQ gene encoding secretin PilQ acquired
by laboratory strains.307 This type of mutation, known as the penC resistance determinant,
decreases β-lactam susceptibility, but its disruption of transformation and piliation make it
unlikely to be found in clinical isolates.
As illustrated by mutations to porB1b and pilQ, changes in outer membrane
permeability alone frequently do not alter susceptibility significantly and are often
associated with additional resistance mechanisms.308 Another mechanism responsible for
diminished intracellular accumulation is the production of multiunit macromolecular
machineries that extrude amphipathic xenobiotic compounds, including dyes, detergents,
solvents, and antimicrobials. These efflux pump systems can be categorized structurally
into the following families: the ATP-binding cassette (ABC) family, the resistance22

nodulation-cell division (RND) family, the multidrug and toxic compound extrusion (MATE)
family, and the small multidrug resistance (SMR) family.309,310 These families are
distinguished from one another by species specificity, macromolecular structure, substrate
range, and energy source. While baseline expression of efflux systems can afford survival
in the presence of certain classes of antimicrobials (i.e., intrinsic resistance), their
overexpression is of key concern in the development of marked or multidrug resistance.311
N. gonorrhoeae possesses a tripartite multiple transferable resistance (Mtr) efflux pump
system belonging to the RND family.312-316 The Mtr system has broad substrate specificity
that includes many classes of antimicrobial drugs, cationic antimicrobial peptides, natural
antibiotics, and detergents.312,317,318 It is encoded by the mtrCDE gene complex and
regulated by the opposing actions of an activator (mtrA) and a repressor (mtrR).319-322
Several mutations conferring resistance are observed this system, but the most common
are single missense mutations to a 13 base-pair inverted repeat in the mtrR promoter
region.320,323-326 Nonconservative mutations in the mtrR DNA binding region have also
been reported.324,326,327 These loss-of-function mutations in mtrR result in the derepression
of mtrCDE, allowing for the overexpression of efflux components and a concomitant
increase in their assembly.
A final, less ubiquitous mechanism by which bacteria hinder antimicrobial entry is
the formation of biofilms.328,329 The biofilm state reduces the overall surface area of
antimicrobial exposure, relative to the bacterium’s planktonic form. Permeation is also an
issue, with thicker biofilms being generally more difficult to fully eliminate. The observed
antimicrobial tolerance is likely influenced by more than simple diffusion mechanics,
however. Studies of expression programs indicate cells in a biofilm go into a dormant
“persister” state that renders them less susceptible to antimicrobial drugs targeting protein
synthesis and cellular division.330,331 The gonococcus has developed means of hindering
antimicrobial access by decreasing exposed bacterial surface area as well. Expression of
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surface molecules (i.e., phase variable pili,

opacity-associated proteins,

and

lipooligosaccharide) promotes gonococcal interactions in vitro, resulting in microcolony
aggregation and, ultimately, in biofilm formation.332-335 Gonococcal aggregation has been
shown to increase ceftriaxone tolerance in vitro, with cultivable bacteria being isolated
after 24-hour exposure to 1 µg/mL.329 In the same set of experiments, residual gonococcal
viability was found even in a 10 µg/mL treatment group, as measured by ATP production.
This phenomenon is relevant in vivo as well, as there is evidence of gonococcal biofilm
formation in cervical biopsies of patients with gonococcal cervicitis.336
Another mechanism of resistance is production of enzymes that inactivate the
molecule by addition or removal of chemical moieties or destroy it by hydrolysis.337 Several
classes of modifying enzymes have been identified that catalyze the following reactions:
acetylation of aminoglycosides, chloramphenicol, and streptogramins; phosphorylation of
aminoglycosides and chloramphenicol; and adenylation of aminoglycosides and
lincosamides.338-343 These reactions alter molecular moieties critical to interaction with
antimicrobial targets, thereby diminishing binding. The predominating degradative
enzymes are the hydrolytic β-lactamases, which cleave β-lactams at the active amide
bond, rendering them incapable of participating in the covalent inhibition process
characteristic to the class.344-348 High-level gonococcal resistance to penicillin can also be
achieved through the acquisition of plasmids containing the blaTEM-1 gene, which encodes
a TEM-1 β-lactamase capable of hydrolyzing penicillins, rendering them inactive.18,19,349
Although no extended-spectrum β-lactamases (ESBLs) have yet been reported in
gonococcal isolates, another plasmid containing blaTEM-135 has been identified.350-352 From
structural and functional comparisons, it is proposed that the encoded TEM-135
penicillinase may be a direct precursor to an ESBL capable of hydrolyzing
cephalosporins.351
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Less studied resistance mechanisms involve the modulation or evolution of
pathways that compensate for loss of an essential cellular component or enzyme. Bacteria
are capable of making sophisticated global adaptations to metabolism, including shifts
between glycolytic and oxidative pathways, alterations in fructose utilization, or changes
in fatty acid oxidation.353-357 Many of these changes are postulated to result in modulation
of cell wall autolytic activity and other cell surface properties. In gonococcal strains
exhibiting mosaic penA, whose gene products likely function suboptimally as
transpeptidases, compensatory metabolic changes ameliorate fitness defects. It has been
shown that introduction of mosaic penA41 to a wild-type strain results in the development
of spontaneous mutations in the acnB gene encoding the TCA cycle enzyme aconitase B,
as well as in other metabolism-related genes, and that these mutations increase the
fitness of strains harboring mosaic penA alleles to near-wild-type levels.353 While the exact
effect of these mutations remains unknown, there are large global shifts in the expression
of genes involved in energy and carbon metabolism that occur in the presence of a specific
acnB-G348D mutation, a change that slows the interconversion of citrate and isocitrate by
the enzyme.
There are yet additional resistance mechanisms in N. gonorrhoeae that have not
yet been fully elucidated. Factor X, as it is termed, is a nontransformable determinant of
unknown identity that can increase penicillin MICs as much as 6-fold.358
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Table 1.1: Summary of non-PBP-mediated β-lactam resistance in N. gonorrhoeae. *Only seen in
laboratory strains. **Plasmid-mediated. ***Observed in laboratory strains transformed with mosaic
penA. Have not yet been confirmed in clinical isolates.
Target (gene)
MtrCDE
(mtrR)
PorB1b
(porB1b)
PilQ (pilQ)*
Opa, Pil, LgtE
Factor X
TEM-1, TEM135 (blaTEM)**
aconitase B
(acnB)***

MleN
(mleN)***

Function
Efflux pump
system
Porin
Pore-forming
secretin of type
IV pilus
intercellular
interactions
Unknown
Penicillinase

Mutations
Single nucleotide
deletion in
promoter region,
G45D
G120K, G120D,
A121D
E666K

Consequence
Overexpression

Mechanism
Increased efflux

Altered
constriction pore
Disruption of pore
formation

Reduced influx

None

Aggregation,
biofilm formation
Unknown
Expression from
plasmid
Decreased flux
through TCA
cycle, changes in
expression of
metabolic genes
Uncharacterized

Decreased
permeability
Unknown
Hydrolysis

Unknown
-

TCA cycle
enzyme (citrate
à isocitrate)

G348D

malate-2H+ /
lactate-Na+
antiporter

ΔA467

Reduced influx

Compensatory
changes in
energy
metabolism
Uncharacterized

1.3.c. Target modification involving gonococcal PBP2
Target modification is a common mechanism of antimicrobial resistance in which
the target active site is obscured or its topology altered to diminish binding of the
antimicrobial. This can be accomplished by mutations to the gene encoding the target,359
enzymatic addition of chemical moieties to critical contact atoms,360,361 or conformational
changes resulting from interaction with other macromolecules.362,363 There exist several
examples of pathogens with modified PBPs that exhibit diminished acylation by β-lactams.
The MRSA mecA determinant is a notable example of target modification; this gene
encodes a homolog of the S. aureus β-lactam target possessing a closed active site, such
that β-lactams cannot gain access for inhibition.364-366 S. pneumoniae develops
chromosomally-mediated high resistance to β-lactams through the acquisition of
mutations in any or all of five of its PBPs.367-374 While point mutations can contribute to a
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resistant phenotype, the hallmark of pneumococcal resistance is horizontal transfer of
portions of the pbpx gene from resistant commensal streptococci with that of
pneumococcus, generating a low-affinity mosaic PBP2x protein. E. faecium not only
acquires point mutations in pbp5 under selective pressure, but it also begins to
overexpress the low-affinity PBP5 mutant.375-377 Point mutations to the ftsl gene encoding
PBP3 have been shown to commonly contribute to β-lactam resistance in H. influenzae,378381

and alterations in PBP1 have been reported in penicillin-resistant C. perfringens.382,383
Biochemical and molecular studies have shown that a majority of the decrease in

susceptibility seen in β-lactam-resistant strains of N. gonorrhoeae is due to chromosomal
alterations resulting in the modification of PBP2.358,384 First, isolated membrane preparations
from β-lactamase-negative penicillin-resistant gonococci show marked reduction in
acylation of PBP2 by [3H]-penicillin G.385,386 These results have been replicated in purified
protein assays, showing decreased acylation of PBP2 from penicillin- and cephalosporinresistant strains by a variety of β-lactams.384,387-390 Additionally, when penA genes from
resistant strains are transformed into the fully susceptible standard FA19 (i.e., in the
absence of other resistance determinants), susceptibility to β-lactams plummets.128,358,384,385
In early studies of penicillin resistance, transformation of penA genes from chromosomally
resistant strains isolated in Australia caused a 100- to 400-fold increase in the minimum
inhibitory concentrations (MIC) of penicillin. More recently, transformation of the penA gene
from a CephDS strain (penA35) into FA19 resulted in 20- and 40-fold increases in the MICs
of ceftriaxone and cefixime, respectively, while transformation of the penA gene from a
CephR strain (penA41) resulted in 300- and 500-fold increases. The MICs exceeded the
European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical resistance
breakpoint of 0.125 μg/mL in both cases (0.31 μg/mL and 1.6 μg/mL for ceftriaxone and
cefixime, respectively). These experiments establish mutations in PBP2 as the primary βlactam resistance determinant in N. gonorrhoeae.
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1.3.d. PBP2 modifications resulting in penicillin resistance
The first use of penicillin against gonococcal infection was in a case of gonococcal
ophthalmia neonatorum in 1930.391 Due to its success in treating the affected infant, and
with growing concerns of sulfonamide resistance at the time, penicillin was tested against
gonococcal urethritis in the early 1940s. In several studies, therapeutic efficacies of 76100% were obtained in men after verified sulfonamide failure.11,13,393-397 Penicillin thus
replaced sulfonamides as first-line treatment for gonococcal infections. Despite early
success, the proportion of penicillin-resistant gonococcal strains climbed steadily over the
coming years.15 In a longitudinal study of 5,700 isolates, conducted from 1959 to 1967, a
marked temporal increase in resistance was observed.14 At the outset of the study, 63%
of isolates were susceptible to 0.01 µg/mL, and all isolates were susceptible to 0.3 µg/mL.
Eight years later, only 13% were susceptible to 0.01 µg/mL, and 83% were susceptible to
0.3 µg/mL, with 9% showing resistance to concentrations greater than 1.0 µg/mL. During
this period, prescribed doses were increased to maintain satisfactory cure rates, and an
increasing number of treatment failures were reported.398-405 In 1976, the first gonococcal
strains possessing plasmid-borne penicillinases were identified in California,17-20,406 but the
growing prevalence of chromosomally mediated resistance is what eventually drove
reevaluation

of

treatment

guidelines

and

a

search

for

more

efficacious

therapies.16,385,386,407-412
Examination of the penA sequences of chromosomally mediated penicillinresistant N. gonorrhoeae (CMRNG) revealed that their PBP2 variants generally contain 5
to 8 amino acid changes compared to wild-type enzyme from FA19.413,414 A key mutation
is the insertion of an Asp (Asp346a) after position 346415,416 (Figure 1.10). This insertion
is positioned in the transpeptidase domain immediately adjacent to another Asp (Asp346),
which forms a functionally significant hydrogen bond with Ser363 of the SXN motif.388 The
hydrogen bond is maintained in the Asp364a mutant, and the insertion appears to confer
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increased flexibility to the β2c-β2d loop.397,389 Additionally, the side chain of Asp346a
projects toward the β-lactam binding site, so while the precise mechanism of resistance is
not entirely clear, it has been proposed that the insertion may sterically hinder antibiotic
binding during Michaelis-Menten complex formation or electronically hinder breakage of
the β-lactam ring during acylation.389 PBP2 variants of PenR strains generally possess
additional mutations in the carboxy-terminal region, further decreasing the acylation rate
and reducing susceptibility.387,389 Interestingly, these mutations do not greatly change the
structure of the enzyme, even locally, indicating that the mechanism of resistance may be
dependent upon protein dynamics.

Figure 1.10: Changes to the active site of penicillin-resistant FA6140 as a result of an Asp346a
insertion. PBP2WT is shown in yellow. PBP26140 is shown in grey.
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1.3.e. PBP2 modifications resulting in cephalosporin resistance
After the withdrawal of fluoroquinolones in the early-to-mid 2000s, cephalosporins
were the only remaining drugs indicated for the treatment of gonococcal infections.39
However, in the last two decades, cephalosporin resistance has emerged as well.41-59
Among the first reported cases of reduced susceptibility (CephDS) was the Swedish 35/02
strain in 2002.417 The 35/02 strain exhibits MIC values of 0.38 and 0.094 µg/mL for
cefixime and ceftriaxone, respectively, corresponding to 25- and 60-fold increases
compared to a wild-type reference strain 119/05. Many additional CephDS strains were
isolated in Sweden, the UK, and the United States around this time, showing MICs of 0.190.38 and 0.094-0.125 µg/mL for cefixime and ceftriaxone, respectively.417
The primary difference between penicillin-resistant and ESC-resistant strains is the
number and types of penA mutations present. Whereas PenDS/R strains contain relatively
few mutations in PBP2, CephDS/R strains possess penA alleles encoding PBP2 variants
with around 60 amino acid changes compared to the wild type protein (Figure 1.11). It is
proposed that these penA genes are acquired by horizontal transfer events between N.
gonorrhoeae and commensal Neisseria species (e.g., N. flavescens, N. cinerea, N.
lactamica, etc.).45,46,418,419 The commensal species, occupying microbiological niches in
the urogenital tract and pharynx, develop chromosomal resistance through frequent
exposure to antimicrobials and subsequently act as reservoirs for antimicrobial resistance
genes.420,421 When prolonged gonococcal infection occurs at these sites, these genes are
readily acquired by the gonococci by transformation and subsequent homologous
recombination, resulting in a “mosaic” allele encoding a PBP2 variant with lowered
cephalosporin acylation.390,417 Three mutations in mosaic PBP235/02 (encoded by the
penA35 allele), G545S, I312M, and V316T, are significant for decreased ESC
susceptibility in 35/02,422 but when incorporated into wild type penA and transformed into
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the PenSCephS FA19 strain, resistance to ESC increased only marginally.128 However,
when these three mutations were reverted to wild-type in the penA35 background, they
were found to have a prominent effect on resistance (Table 4.2). This result indicates that
these resistance mutations require other mutations present in the penA35 mosaic to exert
their effects, a phenomenon known as epistasis.

Figure 1.11: Mosaic penA allele and PBP2 structure. A. Mosaic penA alleles are created by N.
gonorrhoeae through homologous recombination of the penA allele of wild-type N. gonorrhoeae
with those of β-lactam-resistant Neisseria commensal species. B. The PBP2 variants encoded by
mosaic penA have around 60 mutations compared to wild-type enzyme (H041 shown, mutations
indicated as red spheres).

By generating chimeric penA in which segments, or modules, of penA35 were
reverted to the wild-type sequence, information was gained on which mutations in penA35
contribute to β-lactam resistance. FA19 transformants with wild-type module 4 (comprising
residues 489 to 528) on a penA35 background showed the greatest increase in
susceptibility, indicating one or more mutations in this region are critical to resistance.128
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Subsequent transformation experiments with penA35 alleles lacking individual module 4
mutations showed that F504L, A510V, and N512Y also contribute to β-lactam resistance in
the 35/02 strain, with A510V seeming to specifically affect penicillin susceptibility.
Cephalosporin-resistant gonorrhea was first identified in 2009, as a single case
involving a female Japanese sex worker with a pharyngeal infection.62,63 Pharyngeal cultures
came back positive two weeks after standard therapy with ceftriaxone, and infection
clearance was only achieved by a repeat dose upon follow-up. While cultures for the
patient’s second presentation were not tested (indicating the potential for reinfection, rather
than treatment failure), the isolated strain, known as H041, exhibits MIC values of 8 and 2
µg/mL for cefixime and ceftriaxone, respectively, corresponding to 6,000- and 3,000-fold
increases compared to PenSCephS strain FA19. Its notable resistance to many other
antibiotics marks H041 as the first identified pan-resistant strain. This sentinel event in the
timeline of antibiotic resistance led the WHO to declare N. gonorrhoeae a “superbug” in
2012 and the CDC to update its designation to “urgent threat” in 2013.423
The penA gene from the H041 strain (penA41) is a mosaic containing 13 additional
mutations compared to penA35. When transformed into FA19, the penA41 allele increases
the MICs of ceftriaxone and cefixime by 300- and 570-fold, respectively.384 Three mutations,
A311V, T316P, and T483S, were identified in the penA41 allele that, when incorporated into
the penA35 allele, confer a majority of the increased resistance seen in H041 compared to
35/02. A311V and T316P are located near the serine nucleophile (Ser310) and are expected
to affect α2 in some yet unconfirmed way. T483 is predicted to recognize the carboxylate
moiety of β-lactam antibiotics via its hydroxyl group, and while T483S is a conservative
mutation, loss of the methyl group likely alters this interaction. An H541N mutation is present
in many nonmosaic and mosaic penA from strains with decreased cephalosporin
susceptibility as well.45,46,417,422,424-426 In all, the work revealed a total of eight mutations that
together confer a majority of the ESC resistance seen in H041 (Table 1.2, Figure 1.12).
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Figure 1.12: Mutations identified as critical to β-lactam resistance in PBP2H041. Resistance
mutations (yellow) highlighted within the active site of an acyl-enzyme structure of ceftriaxone
(green) in complex with a transpeptidase-only construct of PBP2H041. Polar contacts are shown as
black dashed lines. Figure taken from Singh et al., 2020.134

Transformation of N. gonorrhoeae with a penA construct containing these eight
mutations alone (8M) was unsuccessful, indicating an insurmountable loss of fitness from
a decrease in PBP2 transpeptidase activity [unpublished]. Further experiments revealed
that just one mutation, T483S, is responsible for this failure. A construct lacking this
mutation (7M) successfully transformed N. gonorrhoeae, but to a much lesser level of
resistance. It is thus apparent that background epistatic mutations are required for the
T483S mutation to contribute to resistance without loss of transpeptidase activity.
Transformation experiments have identified these mutations as substitutions within
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hydrophobic cores of the protein distant from the active site – A437V, L447V, and F462I
[unpublished]. A construct including 8M plus the three epistatics (11M) successfully
transformed into N. gonorrhoeae, indicating restored transpeptidase activity. Reversal of
T483S in 11M reduced MICs of transformed bacteria to the same values as for 7M,
confirming the influence of this mutation, and the lack of influence of the epistatic
mutations, on ESC resistance.
Structural analysis of PBP2H041 reveals that several of these mutations act to restrict
protein dynamics required for efficient acylation.134 First, the side chain of S545 participates
in a hydrogen bonding interaction with the side chain of T498, disallowing its rotation upon
recognition of the β-lactam carboxylate. This “locking” of T498 hinders β3 strand twisting
and, thus, oxyanion hole formation. It also affects the final position of the β-lactam by
presenting an alternative hydrogen bonding partner for the carboxylate moiety. Second,
F504L and N512Y appear to prevent hinging of the β3-β4 loop toward the active site, altering
key interactions with the β-lactam acylamino side chain. In fact, the β3-β4 loop occupies an
“outbent” conformation in both apo and acyl forms of PBP2H041. Finally, the α2 mutations
A311V, I312M, and T316P cause no obvious structural changes in PBP2H041. However, the
A311V and I312M mutations involve increased size of hydrophobic side chains and may
increase hydrophobic packing around α2, decreasing its mobility in the acylation reaction.
CephR N. gonorrhoeae has now been reported several times since the emergence
of H041. The first case of successful transmission occurred with the French strain F89,
isolated in 2010. Initially reported in a man who has sex with men (MSM) with urethritis,
the strain came back in a positive repeat urethral culture 3 weeks after cefixime therapy.70
Clearance was attained with gentamicin on follow-up. The strain was subsequently
reported in Spain in two sexually related MSM.64 It exhibits MICs of 4 and 2 µg/mL for
cefixime and ceftriaxone, respectively, and also it possesses resistance to many other
antimicrobials. The penA gene of F89 possesses only one additional mutation compared
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to penA35, A501P. Interestingly, alterations at the 501 position had been hypothesized as
contributing to cephalosporin resistance only two years prior to F89’s isolation. Tomberg
et al., while conducting molecular studies of penA35, noted the frequency of A501V in
nonmosaic

penA

from

gonococcal

strains

with

reduced

cephalosporin

susceptibility128,418,424,425 (Table 1.2). They found not only that transformation of penA35A501V into FA19 increased its MICs for cefixime and ceftriaxone 2.5-fold compared to
penA35, but also that cefixime’s second order acylation rate against a purified PBP235/02A501V construct is half that seen with PBP235/02. The 501 position continues to be the
subject of much investigation due to its differential effects on different classes of βlactams. Despite further increasing cephalosporin resistance, mutations at this position
appear to restore some susceptibility to penams and carbapenems.128,427

Figure 1.13: The impact of A501P on the structure of the β3 strand. P501 causes a displacement
of T500, a critical residue involved in oxyanion hole formation.
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Transformation of FA19 with a diverse set of penA35-A501X genes revealed that
only specific mutations could increase cephalosporin resistance while maintaining
essential transpeptidase function.428 Among these, A501P (found in NgF89) and A501R
(not yet observed in clinical strains) had the biggest impact, increasing MICs for cefixime
and ceftriaxone by 5-fold compared to a penA35-transformed control. Consistent with
previous data from Bharat et al., every successful penA35-A501X transformant had some
restoration of penicillin G susceptibility. The differential effect of mutations at the 501
position on the various classes of β-lactams may have to do with perturbation of the
oxyanion hole. Kinking of β3 strand by the introduction of a proline could displace the
oxyanion hole more distally from S310. Because the distance between the C4 carboxylate
and lactam carbonyl in the cephem framework is typically short, and assuming the SxN,
SxxK, and KTG residues act as an electrostatic anchor for the carboxylate, the lactam
oxygen may not make the appropriate contacts with both S310 and T500 when in its
oxyanionic state, rendering the cephalosporins universally less able to acylate structures
with the 501P mutation.
More reports of full cephalosporin resistance are continuing to emerge at an
accelerated rate worldwide, including strains from the following countries: China, Japan
(GU140106, FC428, FC460, FC498), France (F90), England (G97687/G7944), Denmark
(GK124), Australia (A8806, A7536, A7846), Argentina, and Canada (47707). The PBP2
mutants harbored by most of these strains (excluding that reported in Argentina, which is
nonmosaic) possess structural similarities, sharing A311V and T483S mutations known to
contribute to resistance through studies of H041 (Table 1.2). The functional significance
of additional mutations in penA alleles from these strains has not yet been examined.
Interestingly, sufficient genetic relatedness was found in six of these strains to consider
them clonal, providing the first evidence of sustained international transmission of
cephalosporin-resistant N. gonorrhoeae.
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Non-mosaic PBP2 can also result in ESC resistance, although so far they have
done so to a lesser extent. As mentioned previously, A501V is seen in a variety of nonmosaic penA alleles of strains with reduced ESC susceptibility.418,424,425 In addition to
providing evidence for the role of potential mutations at the 501 position in a mosaic penA,
Tomberg et al. also showed the impact of a variety of these mutations in a non-mosaic
penA4 background.428 The resulting penA4-A501X transformants exhibited MICs 2- to 14fold higher for cephalosporins compared to a penA4-transformed control. A statistical
approach was used to determine if additional common mutations, G542, P551S, and
P551L, have an effect on decreased ESC susceptibility in non-mosaic PBP2 variants. In
this study, Whiley et al. determined that strains harboring non-mosaic penA with any of
the three mutations exhibit a significant decrease in ESC susceptibility, with G542-,
P551S-, and P551L-harboring strains exhibiting median MICs 7.5-, 3.8-, and 7.5-fold
higher than pooled strains lacking the mutations.429 In 2014, a strain possessing a nonmosaic PBP2 variant with P551S was isolated from a young man with purulent urethritis.
Its ceftriaxone MIC was 0.5 µg/mL, marking it as the first reported strain of N. gonorrhoeae
having full resistance to ceftriaxone in the absence of a mosaic PBP2 variant.69
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A311V, I312M, V316T, N512Y, T483S,
F504L, H541N, G545S

Yes
Yes
No
Yes

PenR, CephR
PenR, CephR
PenR, CephR

Australia, 2013

Japan, 2014

Argentina, 2014

Japan, 2015
International, 2017-

Japan, 2015

Japan, 2015

France, 2017

A8806

GU140106

unnamed

FC428

F460

FC498

F90

Yes
Yes
Yes

PenR, CephR
PenR, CephR
PenR, CephR

PenR, CephR

P551L

Yes

PenR, CephR

France, 2010

F89

Yes

PenR, CephR

Japan, 2009

H041

Yes

PenR, CephDS

Sweden, 2002

35/02

No

PenR, CephS

USA, 1983

FA6140

A311V, I312M, V316T, T483S, G545S

A311V, T483S

A311V, T483S

A311V, T483S, V316T

A311V, T483S, V316T

35/02 mutations, A501P

A311V, I312M, V316P, N512Y, T483S,
F504L, H541N, G545S

I312M, V316T, N512Y, G545S

D345a, F504L, A510V, A516G, P551S

-

No

PenS, CephS

Reference

FA19

Key mutations

Mosaic

Phenotype

Location, Year

Strain

-

-

>32.0

>32.0

8

2

1

1

4

2

2

PCN
(µg/mL
)
0.01

1

1

1

1

0.5

2

-

4

8

0.4

0.05

0.001

CFX
(µg/mL)

0.5

0.5

0.5

0.5

0.5

0.5

0.5

1

2

0.1

0.06

0.0006

CRO
(µg/mL)

Table 1.2: Summary of PBP2 structural changes in key strains of N. gonorrhoeae exhibiting a variety of β-lactam susceptibility profiles.
a
Amino acid changes from wild-type characterized as having an effect on β-lactam resistance. bMinimum inhibitory concentration.

1.3.f. PBP1 modifications contributing to β-lactam resistance
While its primary mechanism of β-lactam resistance is the acquisition of mutations
in the penA gene encoding PBP2, N. gonorrhoeae can also acquire mutations in ponA,
the gene encoding the other β-lactam target PBP1, that diminish its acylation.430 A specific
mutation in ponA, L421P (the “ponA1 determinant”), is common and reduces the rate of
PBP1 acylation by a variety of β-lactams by 50-75%. Despite this significant reduction,
ponA1 is not sufficient for clinically significant resistance alone because the ponA1 gene
fails to transform FA19 to a higher level of β-lactam resistance. Moreover, it fails to
transform a series of laboratory-generated intermediate-resistant strains to higher levels
of resistance. However, reversion of ponA1 to wild-type in FA6140 reduces its penicillin
MIC by two-fold, indicating that this mutation requires the presence of a number of other
determinants in order to exert its effect.
1.4. Use of additional antimicrobial classes as antigonococcal therapeutics
1.4.a. FDA-approved therapies
With the fall of β-lactams as useful antigonococcal agents, it may seem attractive
to look toward FDA-approved therapies from other antimicrobial classes. However, as
aforementioned, N. gonorrhoeae has developed marked resistance to a number of other
classes of antimicrobials as well, including sulfonamides, spectinomycin, tetracyclines,
and fluoroquinolones. Some approved therapies show continued activity against
gonococcal isolates, but with each comes a drawback making it a suboptimal candidate
for widespread use (Table 1.3).
In vitro susceptibility to spectinomycin is currently high globally, with rare cases of
resistance, but there is concern that, given rapid resistance development before, resistance
is likely to be selected again. In several countries, gentamicin has been used in combination
with doxycycline for the syndromic management of urogenital infections, and several studies
had shown high microbiological cure rates with the regimen, but no specific data on
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pharyngeal and anorectal infection existed until a study of gentamicin in combination with
azithromycin showed that microbiological cure was achieved in 100% of subjects, including
10 cases of pharyngeal infection.431 Moreover, according to a recent meta-analysis, the cure
rate of single dose is 91.5% across 3 studies with 346 total participants.432,433 An additional
meta-analyses comparing 23 oral and parenteral therapies found gentamicin to rank highly
among them,434 but a third found cure rates with high variability.435 While this could be an
option for cases of treatment failure with other agents, gentamicin is unfavorable as a firstline agent because of the risk for ototoxicity and nephrotoxicity,436,437 and there exists no
data on the relationship between gentamicin MIC and pharmacokinetics with clinical
outcomes to establish evidence-based microbiological resistance breakpoints. Finally, a
randomized control trial comparing 240 mg intramuscular gentamicin and 500 mg
intramuscular ceftriaxone failed to demonstrate noninferiority of the regimen.438,439 The
bacterial cell wall synthesis inhibitor fosfomycin shows good in vitro activity as well,
exhibiting a median MIC of 8-16 μg/mL in several studies.440-444 Studies of acute and
subacute gonococcal urethritis treated with fosfomycin yielded cure rates greater than
90%,445,446 but rapid resistance selection in vitro raises concern for widespread use.447
Nonetheless, a small clinical trial found 3 g oral fosfomycin trometamol (96.8% cure rate) to
be noninferior to 250 mg intramuscular ceftriaxone (95.3% cure rate).448 Like gentamicin,
fosfomycin suffers from a lack of data allowing the establishment of evidence-based
microbiological resistance breakpoints. The glycylcycline tigecycline also shows in vitro
activity against gonococcal isolates,444,449,450 but its primary biliary clearance raises concern
that the drug will not accumulate sufficiently in the urine to treat gonococcal urethritis.451
Carbapenems must bind PBPs in the same way as other β-lactams, and their
activity is dictated by the ability to undergo the same nucleophilic substitution reaction to
form the inactive acyl enzyme. With this mechanistic similarity, known carbapenems
expectedly show decreased efficacy in penicillin- and ESC-resistant strains of N.
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gonorrhoeae due to changes in the PBP2 active site. Due to the aforementioned structural
differences between classes, however, carbapenem reactivity with the target is still much
higher than that of penams or cephems, with meropenem and ertapenem exhibiting MICs
against H041 of 0.125 and 0.064 µg/mL, respectively.63 In a study examining in vitro
activity of ertapenem against clinical N. gonorrhoeae isolates, the antimicrobial potency of
ertapenem was comparable to that of ceftriaxone, with a median MIC of 0.032 µg/mL for
both compounds For isolates with mosaic penA alleles conferring ceftriaxone resistance
(MIC = 0.5 to 4 μg/mL), however, resistance to ertapenem was much less pronounced
(MIC = 0.016 to 0.064 μg/mL).452 While elevated MICs can be seen in strains possessing
mosaic penA alleles,427,452,453 the A501P mutation in PBP2 conferring further
cephalosporin resistance, as seen in strain F89, restores carbapenem susceptibility to
near-wild-type levels.427 In 2018, after reported treatment failures with both ceftriaxone
and spectinomycin, the English strain G97687/G7944 was ultimately cleared with a 3-day
course of intravenous ertapenem, demonstrating its clinical promise as a treatment of last
resort.76
In addition to well-established antimicrobials, newly FDA-approved therapies are
emerging as promising in the treatment of gonococcal infections. One such drug is the
novel fluoroquinolone delafloxacin. In early studies of its in vitro activity, it was consistently
found to inhibit the growth of N. gonorrhoeae clinical isolates more potently than
ciprofloxacin.454-456 However, in a Phase 3 randomized control trial of 460 patients, oral
administration of 900 mg delafloxacin resulted in only an 85.1% cure rate for urogenital
gonorrhea (compared to 91.0% for 250 mg intramuscular ceftriaxone).457 Novel
fluorocycline eravacycline also shows good activity in vitro,444 but its similar
pharmacokinetic profile to tigecycline raises doubts about its ability to treat gonococcal
urethritis.
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Table 1.3: Summary of antigonococcal data for FDA-approved therapies.
FDA-approved
Therapy

In vitro Data

In vivo Data

Limitations

62-98% microbiological
cure rates among 5
studies using gentamicin
monotherapy435
91.5% pooled
microbiological cure rate
from meta-analysis using
gentamicin monotherapy
MIC90 = 8 μg/mL
(333 strains)458

gentamicin
aminoglycoside

MIC90 = 8 μg/mL
(25 strains)459
MIC90 = 12 µg/mL
(32 strains)442
MIC90 = 4 µg/mL
(99 strains)460

432,433

100% microbiological
cure rate in combination
with azithromycin (202
subjects)431
Successful noninferiority
trial of 240 mg IM in
combination with 2 g
azithromycin PO (versus
500 mg ceftriaxone IM
with 2 g azithromycin
PO)461

Failed in noninferiority trial
against ceftriaxone
comparator group
438,439

Adverse effect
profile436,437
No official evidencebased resistance
breakpoints

Found to rank highly in
meta-analysis comparing
23 oral and parenteral
therapies (p score =
0.83 versus 0.924 for
ceftriaxone)434

MIC90 = 16 µg/mL
(89 strains)440
MIC90 = 16 μg/mL
(51 strains)441
fosfomycin

MIC90 = 24 μg/mL
(32 strains)442
MIC range 8-48 μg/mL
(15 strains)443
MIC90 = 32 μg/mL
(112 strains)444

0% microbiological cure
rate (17 subjects)462
90% microbiological cure
rate (70 subjects)446
92% microbiological cure
rate (85 subjects)445
Successful small-scale
noninferiority trial versus
ceftriaxone (62 subjects)

Rapidly selected
resistance in vitro447
No official evidencebased resistance
breakpoints

448
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MIC = 0.064 µg/mL
against H04163
MIC90 = 0.25 μg/mL
(112 strains)444
MIC90 = 0.25 μg/mL
(52 strains)453
ertapenem
carbapenem

MIC90 = 0.008 μg/mL
(22 strains)463

Cure of patient infected
with international FC428
clone76

Elevated MICs in the
presence of βlactam resistance
determinants453,452

900 mg PO failed in
noninferiority RCT
against 250 mg
ceftriaxone IM (85.1%
cure versus 91.0%)457

Modestly elevated
MICs seem to result
in treatment
failure457

MIC90 = 0.062 μg/mL
(654 strains)464
MIC90 = 0.064 μg/mL
(257 strains)452

MIC90 ≤ 0.004 µg/mL
(10 strains)454
delafloxacin
fluoroquinolone

MIC90 = 0.03 µg/mL
(44 strains)455
MIC90 = 0.125 µg/mL
(117 strains)456
MIC90 = 0.5 µg/mL
(54 strains)449

tigecycline
glycylcycline

MIC90 = 0.5 µg/mL
(112 strains)444

NA

Biliary clearance451

NA

Biliary clearance465

MIC90 = 0.25
(120 strains)450

eravacycline
fluorocycline

MIC90 = 0.25 µg/mL
(112 strains) 444

43

1.4.b. Novel analogues of known antimicrobial classes
In addition to considering existing drugs from diverse antimicrobial classes, the
synthesis of novel, potent derivatives of these classes is another potential strategy (Table
1.4). New broad-spectrum semisynthetic fluoroquinolones avarofloxacin and sitafloxacin
exhibit good in vitro activity against gonococcal clinical isolates, with MIC values ranging
from ≤ 0.001 to 1 μg/mL (compared to ≤ 0.001 to > 32 μg/mL for ciprofloxacin).466-468
Macrolide derivatives known as bicyclolides (e.g., modithromycin, EDP-322) have had
promising results in vitro as well, including activity against strains with decreased
macrolide susceptibility.469 The MIC range of modithromycin and EDP-322 against
gonococcal strains of varying resistance profiles were found to be 0.004 to 256 μg/mL and
0.008 to 16 μg/mL, respectively. Unfortunately, high level azithromycin resistance (defined
as an MIC ≥ 256 μg/mL) correlates with decreased susceptibility to these agents as well.
Two newly developed 2-aryl carbapenems, SM-295291 and SM-369926, have shown
variable in vitro antigonococcal activity against clinical isolates (MIC90 ≤ 1 μg/mL).470 The
design and synthesis of novel carbapenem structures that show specifically enhanced
affinity for the PBP2 transpeptidase domain in the presence of CephR mutations thus
presents another strategy for the development of effective therapies against highly
resistant strains.
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Table 1.4: Summary of antigonococcal data for experimental therapeutics belonging to classes of
FDA-approved therapies.
Derivative Compound

Derivative Class

Results

avarofloxacin (JNJ-Q2)

fluoroquinolone

MIC90 = 0.25 μg/mL
(75 strains)468
MIC90 = 0.5 μg/mL
(47 strains)467

sitafloxacin

fluoroquinolone
MIC90 = 0.25 μg/mL
(250 strains)466

modithromycin

macrolide
(bicyclolide)

MIC90 = 1 μg/mL
(254 strains)469

EDP-322

macrolide
(bicyclolide)

MIC90 = 1 μg/mL
(254 strains)469

SM-295291

carbapenem

MIC90 < 1 μg/mL
(16 strains)469

SM-369926

carbapenem

MIC90 < 1 μg/mL
(16 strains)469

1.4.c. Identification of new antimicrobial targets
Several antimicrobial compounds with novel mechanisms of action have been
designed or discovered in the last decade, many of which show in vitro activity against
multi-drug resistant N. gonorrhoeae (Table 1.5). Some successful compounds utilize
known strategies for antimicrobial activity, including novel mechanisms of protein
synthesis inhibition (e.g., pleuromutilin BC-3781, fluoroketolide solithromycin, and
boronate AN3365) and modes of topoisomerase inhibition (e.g., aminobenzimidazole
VXc-486, spiropyrimidinetrione ETX0914, tricyclic 2-quinolone REDX05391, and
triazaacenaphthylene gepotidacin). BC-3781, AN3365, VXc-486, and REDX05931 show
early promise in vitro, with good antimicrobial potency against panels of gonococcal
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strains. REDX05391 has been further tested in a murine model of gonococcal infection.
In this study, significant reductions in gonococcal colonization load were seen with the oral
administration of single 10, 30, or 60 mg/kg doses, and full infection clearance was seen
in the group given 60 mg/kg.471 Solithromycin and ETX0914 have advanced to small
clinical trials of urogenital gonococcal infection, with results indicating a 91% cure rate with
oral administration of 1 g solithromycin and a 96% cure rate with 2 g ETX0914.472,473
Interestingly, in strains exhibiting lowered macrolide susceptibility, solithromycin remains
effective in vitro; however, similar to the bicyclolides, when tested against isolates with
high-level azithromycin resistance, solithromycin begins to fail.
Other compounds in the pipeline exhibit entirely novel mechanisms of antimicrobial
action. One such mechanism is the depletion of essential lipids. FabI is an NADPHdependent trans-2-enoyl-acyl carrier protein reductase identified as a key enzyme in
bacterial fatty acid synthesis. MUT056399, a specific FabI inhibitor, was originally
developed as an anti-staphylococcal agent. Its measured IC50 against S. aureus FabI is
12 nM, and its MIC90 against MRSA is 0.12 µg/mL. In studies of spectrum, MUT056399
was shown to have activity against N. gonorrhoeae, exhibiting an MIC90 of 0.25 µg/mL.474
LpxC is a UDP-3-O-acyl-N-acetylglucosamine deacetylase involved in lipid A
biosynthesis. LPC-067, an LpxC inhibitor designed specifically to target N. gonorrhoeae,
exhibits MICs of 0.1 µg/mL against FA19 and 1.0 µg/mL against 35/02.475 Further
iterations of design, synthesis, and testing have yielded LPC-067 analogues with MICs of
0.005 µg/mL and 0.05 µg/mL against the two strains, respectively.
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Table 1.5: Summary of antigonococcal data for experimental therapeutics with mechanisms of
action distinct from current FDA-approved therapies.
Compound
BC-3781
(lefamulin)

Target

Mechanism

Results
MIC90 = 0.5 μg/mL
(24 strains)476

23S ribosomal
RNA

Inhibited protein
synthesis

CEM-101
(solithromycin)

23S ribosomal
RNA

Inhibited protein
synthesis

MIC90 = 0.25 μg/mL
(246 strains)478

GSK2251052 /
AN3365

leucyl-tRNA
synthetase

Inhibited protein
synthesis

MIC90 = 0.5 μg/mL
(28 strains)479

VXc-486

gyrase B

Dysfunctional
transcription, DNA
replication

MIC90 = 0.125 μg/mL
(220 strains)480

MIC90 = 1 μg/mL
(251 strains)477

MIC90 = 0.25 μg/mL
(250 strains)481
ETX0914 /
AZD0914
(zoliflodacin)

gyrase B

Dysfunctional
transcription, DNA
replication

MIC90 = 0.125 μg/mL
(37 strains)482
MIC90 = 0.125 μg/mL
(873 strains)483

REDX05391

gyrase B
topoisomerase IV

Dysfunctional
transcription, DNA
replication

MUT056399

FabI

Depletion of essential
lipids

LPC-067

LpxC

Diminished lipid A
synthesis

GSK2140944
(gepotidacin)

gyrase A,
topoisomerase IV

Dysfunctional
transcription, DNA
replication

MIC(WHO L) = 4 µg/mL484
MIC(ATCC49226) = 0.12
µg/mL484
MIC90 = 0.25 μg/mL
(10 strains)474
MIC(FA19) = 0.1 µg/mL475
MIC(35/02) = 1 µg/mL475
MIC90 = 0.25 μg/mL
(25 strains)485
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1.5. Development of non-β-lactam PBP inhibitors
1.5.a. Tetrahedral intermediate mimics
In addition to novel PBP-inhibiting compounds based on active β-lactam
frameworks, non-β-lactam compounds can also be explored as antigonococcal agents,
including other covalent inhibitors leveraging the nucleophilic serine. Electron-poor
boronic acids have been known to inhibit serine proteases for several decades,486 and,
after early work showing their utility as β-lactamase inhibitors,487-489 have more recently
been examined as PBP inhibitors as well (Figure 1.14). In 2003, Pechenov et al. explored
several electrophilic functional groups as potential mimics of the transient tetrahedral
oxyanion intermediate generated in the PBP catalytic cycle, and among these, dipeptidic
boronate 1 was found active against several low molecular weight PBPs, exhibiting its
most potent inhibitory activity against N. gonorrhoeae PBP3 (Ki = 0.370 µM).490 Later, a
1.6 Å crystal structure of tripeptide analogue 2 in complex with E. coli PBP5 (Ki = 13 µM)
revealed a covalent adduct in which the Oɣ of Ser44 is bonded to the inhibitor boron and
one boronic acid oxygen projects into the oxyanion hole comprising the backbone amides
of Ser44 and His216, establishing this class of compounds as true tetrahedral intermediate
mimics117 (Figure 1.15A). Another peptidic boronate 3, which possesses a diaminopimelic
acid as its diaminoacyl group, has been shown to bind with high affinity to Actinomadura
R39 DD-peptidase (Ki = 32 nM). In a 2.4 Å crystal structure, 3 was found to bind R39 DDpeptidase in a mode similar to that seen in previous studies of boronates and E. coli PBP5,
with the boron covalently bound to nucleophilic Ser49, and one boronate oxygen
occupying the oxyanion hole491 (Figure 1.15B).
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Figure 1.14: Structures of boronic acid transpeptidase inhibitors.
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Figure 1.15: Crystal structures of boronic acid transpeptidase inhibitors in complex with their
targets, showing their tetrahedral intermediate mimicry. A. Compound 2 (green) in complex with E.
coli PBP5. B. Compound 3 (green) in complex with Actinomadura R39 DD-peptidase. C. Compound
5 (green) in complex with Actinomadura R39 DD-peptidase. D. Compound 5 (green) in complex
with Actinomadura R39 DD-peptidase, showing a unique tricovalent binding mode.
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acylaminoethylboronic acids such as 4, which inhibits both Actinomadura R39 DDpeptidase (IC50 = 0.27 µM) and S. aureus PBP1b (IC50 = 20 µM).492,493 In further
explorations of the class, acylaminomethylboronic acids were found to inhibit
Actinomadura R39 DD-peptidase as well, and subsequent derivatization of this scaffold
yielded 5, which has been shown to inhibit PBPs of classes A (S. pneumoniae PBP1b,
IC50 = 26 μM), B (S. pneumoniae PBP2x, IC50 = 138 μM), and C (Actinomadura R39 DDpeptidase, IC50 = 0.6 μM).494 Distinguishing the methylboronic acids, which mimic a Cterminal glycine, from their alanine-like predecessors is the formation of a tricovalent
complex within the transpeptidase active site, as shown by crystal structures of 5 and
close analogues in complex with R39 DD-peptidase (Figure 1.15D).495 In these structures,
the boronic acid oxygens have been displaced by Oɣ of nucleophilic Ser49, Oɣ of SxN
Ser298, and Nε of KTG Lys410. However, a tetrahedral oxyanion-occupying state similar
to prior published structures was seen in some molecules of the asymmetric unit (Figure
15.C), leading the authors to hypothesize that the ligands bind similarly at the outset, but
that a lack of bulk at Cα allows the ligand to move more freely after initial binding.
A final set of boronic acid-containing scaffolds is the (dihydroxyboranyl)benzoic
acids and [(hydroxyboranyloxy)]benzoic acids. Initial studies found that the m(dihydroxyboranyl)benzoic acid fragment inhibits R39 DD-peptidase, and subsequent
design of 5-acylamino derivatives yielded mid-micromolar inhibitor 6 (IC50 = 23 µM).496
Recent work presents bicyclic o-[(hydroxyboranyl)oxy]benzoic acids as potent inhibitors
of E. coli PBP5, with 7 exhibiting an IC50 of 1.6 nM.497 Although these compounds were
found to have surprisingly little antimicrobial activity alone, they were able to potentiate
meropenem activity against highly resistant E. coli and K. pneumoniae in a dosedependent manner due to their potent metallo-β-lactamase inhibition.
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Table 1.6: Activity of boronic acid compounds against bacterial transpeptidases. aThermodynamic
equilibrium constant (Ki). bHalf-maximal inhibitory concentration (IC50).
Compound
1
2
3
4

5

6
7

Species
N. gonorrhoeae
N. gonorrhoeae
E. coli
E. coli
Actinomadura
spp.
Actinomadura
spp.
S. aureus
Actinomadura
spp.
Actinomadura
spp.
S. pneumoniae
S. pneumoniae
R6
Actinomadura
spp.
E coli

Target
PBP3
PBP4
PBP5
PBP5
R39 DDpeptidase
R39 DDpeptidase
PBP1b
R39 DDpeptidase
R39 DDpeptidase
PBP1b

Activity
0.37 μMa
34 μMa
16 μMa
13 μMa

PBP2x

138 μMb

R39 DDpeptidase
PBP5

a

32 nM

0.27 μMb

Reference
490
117
491
492,493

20 μMb
0.36 μMa

495

0.6 μMb
26 μMb

494

23 μMb

496

b

497

1.6 nM

Additional tetrahedral intermediate analogues synthesized by Pechenov et al.
include peptidic and peptidomimetic aldehydes 8, α-trifluoromethyl ketones 9, and αchloromethyl ketones 10 490 (Figure 1.16). However, these analogues are less potent than
their boronate parent compound (Ki values of 60 μM for both 8 and 9 against N. gonorrhoeae
PBP3, no measurable inhibition by 10), and activated carbonyl analogues of other boronic
acid R39 DD-peptidase inhibitors identified by Woon et al. were found to be inactive up to 1
mM.493 These data indicate that creation of a potent activated carbonyl inhibitor may prove
a futile effort. That said, Dzhekieva et al. hypothesized that attachment of a specific
peptidoglycan fragment was key to inhibition and synthesized compound 11, a direct αtrifluoroketone analogue of 3, with Ki values of 0.37 µM and 13.5 µM against Actinomadura
R39 DD-peptidase and B. subtilis PBP4a, respectively.498 A crystal structure of 11 in complex
with R39 DD-peptidase reveals a tetrahedral adduct with Oɣ of Ser49 and the oxygen from
the inhibitor ketone positioned in the oxyanion hole formed by Ser49 and Thr413 (Figure
1.17A).
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Figure 1.16: Structures of activated carbonyl transpeptidase inhibitors.

Figure 1.17: Crystal structures of activated carbonyl transpeptidase inhibitors in complex with their
targets, showing their tetrahedral intermediate mimicry. A. Compound 11 (green) in complex with
Actinomadura R39 DD-peptidase. B. Compound 14 (green) in complex with β-lactamase OXA-10.
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The chemically similar cyclobutanones were originally synthesized for their
potential as β-lactamase or transpeptidase inhibitors, with the rationale that they, like the
α-trifluoromethyl and α-chloro ketones, would be able to form a stable enzyme-bound
hemiketal. However, several early studies failed to produce agents with any inhibitory
activity against either β-lactamases or transpeptidases499,500 until Lowe & Swain reported
the synthesis of compound 12, capable of inhibiting both E. coli R-TEM and B. cereus I,
as well as Streptomyces R61 DD-peptidase.501 Later, the 7,7-dichloro compound 13 was
also found to inhibit both β-lactamases and R61 DD-peptidase.502,503 Structural studies on
factors influencing hemiketal formation have led to compound 14, 98% of which exists in
the hemiketal state at equilibrium in methanol.504 In addition to structure-activity
relationships showing a correlation of methyl hemiketal formation with activity, crystal
structures with serine lactamase OXA-10 show their tetrahedral intermediate mimicry, with
nucleophilic Ser67 bound covalently to C6 and the hemiketal oxygen occupying the
oxyanion hole created by Ser67 and Phe208 505 (Figure 1.17B). With these new insights
into the synthesis of more electrophilic cyclobutanone scaffolds, as well as definitive
evidence of their hemiketal-based mechanism, perhaps this class can be approached for
new attempts at harnessing their PBP-inhibitory potential.
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Table 1.7: Activity of activated carbonyl compounds against bacterial transpeptidases.
a
Thermodynamic equilibrium constant (Ki) unless indicated otherwise. bMeasured Ki divided by two
under the assumption that one enantiomer is inactive.

Compound
8
9
10
11
12
13

Species
N. gonorrhoeae
N. gonorrhoeae
E coli
N. gonorrhoeae
N. gonorrhoeae
E. coli
N. gonorrhoeae
N. gonorrhoeae
E. coli
Streptomyces
spp.
Actinomadura
spp.
B. subtilis
Streptomyces
spp.

Target
PBP3
PBP4
PBP5
PBP3
PBP4
PBP5
PBP3
PBP4
PBP5
R61 DDpeptidase
R39 DDpeptidase
PBP4a
R61 DDpeptidase

Activitya
60 μM
>1 mM
>1 mM
60 μM
>1 mM
>1 mM
~1 mM
>1 mM
>1 mM

Reference

~0.9 mM

501

0.37 μMb
13.5 μMb
~1 mM

490
490
490

498
502, 503

The phosphonates are another structural class initially examined as inhibitors of
serine proteases, and later expanded to β-lactamases and PBPs due the enzymes’
mechanistic similarities (Figure 1.18). Designed with the rationale that a phosphonate
should form a tetrahedral adduct with the nucleophilic serine similar to that observed with
boronic acids, the acetamidomethylphosphonate 15 was the first of its class to show
potent inhibition of a β-lactamase, capable of phosphonylating Enterobacter cloacae P99
at a rate of 1,120 M-1s-1.506 Equally impressive was the stability of the complex, which
underwent regeneration of the apo-enzyme (k3) at a rate of 2.32×10-6 s-1. However, this
molecule failed to inhibit Streptomyces R61 DD-peptidase, as did its retro-amide
analogue.507 Soon after, a p-nitro analogue of this compound (16) was shown to be a
weak inhibitor of R61 DD-peptidase (k2/Ki = 0.07 M-1s-1), giving credence to the idea of
phosphonates as transpeptidase inhibitors.508
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Figure 1.18: Structures of phosph(on)ate transpeptidase inhibitors.

Since then, a great deal of work has been done to elucidate the basic inhibitory
mechanisms of this class. First, the phosphoester substituent acts as a leaving group, as
evidenced by the formation of stoichiometric quantities of alcohol upon β-lactamase
inactivation. Moreover, good leaving group ability is key for the covalent reaction to
proceed.509 This was further illustrated by experiments with phosphonamidates, which
exhibited much slower rates due to the relative instability of deprotonated amines.510,511
The rate-determining step for this subclass is the acquisition of a proton, a requirement
that may limit their utility in the absence of a general acid catalyst.510 Proof of covalent
adduct formation with β-lactamases was eventually obtained by electrospray mass
spectrometry,512 and later crystal structures showed the formation of covalent complexes
mimicking the β-lactam tetrahedral intermediate state.513-515 In a 2.0 Å structure of TEM-1
in complex with 16, the nucleophilic Ser70 is phosphonylated by the inhibitor, the oxyanion
hole created by Ser70 and Ala237 is occupied by the unsubstituted phosphonate oxygen,
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and the p-nitrophenol leaving group has departed515 (Figure 1.19A). Other studies have
examined structure-activity relationships of the alkyl side chain, demonstrating that the
incorporation of an (acetamido)methyl group increases the rate of β-lactamase
inactivation by 10,000-fold.511 Complementarity (in this case, mimicry of the β-lactam R1
acylamino group) is, therefore, requisite for fast β-lactamase inactivation. Li et al.
established, however, that a sulfonamidomethyl isostere is suitable.516 Compound 17 is
not only an inhibitor of E. cloacae P99 (1.2×103 M-1s-1), but was also identified as another
weakly inhibitory compound against Streptomyces R61 DD-peptidase (k2/Ki = 0.06 M-1s-1).

Figure 1.19: Crystal structures of phosph(on)ate transpeptidase inhibitors in complex with their
targets, showing their tetrahedral intermediate mimicry. A. Compound 16 (green) in complex with
β-lactamase TEM-1. B. Compound 18 (green) in complex with Streptomyces R61 DD-peptidase. C.
Compound 19 (green) in complex with Streptomyces R61 DD-peptidase.
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Cyclic phosphonates like 18,517 while demonstrating improvement compared to
their acyclic analogues (R61 DD-peptidase k2/Ki = 0.46 M-1s-1), still suffer from a lack of
potency. However, they offer the benefit of generating a stable ligand-enzyme complex.
As with the β-lactams, when the leaving group is ejected upon reaction with the target, it
remains tethered to the phosphonate and hinders hydrolysis of the resulting complex (R61
DD-peptidase k3 = 3.4×10-5 s-1). A phosphonate analogue of 18 was found to inactivate the

E. cloacae P99 β-lactamase more rapidly (k2/Ki = 9.8×103 M-1s-1 versus 6.7×103 M-1s-1),
albeit with a faster off-rate (k3 = 9.8×10-2 s-1 versus 1.1×10-3 s-1), but its activity against
transpeptidases was never reported.518 Further derivatization of salicyloyl phosphate and
cyclic benzoyl phosphonate led to compounds capable of inactivating P99 at rates of over
104 M-1s-1,519 but only compound 19 was tested against transpeptidases. Its inactivation
rate against Streptomyces R61 DD-peptidase was measured to be 24 M-1s-1 (k3 = 8.9×105

s-1), a 50- to 400-fold improvement over previous phosphonates for which inhibition data

is available.520 Crystal structures of 18 and 19 in complex with R61 DD-peptidase confirm
tetrahedral intermediate mimicry, showing phosphonylation of nucleophilic Ser62, as well
as occupancy of the oxyanion hole created by Ser62 and T301 by the anionic oxygen520
(Figure 1.19B & C). The emergence of salicyloyl phosphate and cyclic benzoyl
phosphonates led to the pursuit of acyl and diacyl phosph(on)ates as inhibitors of βlactam-recognizing enzymes.521-527 In general, these compounds are poor substrates of
both β-lactamases and DD-peptidases, with low enough turnover to be considered
irreversible inhibitors.521,528 Among these, benzoyl phosphonate 20 was identified as a
poor inhibitor of transpeptidase activity, exhibiting a rate of inactivation of 0.005 M-1s-1
against R61 DD-peptidase.528 Additional variations of the phosphonate have been
attempted for β-lactamase inhibition, including mercaptophosphonates,529.530 2-aryl-2(methoxyimino)acetylamino phosphonates,531 but no activity data against transpeptidases
is available for these scaffolds.
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Other phosphonate and phosphate analogues take advantage of the moiety as an
electrostatic anchor rather than an electrophilic center. The potential for acylation by acyl
phosphonates

was

leveraged

with

the

development

of

electron

withdrawn

ketophosphonates.532,533 While these molecules inhibited β-lactamases, no evidence was
found for the formation of a covalent tetrahedral adduct. Moreover, no substantial inhibition
of R61 DD-peptidase was seen. Inhibition of β-lactam-recognizing enzymes by citrate and
isocitrate and their amino derivatives,534,535 as well as high-occupancy crystal structures
showing their binding in the active sites of β-lactamases,534,536 led to the synthesis and
testing of a series of phosphonic acid isosteres.535 One such compound, 21, is a
bioisostere of aminocitrate that exhibits 53% inhibition of Actinomadura R39 DD-peptidase
at 500 μM. Naturally occurring phosphates, including guanosine monophosphate and
inosine monophosphate, are reported micromolar inhibitors of β-lactamases as well, but
no data is available on potential transpeptidase inhibition.537 Phosphate analogues of
active boronic acids synthesized by Woon et al. have also shown little inhibitory potency,
with the most active (22) showing 35% inhibition of R39 DD-peptidase at 1 mM.493
Dzhekieva et al. have had similar results, with the direct phosphate analogue of boronic
acid 3 and α-trifluoroketone 11 showing no inhibition of R39 DD-peptidase up to 2 mM.498
Heterocyclic methylphosphates have also shown promise as inhibitors of βlactamases,538,539 but no data on transpeptidase inhibition have been reported.
Overall, while synthesized molecules of this class have shown promise in the
inhibition of β-lactamases, all attempts to date have yielded quite poor inhibitors of
transpeptidases. Most compounds of these classes suffer from a slow on-rate, a major
determinant of covalent inhibitors’ potency, and a need for additional derivatization to
increase complementarity with the transpeptidase active site. However, their properties as
electrophiles allow them to inhibit both serine- and metallo-β-lactamases as well as PBPs,
opening possibilities for the development of dual inhibitors.
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Table 1.8: Activity of phosphate and phosphonate compounds against bacterial transpeptidases.
a
Second-order rate of reaction with the target (k2/Ki). bPercent inhibition of target activity at 500 µM.
c
Percent inhibition of target activity at 1 mM.

Compound
16
17
18
19
20
21
22

Species
Streptomyces
spp.
Streptomyces
spp.
Streptomyces
spp.
Streptomyces
spp.
Streptomyces
spp.
Actinomadura
spp.
Actinomadura
spp.

Target
R61 DDpeptidase
R61 DDpeptidase
R61 DDpeptidase
R61 DDpeptidase
R61 DDpeptidase
R39 DDpeptidase
R39 DDpeptidase

Activity

Reference

-1 -1 a

0.07 M s

508

0.06 M-1s-1 a

511

0.46 M-1s-1 a

517

24 M-1s-1 a

520

0.005 M-1s-1 a

528

53%b

535

35%c

493

1.5.b. β-lactam mimics
Other inhibitory chemotypes rely on mimicry of the substrate in a manner similar
to the β-lactams, frequently through acylation of the target by an activated carbonyl
electrophile (Figure 1.20). The first ɣ-lactam-based PBP inhibitors were attempted shortly
after the discovery of penicillin. These molecules were close analogues of penams, such
as penicillin G, but showed neither antimicrobial activity nor hydrolysis in aqueous
solution.540-542 This lack of success continued with a variety of monobactam, penam,
oxapenam, and carbapenam derivatives failing to show any antimicrobial activity.543-546
It was known at the time that a bicyclic β-lactam’s ability to acylate its target is, in
part, due to disrupted amide resonance, and that one valuable measurement of this
disruption is the pyramidalization of the lactam nitrogen.154-162 In computational studies,
1-azabicyclo[3.2.0]heptane systems were predicted to have high degrees of Npyramidalization; however, synthesized molecules of this scaffold still failed to exhibit any
appreciable antimicrobial activity.547,548 It was not until the introduction of the 2-oxo-1azabicyclo[3.2.0]hept-6-enes (23), which combine a high degree of bicyclic strain with a
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competing enamine resonance also known to contribute to amide destabilization,155,159,215
that the ɣ-lactam class gained traction as antimicrobials.549 Subsequent penem and
carbapenem derivatives (24 & 25), which incorporate the resonant olefin into less strained
systems, also showed marginal antimicrobial activity with limited spectrum, indicating that
for the ɣ-lactam to have utility as a potent PBP-acylating scaffold, additional activation of
the ring system would likely be required.550-553
Much of the work that followed was conducted to determine structure-activity
relationships for the class. With the diminished carbonyl electrophilicity seen in ɣ-lactams
compared to β-lactams, affinity for the transpeptidase active site becomes a much more
critical aspect of target binding and biological activity. While penems and carbapenems
lacking an acylamino group still possess antimicrobial activity, their ɣ-lactam analogues
generally do not.554 Further computational studies examined the optimal placement and
stereochemistry of the acylamino side chain, determining that 7R-substitution provides the
most morphological resemblance to the β-lactams (Figure 1.21). These analyses also
suggested that, like cephalosporins, the bicyclic olefinic ɣ-lactams can be activated by
long-range electron-withdrawing inductive effects at the C3 position. The relationship
between biological activity and the C3-substituent is supported by the increased potency
of compounds possessing cyano, carboxylic, and sulfonyl moieties compared to those
with methyl and acetoxy groups.554,555
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Figure 1.21: Structural alignments of ɣ-lactams with penicillin G. A. Alignment of penicillin G (grey)
with ɣ-lactams 24 (magenta) and 25 (lime), showing good agreement of key features. B. Alignment
of penicillin G with the 7S stereoisomer ɣ-lactam 24. There is still good agreement between
features, consistent with the activity of both stereoisomers. C. Alignment of penicillin G with an
inactive 1H-pyrrole-2,3-dione derivative. The inactivity of this scaffold suggests that the 3-oxo group
projects into space unfavorable for productive binding to the transpeptidase active site. D.
Alignment of penicillin G with pyrazolidin-5-one 27, showing retention of feature agreement from
24, but with a more activated ring system. E. Alignment of penicillin G with an inactive δ-lactam
derivative. The inactivity of this scaffold suggests that the larger, more flexible ring system group
presents conformational uncertainty and projects into space unfavorable for productive binding to
the transpeptidase active site.

Parallel efforts to increase the reactivity of the β-lactam ring itself led to the
syntheses of 1,2-diazetidin-3-ones.556,557 The resulting scaffolds were too successful,
however, because they lacked the stability to be useful in drug-like molecules. Seeing this
work, and recognizing a need for more reactivity in the ɣ-lactam ring system, Jungheim et
al. designed and synthesized a series of bicyclic pyrazolidin-5-ones (26) that, despite a
bulky and ill-positioned gem-dimethyl group, exhibited good antimicrobial activity.558
Development of novel synthetic schema, in combination with the structure-activity
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relationship data available for ɣ-lactam derivatives of penems and carbapenems, allowed
derivatization of this class to yield highly biologically active compounds 27 and 28.559-566
Compound 27 exhibits good spectrum, and decreases cell wall synthesis and crosslinking
without effects on the synthesis of other macromolecules. It binds E. coli PBP3 at
concentrations as low as 0.1 µg/mL.567 Compound 28 has antimicrobial activity against a
variety of Gram positive and Gram negative species, and exhibits high potency against E.
coli PBP3 as well (IC50 = 0.25 µg/mL).568,569
Further exploration of structure-activity relationships in this active scaffold has led
to very few positive results. Modifications at C7 based on the 6R-hydroxyethyl side chain
of carbapenems led to a reduction in activity,570 as did expansion to a more cephem-like
[4.3.0] bicyclic system.566,571,572 Notably, removal of the C7 substituent altogether
decreases antimicrobial potency but does not abolish it entirely.573 Monocyclic pyrazolidin5-ones suffer from a similar lack of potency.574 That these C7-unsubstituted and
monocyclic pyrazolidin-5-ones retain antimicrobial activity while their monoaza analogues
do not, indicates the marked activation of this scaffold, and demonstrates its promise in
the development of PBP-acylating antimicrobials.
Other attempts have been made to activate ɣ-lactam ring systems, including the
introduction of electron-withdrawing groups to the ring itself. Synthesis of bicyclic 1Hpyrrole-2,3-diones showed adduct formation with methanol, indicating successful
activation and potential for PBP acylation;575 however, these compounds lack
antimicrobial activity, and fit poorly into the transpeptidase active site (Figure 1.21). Other
groups have surveyed additional ring strain through the synthesis of bridged ɣ-lactams.
To this end, the 7-oxo-1-azabicyclo[3.2.1]oct-2-ene 29 was synthesized.576 The compound
has an IC50 of 5 μM against both PBP3 and PBP4 of P. aeruginosa and exhibits modest
antimicrobial activity against a variety of species.
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In kinetics studies to determine which other cyclic amides, if any, hold promise in
transpeptidase or serine protease acylation, hydrolysis of monocyclic lactams was
measured to determine reactivity with nucleophiles. Surprisingly, δ-valerolactam
underwent alkaline hydrolysis at a rate almost equivalent to that of β-propiolactam
(second-order rate constants of 1.21×10-4 M-1s-1 and 2.37×10-4 M-1s-1, respectively), while
all other ring sizes were 40- to 1,700-fold less reactive.577 However, early syntheses of
direct δ-lactam penam analogues yielded no biological activity.578 Even in the context of
the activated diaza scaffold discussed above, δ-lactams failed to show much potency
despite high pseudo-first order rates of alkaline hydrolysis (k = 8.8×10-4 s-1).569 Through
computational modeling and structural alignment of the synthesized compounds with
known actives, it was concluded that the disparity between chemical reactivity and
biological activity could be explained by three factors unique to the larger ring system that
decrease productive binding to the transpeptidase active site: 1) the spatial arrangement
of the acylamino side chain, 2) additional steric bulk, and 3) increased conformational
freedom (Figure 1.21).

Table 1.9: Activity of ɣ-lactams against bacterial transpeptidases. aHalf-maximal inhibitory
concentration (IC50). bApproximation from PBP-binding shown for isolated membrane proteins.

Compound
27
28
29

Species
E. coli
E. coli
P. aeruginosa
P. aeruginosa

Target
PBP3
PBP3
PBP3
PBP4

Activitya
~1.5 μg/mLb
0.25 μg/mL
5 μM
5 μM

Reference
567
569
576
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Lactivicin (30), a cycloserine- and ɣ-lactone-containing natural product, has also
been shown to inhibit a variety of PBPs at micromolar concentrations579 (Figure 1.22). It
is highly active against Gram positive organisms, but its modest Gram negative activity
revealed a need for derivatization. Early analogues employing acylamino side chains
similar to third-generation cephalosporins (31) exhibited improved antimicrobial spectrum,
likely due to enhanced outer membrane permeability, as well as improved interactions
with the transpeptidase active site.580,581 Improved target inhibition by such modifications
was later shown by phenoxylacetyl lactivicin 32, an analogue of penicillin V, which is 6and 40-fold more potent against two different S. pneumoniae PBP2x variants than the
parent compound.582 Further attempts to extend spectrum involved the use of specific,
charged acylamino side chains employed in antipseudomonal cephalosporins. Compound
33, which shares an acylamino group with ceftazidime, shows both increased potency
against Gram negatives and enhanced inhibition of pseudomonal PBPs.583 Conjugation of
this molecule to siderophoric 4,5-dihydroxyphthalimide (compound 34) improves its
uptake into Gram negative bacilli without negatively affecting target inhibition, enhancing
its antimicrobial activity by as much as 500-fold.583.584
Through mechanistic studies conducted by Macheboeuf et al., it is now known that
the lactivicins inhibit PBPs covalently via an acylation reaction distinct from β-lactams.582
In a crystal structure of lactivicin in complex with S. pneumoniae PBP1b, Oɣ of nucleophilic
Ser460 has formed a covalent bond with the cycloserine carbonyl carbon, causing the
cycloserine ring to open and, by resonance, the ɣ-lactam as well (Figure 1.23). The
oxygen of the resulting ester carbonyl is located in the oxyanion hole formed by Ser460
and Thr654. The ɣ-lactone ɣ-carboxylate group makes polar contacts with the side chains
of Thr652 (KTG) and Thr654, and the carbonyl oxygen of the cycloserine N-acetyl group
contacts Asn518 (SxN). The structure has marked similarities with a PBP1b-cefotaxime
acyl-enzyme structure,585 indicating a similarity of precovalent binding mode that allows
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the acylation reactions to proceed. Like β-lactams, lactivicins probably act as C-terminal
peptidomimetics, where the ɣ-lactone ɣ-carboxylate acts as the C-terminus, an
electrostatic anchor that helps to position the electrophilic carbonyl for attack by the serine
nucleophile, while the acetylamino group aids in complex formation by mimicking the
peptide bond of a third amino acid.
The reactivity of the lactivicin cycloserine (4-aminoisoxazolidin-3-one) moiety has
led to the exploration of novel isoxazolidin-5-one compounds. While several of the initial
compounds to come out of this work, including 35, had only marginal antimicrobial activity,
they readily formed adducts with methanol, showing that they are reactive to nucleophilic
species.586 It should be noted that many of these molecules are esterified and would likely
be manifold more potent as carboxylic acids. Cao et al. subsequently designed and
synthesized a series of 3-alkoxyisoxazolidin-5-ones possessing carboxylic acid moieties
in accordance with the geometric requirements established for transpeptidase inhibition
by β-lactams.587 These compounds represent a significant improvement over earlier
efforts, with the 3-isopropoxyisoxazolidin-5-one 36 inhibiting B. subtilis growth at 0.2
µg/mL. Target inhibition was confirmed via spectroscopic PBP labeling with a dansylated
version of the 5-methoxy analogue, but no determinations of potency were made.
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Table 1.10: Activity of lactivicins against bacterial transpeptidases. aHalf-maximal inhibitory
concentration (IC50) unless otherwise denoted. bSecond-order acylation rate constant (k2/Ks).
Compound

30

32
33

34

Species
B. subtilis
B. subtilis
B. subtilis
B. subtilis
E. coli
E. coli
E. coli
S. pneumoniae R6
S. pneumoniae 5204
S. pneumoniae R6
S. pneumoniae 5204
P. aeruginosa
P. aeruginosa
P. aeruginosa
P. aeruginosa
P. aeruginosa
P. aeruginosa
P. aeruginosa
P. aeruginosa

Target
PBP1
PBP2
PBP3
PBP4
PBP1a
PBP1b
PBP2
PBP2x
PBP2x
PBP2x
PBP2x
PBP1a
PBP1b
PBP2
PBP3
PBP1a
PBP1b
PBP2
PBP3

Activitya
0.28 μg/mL
1.0 μg/mL
12 μg/mL
0.05 μg/mL
5.0 μg/mL
14 μg/mL
22 μg/mL
380 M-1s-1 b
0.6 M-1s-1 b
2,150 M-1s-1 b
25 M-1s-1 b
0.046 μM
1.23 μM
33.3 μM
0.092 μM
0.03 μM
0.27 μM
3.7 μM
0.046 μM

Reference

579

582
582
583

583

A more recently identified class of β-lactam-mimicking compounds is the 1,6diazabicyclo[3.2.1]octan-7-ones (DBO), which possess a 5-membered diazacyclic system
resembling that seen in pyrazolidinones 26-28 discussed above, as well as a bridged
structure similar to 29 (Figure 1.24). The DBO carbonyl is activated by a disruption of urea
resonance caused by geometric constraints of the bicyclic system on the bridgehead
nitrogen side, and by an electron-withdrawing inductive effect on the N-sulfonic acid side,
as shown in the prototypical compound NXL104 (avibactam, 35). Avibactam was originally
developed as a covalent β-lactamase inhibitor with a fast on-rate (k2/Ki > 104 M-1s-1)
against a variety of classes, as well as a slow off-rate (k3 < 10-3 s-1).588-591 Early crystal
structures of avibactam with serine β-lactamases show carbamoylation of the serine
nucleophile and occupancy of the oxyanion hole by the carbonyl oxygen.590,592-594 Unlike
other β-lactamase inhibitors, however, avibactam exhibits intrinsic antimicrobial
activity.595,596 In subsequent investigations of this activity, it was found to bind PBPs with
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low- to mid-micromolar affinity, with a notable preference for PBP2 from a variety of
species.597,598 From these data, the DBO scaffold has become a jumping off point for one
of the first successful ventures into dual inhibition.
Many derivatization efforts have focused on modification of the avibactam 2carbamoyl moiety. Synthesis and testing of direct N-alkyl and N-aryl derivatives was
reported by Blizzard et al., who explored a series of carbocyclic and heterocyclic
substitutions.599 Interestingly, N-(pyridin-2-yl) compounds exhibited nanomolar inhibition
of class A, C, and D β-lactamases, but they failed to show much synergy with
carbapenems against resistant Gram negative bacilli. The best synergy results were
obtained with N-(pyrrolidin-3-yl) and N-(piperidin-4-yl) analogues, the latter of which has
been pursued as MK7655 (relebactam, 36). While relebactam’s carbapenem-potentiating
effects are well documented,600-603 it has relatively weak intrinsic antimicrobial activity,604
and its PBP-binding profile has not been characterized. Further investigations of the 2carbamoyl group led to the N-alkoxycarboxamides FPI1459 (nacubactam, 37) and
FPI1465 (38). Nacubactam is an N-(2-aminoethoxy) derivative with potent β-lactamase
inhibition and better intrinsic antimicrobial activity than either avibactam or relebactam
against a variety of problematic Gram negative species.605 In keeping with its improved
intrinsic activity, it also inhibits E. coli PBP2 more potently than avibactam, with an IC50 of
0.12 μg/mL. FPI1465 is a ring-constrained N-(pyrrolidin-3-yloxy) analogue of nacubactam
with similar antimicrobial activity.606 Although its reported IC50 against E. coli PBP2 is
higher than that reported for nacubactam, the enzymatic assays reported by King et al.
were done under conditions of simultaneous addition rather than preincubation.
Comparing results from similar techniques, both compounds represent an ~5-fold
improvement over avibactam. A 2.9 Å crystal structure of FPI1465 in complex with E. coli
PBP1b reveals marked similarities between the PBP binding modes of DBOs and βlactams606 (Figure 1.25). The nucleophilic Ser510 is carbamoylated, and the ligand
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carbonyl oxygen occupies the oxyanion hole created by Ser510 and Thr701. The sulfonic
acid makes polar contacts with Thr699 (KTG) and Thr701, similar to what is seen in
complex structures of aztreonam, ampicillin, and cephalexin, and it is also within hydrogen
bonding distance of Ser572 (SxN).607 Neither the FPI1465 2-carbamoyl group nor the
aztreonam C3 acylamino group contact Asn574 (SxN), a common point of interaction with
6-acylamino and 7-acylamino groups of penams and cephems, respectively. A final
subclass arising from modifications to the 2-carbamoyl group are the diacylhydrazines
FPI1523 (39), FPI1602 (40), WCK5153 (41), and WCK5107 (zidebactam, 42). FPI1523 is
a simple acetyl derivative with 20-fold better E. coli PBP2 inhibition than avibactam, as
well as 8- to 16-fold better antimicrobial activity against E. coli transformed with a variety
of β-lactamases.606 FPI1602, WCK5153, and zidebactam are a series of nitrogen
heterocycle-substituted acyl hydrazines of increasing ring size. Of the compounds
reported by King et al., FPI1602 is the most potent single agent antimicrobial, with MICs
less than 0.5 μg/mL against E. coli transformed with a variety of β-lactamases and good
activity against NDM-1-producing clinical isolates of E. coli and E. cloacae.606 It exhibits
E. coli PBP2 inhibition similar to FPI1523. WCK5153 and zidebactam have been
characterized largely for their considerable antipseudomonal properties.608 They exhibit
submicromolar inhibition of P. aeruginosa PBP2, as well as antimicrobial activity against
even metallo-β-lactamase-producing strains. While they are potent inhibitors of PBP2 from
K. pneumoniae and A. baumanii as well, WCK5153 and zidebactam are only capable of
inhibiting growth of non-MBL-producing K. pneumoniae and fail against A. baumanii
entirely.609-611
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Other groups have explored the chemistry of the 3- and 4-positions. One such
example is ETX2514/durlobactam (43), a 3-unsaturated 3-methyl analogue of avibactam.
Durlobactam shows good antimicrobial activity against a series of Gram negative bacilli,
including K. pneumoniae and S. maltophila.612 However, despite its relatively rapid
carbamoylation of A. baumanii PBP2 and its marked potentiation of carbapenem and
sulbactam activity against metallo-β-lactamase-producing strains, durlobactam does not
have significant intrinsic anti-acinetobacter activity itself.612,613 Durlobactam is a poor
antipseudomonal agent, perhaps due to its poor carbamoylation of P. aeruginosa PBPs.
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Additional 3-unsaturated DBOs include 2-decarbamoyl 4-(oxazol-4-yl) product
CPD3 (44) and its 2-aminomethyl analogue CPD4 (45). In this work, Levy et al. explored
a series of 4-substituted analogues and found that, with few exceptions, those with a 4heterocyclic moiety are more potent than the unsubstituted parent compound.614 CPD3
and CPD4 are both nanomolar E. coli PBP2 inhibitors, but addition of the aminomethyl
group seen in CPD4 improves its antimicrobial potency considerably, making it among the
most intrinsically active of the DBOs reported to-date (mean MIC values of 0.031 μg/mL
and 1 μg/mL against E. coli and P. aeruginosa clinical isolates, respectively). Fused
pyrazolo[3,4-e] (NXL105, 46) and oxazolo[4,5-e] (47) products and derivatives show
intrinsic activity against E. coli and a series of P. aeruginosa strains, but no further reports
of spectrum or PBP inhibition could be found.615-618 However, resistance to these
compounds in E. coli has been ascribed to mutations in the mrdA gene encoding PBP2,
indicating significant binding in susceptible strains.615 ETX1317 (48) occupies unique
chemical space, with a 2-fluoroacetic acid in place of the sulfonic acid seen in other DBOs.
ETX1317 has potent intrinsic antimicrobial activity, with a median MIC of 0.25 μg/mL
against a panel of 1,875 clinical isolates of Gram negative enterics, and has been shown
to bind E. coli PBP2 from membrane preparations.619
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Table 1.11: Activity of DBOs against bacterial transpeptidases. aHalf-maximal inhibitory
concentration (IC50) unless otherwise denoted. bConducted with simultaneous addition of inhibitor
and substrate, as opposed to an inhibitor preincubation period usually used for IC50 measurements.
c
Second-order carbamoylation rate constant (k2/Ks).
Compound

35

37
38
39
40
41
42

43

44
45

Species
E. coli
P. aeruginosa
P. aeruginosa
P. aeruginosa
H. influenza
S. pneumoniae
S. aureus
S. aureus
E. coli
E. coli
K. pneumoniae
E. coli
E. coli
E. coli
E. coli
P. aeruginosa
A. baumanii
K. pneumoniae
P. aeruginosa
A. baumanii
K. pneumoniae
A. baumanii
A. baumanii
A. baumanii
P. aeruginosa
P. aeruginosa
P. aeruginosa
E. coli
E. coli
E. coli
E. coli
E. coli

Target
PBP2
PBP2
PBP3
PBP4
PBP2
PBP3
PBP2
PBP3
PBP2
PBP2
PBP2
PBP2
PBP2
PBP2
PBP2
PBP2
PBP2
PBP2
PBP2
PBP2
PBP2
PBP1a
PBP2
PBP3
PBP1a
PBP2
PBP3
PBP1a
PBP2
PBP3
PBP2
PBP2

Activitya
0.92 μg/mL
1.1 μg/mL
1.8 μg/mL
11 μg/mL
3.0 μg/mL
8.1 μg/mL
51 μg/mL
156 μg/mL
0.59 μM
63 μMb
2 μg/mL
0.12 μg/mL
14.8 μMb
3.2 μMb
3.6 μMb
0.14 μg/mL
0.01 μg/mL
0.07 μg/mL
0.26 μg/mL
0.01 μg/mL
0.08 μg/mL
180 M-1s-1 b
1,800 M-1s-1 b
3.37 M-1s-1 b
12 M-1s-1 b
24.3 M-1s-1 b
60 M-1s-1 b
120 M-1s-1 b
17,000 M-1s-1 b
2.3 M-1s-1 b
25 nM
10 nM

Reference

597

614
606
598
605
606
606
606
608
609
610
608
609
610

612

614
614
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1.5.c. Other reactive (presumed covalent) inhibitors
There are several identified PBP inhibitors that possess functional groups reactive
to nucleophiles, but which have not been fully characterized as covalent in mechanism.
Two such classes are the arylalkylidene rhodanines and arylalkylidene iminothiazolidin-4ones, identified as inhibitory scaffolds in a high-throughput screen and subsequently
derivatized to yield 49 and 50

620

(Figure 1.26). These compounds exhibit single-digit

micromolar inhibition of S. aureus PBP2a and are active against a series of diverse
transpeptidases, including S. pneumoniae PBP2x, E. coli PBP3, E. coli PBP5,
Streptomyces R61 DD-peptidase, and Actinomadura R39 DD-peptidase. They were also
shown to inhibit growth of several pathogens and confirmed to inhibit cell wall synthesis in
[3H]-glycine incorporation assays. Arylalkylidene rhodanine 51 was identified in a highthroughput screen, this time against PBP2 of N. gonorrhoeae.621 This compound was
found to have much more potent antimicrobial activity (2 µg/mL) than expected from its
modest target inhibition (153 µM), suggesting potential off-target effects. The
arylalkylidene rhodanines and arylalkylidene iminothiazolidin-4-ones contain an electron
withdrawing olefin motif that can act as a Michael acceptor, and the former have been
shown to bind covalently to cysteine residues through nucleophilic attack by the side chain
thiol.622 Moreover, they have been found to inhibit S. pneumoniae PBP2x
noncompetitively.620 These molecules may, therefore, bind to the activated serine
nucleophile of transpeptidases through a similar mechanism (Figure 1.27). The
arylalkylidene rhodanine structure is considered a pan-assay interference (PAIN)
compound substructure, but because derivatization can result in high selectivity for a given
target, it is considered a privileged scaffold.612

77

O

O
OH

O

S

O

N

N

OH
S

S

CF3

49

50

Br

O

N

N
N

NH
S

51

O

S

O

Figure 1.26: Structures of arylalkylidene rhodanine and arylalkylidine iminothiazolidin-4-one
transpeptidase inhibitors.

S

S

NH
S

O
R

arylalkylidene
rhodanine

Nu

NH
S
Nu

O

O

H 2O

HS
Nu

R

Michael addition product

OH
R

hydrolysis product

Figure 1.27: Proposed mechanism of arylalkylidene rhodanine PBP inhibition.

78

Table 1.12: Activity of arylalkylidene rhodanines and arylalkylidene iminothiazolidin-4-ones against
bacterial transpeptidases. aHalf-maximal inhibitory concentration (IC50). bPercent inhibition at 50
µM. cPercent inhibition at 100 µM.

Compound

49

Species
S. aureus
S. pneumoniae
S, pneumoniae
E. coli
E. coli
Streptomyces spp.
Actinomadura spp.

50

S. aureus
S. pneumoniae
S, pneumoniae
E. coli
E. coli
Streptomyces spp.
Actinomadura spp.

51

N. gonorrhoeae

Target
PBP2a
PBP2x, S
PBP2x, R
PBP3
PBP5
R61 DDpeptidase
R39 DDpeptidase
PBP2a
PBP2x, S
PBP2x, R
PBP3
PBP5
R61 DDpeptidase
R39 DDpeptidase
PBP2

Activity
5 µMa
96%b
90% c
87% b
94% b

Reference

620

75% b
95% b
9 µMa
31% b
90%c
86% b
83% b

620

44% b
55% b
153 µMa

621

1.5.d. Noncovalent inhibitors
Physical screening of molecules against PBPs has resulted in the discovery and
development of many classes of noncovalent inhibitors, but very few have been pursued
for optimization and development into preclinical leads. Some initial hits were found
serendipitously in the course of other experiments, followed by more purposeful physical
screening (Figure 1.28). In early studies of S. aureus PBP2a, it was noted that
chromatographic stationary phase Cibacron blue (52) bound the protein tightly, such that
it would not elute upon introduction of a salt gradient.624 Subsequent testing of Cibacron
blue revealed that it is a mid-micromolar inhibitor of PBP2a, and screening of chemically
similar compounds from a Merck collection allowed the identification of the more potent
Erie yellow (53), which exhibits an IC50 of 13 µM. No antimicrobial data was reported for
these hits, however. In another study, a PBP inhibitor was found by testing a hit from
screens against a different enzyme. Physical screening of a cyclic heptapeptide
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bacteriophage display library revealed 54 to inhibit activity of a synthetic catalytic antibody
with β-lactamase-like activity.625 During biochemical characterization, 54 was found to
inhibit TEM-1, as well as several high- and low-molecular weight PBPs to varying
degrees.626 Although this scaffold was subject to some minor derivatization, the βlactamases were the primary focus of this work, and none of the analogues were tested
against PBPs. No antimicrobial data was reported from these studies.
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Figure 1.28: Structures of transpeptidase inhibitors discovered through serendipity.
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Focused physical screening with the aim of discovering more drug-like small
molecule PBP inhibitors followed these initial ventures (Figure 1.29). One class of such
inhibitors was identified from small parallel physical screens against MRSA PBP2a,
Streptococcus pneumoniae PBP2x, and Enterococcus faecium PBP5.627 The screen and
subsequent analogue search, synthesis, and testing identified anthranilic acid-derived
arylsulfonamides and their isosteric arylamide derivatives as mid- to high-micromolar
inhibitors of the tested PBPs.627,628 The most potent inhibitors from each scaffold, 55 and
56, exhibit half-maximal inhibition of MRSA PBP2a at 80 µM and 210 µM, respectively.
Both compounds show only marginal suppression of staphylococcal growth, however.
Shortly thereafter, high-throughput screening of a 50,000-compound library from the
ChemBridge Corporation identified a number of compounds that exhibit activity against N.
gonorrhoeae PBP2 in the micromolar range.621 While a few of the compounds from this
study possess functional groups concerning for nonspecific binding (e.g., arylalkylidene
rhodanine 51 above), arylsulfonamides 57 and 58 are promising hits, exhibiting halfmaximal inhibition of PBP2 at 50 µM and 56 µM, respectively, as well as comparable
activities against penicillin-susceptible and -resistant strains of N. gonorrhoeae (MIC = 816 µg/mL).621
Screening for antimicrobial natural products has also successfully identified PBPinhibitory compounds. The endophytic fungus Aspergillus TJ23 was found to inhibit the
growth of ATCC43300 (MRSA) in vitro.629 Subsequent separation of liquid culture
components yielded the active species 59, a meroterpenoid metabolite with a
dioxabicyclo[2.2.1]heptane skeleton. This compound, named aspermerodione, inhibits
MRSA growth at 32 µg/mL and PBP2a at 18.4 µM.
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Figure 1.29: Structures of transpeptidase inhibitors identified through physical screening methods.

In addition to physical screening, in silico tools have also been utilized for PBP
drug discovery because this approach forgoes the need for large physical libraries, a highthroughput transpeptidase assay or liquid handling robot, or large repositories of natural
product sources (Figure 1.30). One early study employed a four-point pharmacophore
model to conduct a high-throughput virtual screen of the NCI database (~260,000 ligands)
against S. pneumoniae PBP2x.630 The screen successfully identified 2-((1,3,4-thiadiazol2-yl)amino)benzenesulfonic acid 60 and 2-ureidobenzenesulfonic acids 60 and 61 as
inhibitors of PBP2x. While 61 and 62 show similar potency against PBP2x from penicillinresistant S. pneumoniae 5204 (IC50 = 71 µM and 72 µM, respectively), 62 shows
significantly better inhibition of PBP1b.
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In another study, a fragment-based docking protocol was used against the active
site of E. coli PBP5.631 The computational analysis revealed the 4-quinolone scaffold as a
putative binder of the active site, and upon synthesis of derivatized 4-quinolones, several
were shown to inhibit high molecular weight PBPs of E. coli at mid-micromolar
concentrations. While the best inhibitor reported, 63, demonstrates affinity for every PBP
from E. coli, this compound showed no suppression of E. coli growth up to 1 mM.
Among the most successful noncovalent PBP inhibitors discovered to date are the
1,2,4-oxadiazoles (Figure 1.30). The prototype of this class, 64, was identified from a
high-throughput virtual screen of the ZINC database against MRSA PBP2a, with energy
scoring performed by four separate algorithms.632 The hydroxyl derivative 65 is a
micromolar-range inhibitor of PBP2a with antimicrobial activity against a series of Gram
positive organisms (MIC = 1-2 µg/mL against a series of staphylococci and enterococci).
The compound was also observed to be on-target, inhibiting [3H]-alanine incorporation into
peptidoglycan without effects on the synthesis of protein or polynucleotides. From
extensive exploration of the scaffold through medicinal chemistry, 66 has emerged as a
promising antimicrobial candidate, exhibiting favorable pharmacokinetic properties as well
as efficacy in a murine model of staphylococcal peritonitis.633-635 While the 1,2,4oxadiazoles have excellent activity against staphylococci and other Gram positives,634-636
no antimicrobial data against Gram negative organisms has been published. Additional
computational work has been done to determine quantitative structure-activity
relationships (QSAR) for the class using comparative molecular field analysis (CoMFA),
comparative molecular similarity indices analysis (CoMSIA), and field-based 3D-QSAR,
but no compounds designed with the guidance of these models have been reported.637
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While many of the noncovalent PBP inhibitors mentioned here are in need of
additional testing and medicinal chemistry to achieve standards of potency and selectivity
required of a preclinical lead, these studies suggest that novel classes of PBP-targeted
drugs may provide a workable route toward antimicrobials that 1) circumvent the changes
associated with resistance that affect β-lactam binding, and 2) proactively avoid the
potential issue of ESBL acquisition by N. gonorrhoeae. Moreover, because there are so
few examples of successful compounds from which to draw, this is an area of need in
antigonococcal therapeutic discovery.
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Table 1.13: Activity of noncovalent inhibitors against bacterial transpeptidases. aHalf-maximal
inhibitory concentration (IC50) unless otherwise noted. bPercent inhibition at 1 mM.
c
Thermodynamic equilibrium constant (Ki)
Compound
52
53

54

Species
S. aureus
S. aureus
E. coli
E. coli
E. coli
E. faecium
Streptomyces spp.

55

56
57
58
59
60
61
62

63
65

S. aureus
E. faecium
S. pneumoniae
S. aureus
E. faecium
S. pneumoniae 5204
N. gonorrhoeae
N. gonorrhoeae
S. aureus
S. pneumoniae 5204
S. pneumoniae 5204
S. pneumoniae R6
S. pneumoniae
S. pneumoniae 5204
S. pneumoniae R6
S. pneumoniae
E. coli
E. coli
E. coli
E. coli
E. coli
S. aureus

Target
PBP2a
PBP2a
PBP1b
PBP3
PBP5
PBP5
R61 DD-

peptidase
PBP2a
PBP5
PBP1b
PBP2a
PBP5
PBP2x
PBP2
PBP2
PBP2a
PBP2x
PBP2x
PBP2x
PBP1b
PBP2x
PBP2x
PBP1b
PBP1a/1b
PBP2
PBP3
PBP4
PBP5/6
PBP2a

Activitya
24 µM
13 µM
28.6 µM
62.5 µM
6.3 µM
21.6 µM

Reference
624
624

626

26.8 µM
80 µM
0%b
60%b
210 µM
32%b
59%b
50 µM
56 µM
18.4 µM
219 µM
71 µM
336 µM
259 µM
72 µM
255 µM
88 µM
27 µMc
26 µMc
27 µMc
4.8 µMc
220 µMc
8 µg/mL

628

627
621
621
629
630
630
630

631
632
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1.6. Goal and Significance
With the emergence and spread of multi-drug resistant strains, the therapeutic
landscape for Neisseria gonorrhoeae has become increasingly barren. The bacterium has
demonstrated a strong proclivity for development of resistance against each FDAapproved therapy tried in the last 90 years. Furthermore, any existing FDA-approved
alternatives suffer from some weakness, and other experimental therapies that show
promise are still in the early stages of their development. For this reason, continued efforts
to identify antigonococcal compounds using all avenues of drug discovery (e.g.,
repurposing of FDA-approved therapies, in silico tools, physical screening, etc.) are
necessary to ensure a future in which disease caused by this pathogen is still treatable.
Much work has been done in our laboratory regarding the structural mechanisms
of PBP2-mediated β-lactam resistance in Neisseria gonorrhoeae. In the past several
years, our efforts have been focused on determining how specific amino acid changes in
mosaic PBP2, including that expressed by strain H041, affect its structure, function, and
ability to bind various β-lactams. In this project, the focus was reframed toward the ligand
to examine what features are shared among active compounds with the goal of designing
new compounds, or unearthing existing ones, capable of inhibiting PBP2 variants from
both β-lactam-susceptible and -resistant strains. Here, we report data from three studies.
The first is an analysis of the structure-activity relationships for inhibition of PBP2H041 by
cephalosporins, as well as for antimicrobial activity against the strain itself. The second
applies the knowledge gained from the structure-activity relationships to discover several
novel scaffolds capable of inhibiting PBP2. Finally, the third explores the chemical space
surrounding one of the identified scaffolds using medicinal and synthetic chemistry in order
to improve potency and begin the process of hit-to-lead optimization.
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CHAPTER 2: Materials & Methods
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2.1. Materials
Fifth Generation cephalosporins were kindly provided by Basilea (ceftobiprole),
Merck (ceftolozane), and Allergan (ceftaroline). Other cephalosporins were purchased
from TCI America Inc, Sigma Aldrich Inc, and Alfa Aesar Inc, and Bocillin-FL was
purchased from ThermoFisher Scientific Inc. Compounds coded NSC in the text were
kindly provided by the Developmental Therapeutics Program at NCI from their Open
Chemicals Repository. Compounds coded Z/EN, CB, and STK/STL were purchased from
Enamine Ltd, ChemBridge Corp, and Vitas-M Chemicals Ltd, respectively.
2.2. Biochemical and microbiological methods
2.2.a. Cloning, expression, and purification of truncated N. gonorrhoeae PBP2
constructs
Truncated constructs comprising only the transpeptidase domain of PBP2 (tPBP2)
were generated as previously described.389 The expression construct was transformed
into Escherichia coli BL21 (DE3) cells; 2 L of cell culture were grown at 37 °C, and protein
expression was induced by addition of 0.3 mM isopropyl β-D-thiogalactoside, followed by
overnight incubation at 20 °C. Cells were harvested by centrifugation, lysed in 20 mM TrisHCl (pH 8.0), 500 mM NaCl, and 10% glycerol (TNG), and the MBP-PBP2 fusion protein
was purified on a 5 mL HisTrap FF Ni2+ affinity column (GE Healthcare, Piscataway, NJ).
The fusion protein was pooled, mixed with His6-tagged TEV protease at a molar ratio of
50:1, and dialyzed overnight at 4 °C against TNG to allow cleavage of the fusion protein
and to remove imidazole. The resulting digest was then passed over a 5 mL HisTrap HP
column equilibrated with TNG. Purified tPBP2 did not elute in the flow-through but instead
was eluted by a TNG/15 mM imidazole step gradient. Uncleaved fusion protein, His6-TEV,
and His6-maltose-binding protein remained bound to the column and were eluted with a
TNG/250 mM imidazole wash step. The purified protein was pooled, dialyzed into 20 mM
Tris (pH 8.0), 500 mM NaCl, and 10% glycerol, and concentrated by ultrafiltration.
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2.2.b. Site directed mutagenesis of tPBP2H041
A K361E mutation was introduced into tPBP2H041 using the QuikChange Lightning
Kit (Agilent, Santa Clara, CA). The forward 5’-CATTATGCAAGAATCTTCCAACGTCG-3’
and reverse 5’-CCGCGCACATCCAAAGTA-3’ primers were used to amplify the plasmid
DNA containing penA41 as per the manufacturer’s recommended protocol. The amplified
PCR product was treated with Dpn1 enzyme and then used to transform in E. coli BL21
(DE3) cells. The mutant was confirmed by sequencing.
2.2.c. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)based binding assay for Bocillin-FL
The rate of acylation of PBP2 by the fluorescent Bocillin-FL638 was determined by
time-course kinetics experiments in which 1 μM tPBP2 was incubated with Bocillin-FL
under pseudo-first order conditions. Aliquots were removed at specified time points
between 2 seconds and 1 hour, and the reaction quenched by 4X SDS-PAGE sample
buffer. Samples were heated at 95°C for 2 minutes, and acylated protein was separated
from free Bocillin-FL using 12% Mini-Protean TGX SDS-PAGE gels. Gels were scanned
using a Kodak EDAS 290 UV imaging system, followed by staining with Coomassie R-250
to confirm equal loading. Bocillin-FL-bound PBP2 was quantified by densitometry using
ImageJ.639 Data were normalized to the maximum fluorescence intensity and fit to a onephase association curve to determine pseudo-first order rate constants, which were
plotted against Bocillin-FL concentration and fit to a linear regression to give the secondorder acylation rate as the slope.
2.2.d. SDS-PAGE-based competition binding assay for β-lactams
Acylation rates for β-lactam compounds were derived by determining the
concentration of β-lactam required to inhibit half the binding of a known amount of BocillinFL. tPBP2 was co-incubated with a specified concentration of Bocillin-FL (10 or 100 μM)
and increasing concentrations (1 μM to 1 mM) of β-lactam for 1 hour. Samples were
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denatured, separated by SDS-PAGE, and imaged as above. Data were normalized to the
maximum fluorescence intensity and fit to a four-parameter inhibitor-response curve to
determine half-maximal inhibitory concentrations (IC50), and the acylation rates of the βlactams were determined by the following relationship:

𝑘%.
𝑘%
𝐾& (𝐵𝑂𝐶) ∙ [𝐵𝑂𝐶 ] = .𝐾& (𝛽𝐿) ∙ 𝐼𝐶'( (𝛽𝐿)
2.2.e. SDS-PAGE-based binding assay for noncovalent inhibitors
Potency of noncovalent inhibitors was measured by determining the concentration
of compound required to inhibit half the binding of a known amount of Bocillin-FL. PBP
was incubated with 1 µM to 1 mM test compound for one hour, followed by the addition of
1 µM Bocillin-FL. The reaction was allowed to proceed for a time period corresponding to
the linear phase of Bocillin-FL binding for the PBP used. Samples were denatured,
separated by SDS-PAGE, and imaged as above. Data were normalized to the maximum
fluorescence intensity to give fractional residual activity. For IC50 determinations, data
were then fit to a four-parameter inhibitor-response curve.
2.2.f. Crystallization of tPBP2H041 in complex with cefoperazone
tPBP2H041 was concentrated to 13 mg/mL, and crystallization conditions were set
using a Gryphon liquid dispensing system (Art Robbins, Sunnyvale, CA, USA) in a 96-well
sitting drop format in which 200 nL protein solution was mixed with 200 nL well solution.
Crystals were obtained at 18°C over wells containing 37-40% PEG 600, buffered with 0.1
M CHES at pH 9.1-9.3. Crystals appeared after 3-4 days and exhibited a plate-like
morphology.
To generate an acylated complex of tPBP2H041, crystals were soaked in a 60 mM
solution of cefoperazone for 30 minutes at room temperature, followed by flash freezing
without adding cryo-protectant. Diffraction data were collected at a wavelength of 1.00 Å
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on a MX300-HS detector at the SER-CAT 22-BM beamline at the Advanced Photon
Source in Argonne, IL, USA. 360° of data were collected in 1° oscillations, with an
exposure time of 2 s/frame and a crystal-to-plate distance of 220 mm, and were processed
using HKL2000.640 The structure was solved by refinement of the tPBP2H041 structure.
Cefoperazone was modeled using the |Fo|-|Fc| difference electron density map, followed
by iterative cycles of model building and refinement using the graphics programs O641 or
COOT642, and REFMAC.643 The stereochemistry of models was analyzed with
PROCHECK.644
2.2.g. Disc diffusion against Neisseria gonorrhoeae
N. gonorrhoeae (FA19 and H041) was streaked onto gonococcal medium base
(GCB) agar plates and incubated overnight at 37°C under 5% CO2. The next day, N.
gonorrhoeae growth was collected from the overnight plates, resuspended in GCB+
(composed of GCB broth, supplements I and II, 20 mM NaHCO3, and 10 mM MgCl2), and
diluted to a final OD600 of 0.18. Aliquots of dilute gonococcal cells (200 µL, ~50,000 CFU)
were added to 3 mL GCB top agar (GCB broth + 0.7% agar), and the mixtures were gently
poured onto new GCB plates and allowed to set. For each compound tested, 5 µL of a 2
mg/mL solution in DMSO (10 µg total) was pipetted onto a disc, and each disc was placed
on a prepared plate. Plates were then incubated at 37°C under 5% CO2 for 24 hours, at
which time the diameter of the zone of inhibition was measured. These experiments were
conducted in the laboratory of Robert Nicholas, PhD, at the University of North Carolina
Chapel Hill.
2.2.h. Minimum inhibitory concentrations against Neisseria gonorrhoeae
Neisseria gonorrhoeae H041 was passaged on GCB plates and resuspended at
an OD600 of 0.18. GCB plates containing 2-fold changes in concentrations of test
compound were poured on the day of the experiment, and agar dilution minimum inhibitory
concentrations (MIC) were determined by the spot method. Briefly, aliquots (~50,000
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CFU) of each clone were spotted onto the antimicrobial-containing plates, and the plates
were incubated overnight. The next morning, the plates were examined, and the MIC was
reported as the lowest concentration of antimicrobial suppressing growth (growth is
defined as > 5 colonies growing in the spot of inoculation). MIC determinations were
repeated a minimum of two times. These experiments were conducted in the laboratory of
Robert Nicholas, PhD, at the University of North Carolina Chapel Hill.
2.3. Computational methods
2.3.a. Pharmacophore-constrained docking of β-lactams against tPBP2 variants
Structures used in pharmacophore-constrained docking experiments can be
accessed through the Protein Databank. PDB accession codes: 6P53 (tPBP2WT
apoenzyme), 6P54 (tPBP2WT-ceftriaxone), 6VBC (tPBP2H041 apoenzyme), 6VBD
(tPBP2H041-ceftriaxone). tPBP2 coordinates were prepared by protonation at pH 7.4,
explicit solvation with water, and minimization under the AMBER12 forcefield.645 The
minimized structure was then allowed to relax by with a short (1,000 ps) molecular
dynamics simulation at 2 fs resolution using the Nosé-Poincaré-Andersen (NPA)
algorithm.646 A pharmacophore model was then generated to constrain the β-lactam ring
to the area surrounding Ser310 of PBP2, including the oxyanion hole formed by Ser310
and Thr500. Selected β-lactams were then docked to the receptor using an induced-fit
protocol in which compounds were first placed in the active site using the pharmacophore
and scored using the London dG algorithm. The top 50 scored conformers were then refined
against the AMBER12 forcefield with flexible rotation of receptor side chains and rescored
using GBVI/WSA dG algorithm. All rescored conformers were retained for analysis by
energy score amplitude, as well as protein-ligand interaction fingerprint (PLIF). All
calculation used Molecular Operating Environment 2018.01.
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2.3.b. Quantitative-structure activity relationship (QSAR) for cephalosporins
against N. gonorrhoeae H041
Partial least squares (PLS) analysis was used to examine the relationship between
activity measurements, reported as log(k2/Ks), and descriptor variables, including
structural and molecular properties of the cephalosporins tested. The generated PLS
model was validated using the square of the correlation coefficient obtained by the leaveone-out cross-validation method. The resulting model was also validated using yrandomization, as well as application to a small test set of null cephalosporins. All
analyses, including descriptor calculations and PLS model generation, were conducted in
MOE 2018.01.
To examine the relationship between MICs and molecular descriptors, a
classification QSAR model was developed, with an activity cutoff set at median MIC ≤ 4
μg/mL. Cefdinir consistently modeled as an outlier, as it exhibits a low rate of PBP2
acylation and yet has high antimicrobial potency, and likely has a different mechanism of
action (e.g., rapid PBP1 acylation). For this reason, it was excluded from the model. The
generated classification model was validated using the leave-one-out cross-validation
method, as well as by y-randomization. All analyses, including descriptor calculations and
model generation, were conducted in MOE 2018.01.
2.3.c. Homology modeling and rigid alignment of class B PBPs
To generate homology models of class B penicillin-binding proteins, amino acid
sequences were obtained from the NCBI Protein database and used as templates in the
SWISS-MODEL server.647 Template searching and target-template sequence alignment
were then performed by BLAST and HHBlits analysis of the PDB repository to identify
structural models of highly similarity. The best templates were selected according to
sequence identity, quality of the available structural data, and the Global Model Quality
Estimation (GMQE). Models were exported to the Structural Analysis and Verification
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Server (SAVES) v5.0, and their overall stereochemical quality was checked in
PROCHECK. Crystal structures of additional class B PBPs were accessed (PDB
accession codes can be found in Table 3.6), and all models were subjected to sequence
alignment and rigid-body superposition to examine conservation of residues.
2.3.d. tPBP2-ceftriaxone structure-guided docking of JEK-42 and JMT-1 to tPBP2
variants
Using tPBP2-ceftriaxone complex coordinates (tPBP2WT-ceftriaxone: 6P54,
tPBP2H041-ceftriaxone: 6VBD), pharmacophore constraints were placed around the
cephem C4 carboxylate (CO2- centroid, radius 2.0 Å) and the acyl carbonyl oxygen
(hydrogen bond acceptor, radius 1.0 Å). The receptor was prepared for docking by the
deletion of ceftriaxone from the active site and subsequent protonation at pH 7.4.
Prototype PBP2 inhibitors (amide JEK-42 and sulfonamide JMT-1) were then docked to
the receptor using an induced-fit protocol in which ligands were first placed in the active site
using the pharmacophore and scored using the London dG algorithm. The top 10 scored
conformers were then refined against the AMBER12 forcefield with flexible rotation of
receptor side chains and rescored using the GBVI/WSA dG algorithm, and the top rescored
conformer was retained. The tPBP2-JMT complex was prepared for molecular dynamics
by explicit solvation with water and minimization under AMBER12 forcefield. The
minimized structure was then allowed to equilibrate with a short (100 ps) molecular
dynamics simulation (NPA algorithm, time step = 2 fs) with constraints placed on bond
length. After equilibration, the solvated complex underwent 5 ns of molecular dynamics
without constraints, and the overall structure of the complex, energies of ligand-receptor
interaction, and trajectories of ligands were analyzed. These experiments were conducted
in MOE 2018.01.
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2.3.e. Virtual screening of fragments against a three-point pharmacophore
The base structures of JEK-42 and JMT-1, N-acetylanthranilic acid and N(methylsulfonyl)anthranilic acid, were flexibly aligned to the bicyclic penam, carbapenem,
and cephem systems using a stochastic conformational search. From the alignment, a
consensus pharmacophore was generated using a 100% threshold and 1.0 Å tolerance,
yielding a model with three features: anionic (radius = 0.7 Å), hydrophobic/aromatic (radius
= 0.9 Å), and hydrogen bond accepting (radius = 1.0 Å). This model was used to screen
a custom ZINC library of 790,417 molecular fragments, defined as having a molecular
weight < 250, for matching structures. This experiment was conducted in MOE 2018.01.
2.3.f. Validation of in silico methods for Pseudomonas aeruginosa PBP3
β-lactam antibiotic structures were uploaded to the Database of Useful Decoys:
Enhanced (DUD-E) server,648 and physicochemically matched decoy structural files were
generated. All structures, true ligands and decoys, were combined into a single file for
docking. The transpeptidase domain of PBP3 (PDB accession code: 3PBN) was prepared
for docking using by protonation at pH 7.4, addition of partial charges, and the
identification of potential binding sites by the calculation of alpha spheres. True ligands
and decoys were then docked flexibly to the receptor using the rigid-receptor DOCK6.5
protocol with 1,000 orientations.649 The compounds were scored against the AMBER
forcefield and ranked. Receiver operator and enrichment curves were generated from the
docking scores and ranks, and an area under the curve (AUC) was calculated for each.
Using MOE 2018.01, coordinates for the transpeptidase domain of PBP3 prepared
by removal of crystallographic waters and ions, correction of structural incompletions,
addition of partial charges, and protonation at physiologic pH. The structure was then
energy minimized and allowed to relax with a short (500 ps) molecular dynamics
simulation at 2 fs resolution using the NPA algorithm. The active site was defined by the
cluster of alpha spheres containing the active serine residue (Ser294), and the database
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of β-lactams and decoys was then docked flexibly to the defined site using triangle matching.
Top conformers were refined against the AMBER12 forcefield with flexible rotation of
receptor side chains, and conformers were ranked via GBVI/WSA dG scoring. Receiver
operator and enrichment curves were generated from the docking scores and ranks, and an
AUC was calculated for each.
2.3.g. In silico virtual screen against Pseudomonas aeruginosa PBP3
A custom library of 100,000 ligands derived from the ZINC database650 was docked
to previously prepared P. aeruginosa PBP3 coordinates using the rigid-receptor DOCK6.5
protocol above. Ranked ligands with docking scores two standard deviations below the
mean of all docked compounds (Z < -2) were selected for consensus analysis via an
induced-fit docking protocol in MOE2018.01 as done for the database of β-lactams and
decoys above. Molecules were scored according to their overall binding by both protocols
(i.e., sum of ranks), as well as agreement between protocols (i.e., difference between ranks).
2.4. Synthetic methods
2.4.a. Synthesis of 5-fluoro-2-(4'-methyl-[1,1'-biphenyl]-4-carboxamido)benzoic acid
(JEK-42)
To a solution of 4’-methyl-[1,1’-biphenyl]-4-carboxylic acid (1.0 eq) in DCE were
added oxalyl chloride (1.1 eq) and DMF (cat.) with stirring. Acyl chloride formation was
allowed to proceed for 12 hours at room temperature. Volatiles were removed under
reduced pressure to give 4’-methyl-[1,1’-biphenyl]-4-carbonyl chloride, which was used
without further workup. A solution of methyl 2-amino-5-fluorobenzoate (1.0 eq) in
anhydrous DCM was added, followed by pyridine (1.0 eq) portionwise, and the reaction
was allowed to proceed at room temperature for 8 hours. After completion, as determined
by TLC, the reaction was acidified to pH 2 with 1 M HCl, and the product was extracted
with dichloromethane. The combined organic phases were washed with saturated
NaHCO3 and brine, dried over Na2SO4, and filtered. Solvent was then removed under
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reduced pressure, and the crude reaction mixture was purified by trituration using
dichloromethane and hexanes.
To a stirred solution of product methyl 5-fluoro-2-(4'-methyl-[1,1'-biphenyl]-4carboxamido)benzoate in tetrahydrofuran, 1 M aqueous LiOH (2 eq) was added. The
reaction was allowed to proceed with stirring at room temperature overnight. Solvent was
then evaporated under reduced pressure, and the residue was subsequently diluted with
water and acidified to pH 2 using 1 M HCl. The mixture was then extracted using EtOAc,
and the combined organic phases were washed with brine, dried over Na2SO4, and filtered.
Solvent was then removed under reduced pressure to provide 5-fluoro-2-(4'-methyl-[1,1'biphenyl]-4-carboxamido)benzoic acid as a white solid. The product was purified by normal
phase flash chromatography using a dichloromethane / methanol mobile phase. Products
needing additional purification were recrystallized from ethyl acetate and hexanes.
2.4.b. General procedure I: Synthesis of 2-(arylsulfonamido)benzoic acids
Arylsulfonyl chloride (1.0 eq) and methyl 2-aminobenzoate (1.0 eq) were dissolved
in anhydrous dichloromethane and stirred for 10 minutes, at which time pyridine (1.0 eq)
was added dropwise. The reaction was allowed to proceed with stirring at room
temperature for 12 h. After completion, as determined by TLC, the reaction was acidified
to pH 4 with 1 M HCl, and the product was extracted with dichloromethane. The combined
organic phases were washed with brine, dried over Na2SO4, and filtered. Solvent was then
removed under reduced pressure, and the crude reaction mixture was purified by
trituration using dichloromethane and hexanes.
To a stirred solution of product methyl 2-(arylsulfonamido)benzoate in
tetrahydrofuran, 1 M aqueous LiOH (2 eq) was added. The reaction was allowed to
proceed with stirring at room temperature overnight. Solvent was then evaporated under
reduced pressure, and the residue was subsequently diluted with water and acidified to
pH 2 using 1 M HCl. The mixture was then extracted using EtOAc, and the combined
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organic phases were washed with brine, dried over Na2SO4, and filtered. Solvent was then
removed

under

reduced

pressure

to

provide

the

corresponding

2-

(arylsulfonamido)benzoic acid as an off-white solid. The product was purified by normal
phase flash chromatography using a dichloromethane / methanol mobile phase. Products
needing additional purification were recrystallized from ethyl acetate and hexanes.
2.4.c.
General
procedure
yl)phenyl)benzenesulfonamides

II:

Synthesis

of

N-(2-(1H-tetrazol-5-

Arylsulfonyl chloride (1.0 eq) and methyl 2-aminobenzonitrile (1.0 eq) were
dissolved in anhydrous dichloromethane and stirred for 10 minutes, at which time pyridine
(1.0 eq) was added dropwise. The reaction was allowed to proceed with stirring at room
temperature for 12 h. After completion, as determined by TLC, the reaction was acidified
to pH 5 with HCl, and the product was extracted with dichloromethane. The combined
organic phases were washed with brine, dried over Na2SO4, and filtered. Solvent was then
removed under reduced pressure, and the crude reaction mixture was purified by
trituration using dichloromethane and hexanes.
To a stirred solution of product 2-(arylsulfonamido)benzonitrile (1.0 eq) in DMSO,
sodium azide (1.0 eq) and copper(II) sulfate (0.02 eq) were added. The reaction was
heated to 150 °C and allowed to proceed with stirring for 1 h. After cooling, the reaction
mixture was diluted with water and acidified to pH 2 using 1 M HCl. The mixture was then
extracted using EtOAc, and the combined organic phases were washed with brine, dried
over Na2SO4, and filtered. Solvent was then removed under reduced pressure to provide
the corresponding N-(2-(1H-tetrazol-5-yl)phenyl)benzenesulfonamide as an off-white
solid. The product was purified by normal phase flash chromatography using a
dichloromethane / methanol mobile phase. Products needing additional purification were
recrystallized from ethyl acetate and hexanes.
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CHAPTER 3: Structure-Activity Relationships of Cephalosporins against
Penicillin- and Cephalosporin-Resistant Neisseria gonorrhoeae H041
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3.1. Introduction
The cephalosporins are a structurally diverse class of antibiotics divided into
generations based on their timeline of development, as well as specific medicinal chemical
modifications that affect activity and antimicrobial spectrum. While the 3rd generation
agents cefixime and ceftriaxone have been the most commonly prescribed cephalosporins
for gonorrhea over recent years, few members of this class have been tested against ESCresistant (ESCR) strains. This is especially the case for 4th and 5th generation
cephalosporins such as ceftaroline and ceftobiprole that have been approved relatively
recently. Building structure-activity relationships (SAR) for cephalosporins against their
PBP2 target and an ESCR strain of N. gonorrhoeae offers the potential to address ESCR
N. gonorrhoeae in two ways: it may reveal existing FDA-approved cephalosporins that
exhibit efficacy against such strains, and suggest ways in which the efficacy of specific
cephalosporins can be improved by chemical modification.
Here, we report a quantitative structure-activity relationship (QSAR) of 22
cephalosporins for inhibition of PBP2 from H041 and antimicrobial activity against N.
gonorrhoeae. The data reveal key features of cephalosporins that enhance formation of the
precovalent PBP2-cephalosporin complex, as well as those that may independently hinder
or enhance antimicrobial activity. The study also reveals that FDA-approved agents
cefoperazone (Cefobid, Pfizer), ceftaroline (Teflaro, Allergan), and ceftobiprole (Zevtera,
Basilea) acylate mosaic PBP2 at higher rates than ceftriaxone, and that cefoperazone
exhibits higher antimicrobial activity against H041. Overall, our data reveal there is
considerable potential in adopting and/or adapting these cephalosporins as anti-gonococcal
agents to address ESCR N. gonorrhoeae.
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3.2. Computational predictions of precovalent cephalosporin-PBP2 interactions
3.2.a. Pharmacophore-constrained docking of cephalosporins against tPBP2H041
In order to identify residues of PBP2 involved in the recognition of cephalosporins
in the precovalent complex, cephalosporins were docked to the active site of tPBP2H041. A
pharmacophore constraint (shown in Appendix A) was used to confine the β-lactam ring
system to the area around the Ser310 nucleophile and the oxyanion hole formed by the
amide nitrogens of Ser310 and Thr500, and the refined poses for all compounds remained
largely within the volume specified. Protein-ligand interaction fingerprints (PLIF) of all
poses were generated for each molecule, their interactions with individual residues were
analyzed by frequency and type of interaction (Figure 3.1), and the predominant
interactions were used to generate a consensus pharmacophore (Figure 3.2).
For all cephalosporins, S310 and T500 contact the β-lactam carbonyl oxygen with
side chain and main chain hydrogen bonding interactions, respectively, while K313 and
K497 are predominantly involved in side chain ionic interactions with the cephem C4
carboxylate group. In addition, most of the cephalosporins contact T347, K361, S483, and
S545. The C4 carboxylate moiety participates in additional hydrogen bonding interactions
with the hydroxyl group of S483, and in most poses, S1 of the cephem dihydrothiazine
ring participates in weak hydrogen bonding with the side chain hydroxyl group of T347.
Electronegative elements of many of the cephalosporin R2 groups make side chain and
main chain polar contacts with K361, including the thiotriazinone (TTN) moiety of
ceftriaxone (Figure 3.3A). Finally, the common amide moiety of all R1 groups makes
variable polar contacts within the active site. In some poses, the amide nitrogen
participates in hydrogen bonding with S545 and the carbonyl oxygen with N364, while in
others, the C7-N bond is rotated such that the carbonyl oxygen interacts with S545. This
rotation also affects the position of the R1 aromatic ring systems of several cephalosporins,
leading to two distinct conformational states: one in which the rings reach toward the
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hydrophobic pocket formed by Y422 on the α8-β2f loop, and one in which they project
toward Y544 on the β5-α11 loop (Figure 3.3B). The aromatic rings do not make
substantial formal contacts with the active site in either of these conformations, however.
Closer inspection of the poses reveals two possible binding modes for all
cephalosporins examined: a “major pose” is observed for approximately 60% of poses
(131/220), and a “minor pose” for 40% (89/220) (Figure 3.4). While there appear to be to
no differences in docked energy scores for the major pose (-6.39 ± 0.56 kcal·mol-1) over
the minor pose (-6.54 ± 0.79 kcal·mol-1, p = 0.17), compounds with faster acylation rates
tend to occupy the minor pose (OR = 0.38, p = 0.01). Representative examples of each
pose for ceftriaxone and cefoperazone are shown in Figure 3.5. In the major pose, the C4
carboxylate of the cephalosporin interacts with Oɣ of S483, and the β-lactam ring is
positioned away from the nucleophile (Figure 3.5A and C). In the minor pose, the
carboxylate is situated within the hydrogen bonding network created by K313 and S310,
bringing the β-lactam ring in closer proximity to S310 (Figure 3.5B and D). Interestingly,
neither pose overlaps with ceftriaxone observed in the crystal structure of tPBP2H041
acylated by this antibiotic134 (Figure 3.6). Of the two binding modes, the minor pose
appears more favorable for initiation of the acylation reaction. The β-lactam carbonyl is
well-situated for attack by the Oɣ of S310 and for subsequent stabilization of the resulting
tetrahedral intermediate by the oxyanion hole created by the amides of S310 and T500
(Figure 3.5B and D).
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Figure 3.1: Protein-ligand interaction fingerprints (PLIFs) for pharmacophore-constrained induced-fit
docking of cephalosporins to tPBP2H041. A. Heat map of cephalosporin-tPBP2H041 interactions colored
by number of poses interacting with a given residue. B. Heat map of cephalosporin-tPBP2H041
interactions, colored by the cephalosporin moiety interacting with a given residue. Key: cefoperazone
(CFP), ceftaroline (CPT), ceftobiprole (BPR), ceftriaxone (CRO), ceftizoxime (ZOX), cefotaxime (CTX),
ceftazidime (CAZ), cefixime (CFM), cefepime (FEP), cefpodoxime (CPD), ceftolozane (TOL), cefdinir
(CDR), cefaclor (CEC), ceftibuten (CTB), cefuroxime (CXM), cefmetazole (CMZ), cefoxitin (FOX),
cefsulodin (CFS), cephalexin (LEX), cefazolin (CFZ), cephalothin (LOT), cephaloridine (LOR)
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Figure 3.2: Consensus pharmacophore generated from all docked poses of cephalosporins in tPBP2H041, set against a
representative pose of ceftriaxone. The radius of the sphere indicates the variance of a given feature across all poses.

Figure 3.3: Positioning of the R1 and R2 groups of ceftriaxone within the active site of tPBP2H041.
A. The thiotriazinone (TTN) R2 of ceftriaxone (CRO, orange) makes contact with K361 (yellow) in
a majority of docked poses. B. The 2-(aminothiazol-4-yl)-2-(alkoxyiminoacetyl) (ATAO) R1 group of
CRO (orange) adopts two conformations in the docked poses, consistent with electron density seen
in the published crystal structure of tPBP2H041 acylated by ceftriaxone.134 In each conformation, R1
is in close proximity to Y422 or Y544 (both yellow).
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Figure 3.4: Statistical analysis of docked poses, showing two distinct predicted binding modes. A.
Pie chart showing relative abundance of the two predicted binding modes. B. Predicted binding
mode abundance stratified by second-order acylation rate constant. C. Pooled energy scores for
poses in each of the two predicted binding modes. Error bars are standard deviation.
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Figure 3.5: Representative poses of ceftriaxone and cefoperazone docked to tPBP2H041. A. In the
major pose predicted by the pharmacophore-constrained docking protocol, the C4 carboxylate of
ceftriaxone interacts with S483, its R2 side chain interacts with K361, and the β-lactam ring system
is not optimally oriented for nucleophilic attack by S310. Ceftriaxone (CRO) is shown in orange,
and potential hydrogen bonds made by the antibiotic are indicated by dashed lines. B. In the minor
pose for CRO, the C4 carboxylate interacts with the side chains of K313 and S310, and the βlactam ring is available for attack by S310. C. Cefoperazone (CFP) in the major pose. D. CFP in
the minor pose.
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Figure 3.6: Overlay of docked ceftriaxone poses with tPBP2H041-CRO complex structure. Docked
precovalent poses of ceftriaxone (major in orange, minor in purple) show marked differences from
the acylated structure (green). In the minor pose, in which the β-lactam ring is well-positioned for
attack by nucleophilic Oɣ of S310, the aromatic thiazole ring has moved further from its final position
near α8.

3.2.b. Pharmacophore-constrained docking of cephalosporins against tPBP2WT
In order to draw more direct comparisons between tPBP2H041 and tPBP2WT, the
panel of cephalosporins was docked to the active site of tPBP2WT using the same
pharmacophore-constrained docking protocol as above. Because T498 rotation has been
shown as critical for triggering the acylation reaction, the protocol was run for both apo
and ceftriaxone-bound (T498-rotated) forms of tPBP2WT. PLIF analysis for each ligand
docked to apo-tPBP2WT is shown in Figure 3.7. In this system, the side chains of S310
and T500 contact the β-lactam carbonyl oxygen with side chain hydrogen bonding
interactions, and T483 and S362 are predominantly involved in side chain hydrogen
bonding interactions with the cephem C4 carboxylate group. In most poses, S1 of the
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cephem dihydrothiazine ring participates in weak hydrogen bonding with the side chain
hydroxyl group of T347. The common C7 acylamino moiety on R1 of all cephalosporins
forms a hydrogen bond with N364 in some poses, and some R1 aromatic ring systems
make contact with R502 and H514 of the β3-β4 loop. Large R2 groups adopt two distinct
conformations in the dataset: one in which electronegative elements make side chain and
main chain polar contacts with K361 on α4 and one in which they are rotated toward
residues on α11. A representative pose is shown in Figure 3.9A.
The picture is significantly different for the poses of cephalosporins docked to a
structure of tPBP2WT in which the T498 side chain is rotated toward the active site (Figure
3.8). First, the C4 carboxylate is in direct contact with the side chains of K497, T498, and
T500 in a majority of poses, consistent with the post-covalent crystal structures of cefixime
and ceftriaxone in complex with tPBP2WT (Figure 3.10). In these poses, the β-lactam ring
is in a more favorable position for attack by Oɣ of Ser310. Similar to what is seen in docking
against the apo structure, S1 of the dihydrothiazine ring participates in weak hydrogen
bonding interactions with the side chain of T347. The R1 adopts a position in which the C7
acylamino forms consistent hydrogen bonding interactions with the side chain of N364,
and aromatic systems generally come in close enough proximity to Y422 to form H-𝜋 or
𝜋-𝜋 interactions with its side chain. While there is a small subset of poses in which R2
groups interact with K361, a majority occupy the cleft between the α10-β3 loop and α11,
consistent with a crystal structure of tPBP2WT-ceftriaxone in which the leaving group is
trapped before departure. A representative pose for this analysis is shown in Figure 3.9B.
Together, the results of our docking experiments suggest that the initial recognition of the
C4 carboxylate is similar for tPBP2WTand tPBP2H041. Subsequent rotation of T498 in
tPBP2WT may result in a dramatic change in ligand position preparing it for acylation, a
repositioning that does not occur in tPBP2H041 due to locking of T498 by a hydrogen bond
with S545.
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Figure 3.7: Protein-ligand interaction fingerprints (PLIFs) for pharmacophore-constrained induced-fit
docking of cephalosporins to apo tPBP2WT. A. Heat map of cephalosporin-tPBP2WT interactions colored
by number of poses interacting with a given residue. B. Heat map of cephalosporin-tPBP2WT
interactions, colored by the cephalosporin moiety interacting with a given residue. Key: cefoperazone
(CFP), ceftaroline (CPT), ceftobiprole (BPR), ceftriaxone (CRO, ceftizoximine (ZOX), cefotaxime (CTX),
ceftazidime (CAZ), cefixime (CFM), cefepime (FEP), cefpodoxime (CPD), ceftolozane (TOL), cefdinir
(CDR), cefaclor (CEC), ceftibuten (CTB), cefuroxime (CXM), cefmetazole (CMZ), cefoxitin (FOX),
cefsulodin (CFS), cephalexin (LEX), cefazolin (CFZ), cephalothin (LOT), cephaloridine (LOR)
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Figure 3.8: Protein-ligand interaction fingerprints (PLIFs) for pharmacophore-constrained induced-fit
docking of cephalosporins to tPBP2WT with T498 rotated toward the active site, as is seen in the
ceftriaxone-bound structure . A. Heat map of cephalosporin-tPBP2WT interactions colored by number of
poses interacting with a given residue. B. Heat map of cephalosporin-tPBP2WT interactions, colored by
the cephalosporin moiety interacting with a given residue. Key: cefoperazone (CFP), ceftaroline (CPT),
ceftobiprole (BPR), ceftriaxone (CRO, ceftizoximine (ZOX), cefotaxime (CTX), ceftazidime (CAZ),
cefixime (CFM), cefepime (FEP), cefpodoxime (CPD), ceftolozane (TOL), cefdinir (CDR), cefaclor
(CEC), ceftibuten (CTB), cefuroxime (CXM), cefmetazole (CMZ), cefoxitin (FOX), cefsulodin (CFS),
cephalexin (LEX), cefazolin (CFZ), cephalothin (LOT), cephaloridine (LOR)
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Figure 3.9: Representative poses of ceftriaxone docked to tPBP2WT. A. When docked to apo
tPBP2, the C4 carboxylate of ceftriaxone interacts with T483, and the β-lactam ring system is not
optimally oriented for nucleophilic attack by S310. Ceftriaxone (CRO) is shown in orange, and
potential hydrogen bonds made by the antibiotic are indicated by dashed lines. B. When docked to
tPBP2WT in which T498 is rotated toward the active site, the C4 carboxylate interacts with the side
chains of T498 and T500, and the β-lactam ring is available for attack by S310.
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Figure 3.10: Overlay of docked ceftriaxone poses with tPBP2WT-CRO complex structure. Docked
precovalent poses of ceftriaxone with apo tPBP2WT (orange) show marked differences from the
acylated structure (green). When T498 is rotated toward the active site, however, the docked poses
(purple) better resemble the post-covalent state.

3.3. Activity data for cephalosporins against N. gonorrhoeae strain H041 and its
PBP2
3.3.a. Second-order acylation rate constants against tPBP2H041
As a prerequisite to determining the second-order rates of acylation for the panel
of cephalosporins against tPBP2H041, we first measured the second-order acylation rate of
Bocillin-FL against tPBP2H041 using a time-dependent gel-based assay (Figure 3.11). The
obtained value, 275 ± 9 M-1s-1, is consistent with values previously reported for
[14C]penicillin G against PBP2 from H041.384 k2/Ks was then determined for each
cephalosporin with a gel-based competition assay using Bocillin-FL (untransformed
inhibition data shown in Appendix B). The 22 cephalosporins exhibit a wide range of
activities against tPBP2H041(Table 3.1), with acylation rates ranging from 0 to over 10,000
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M-1s-1. Three of the cephalosporins exhibit 2-7 fold faster rates of acylation than thirdgeneration ceftriaxone (1,710 ± 320 M-1s-1). These are the third-generation agent
cefoperazone (11,800 ± 1,300 M-1s-1) and the fifth-generation agents ceftaroline (10,900
± 1,700 M-1s-1) and ceftobiprole (3,230 ± 190 M-1s-1). Ceftizoxime (third-generation)
exhibits activity comparable to that of ceftriaxone (1,000 ± 210 M-1s-1), whereas several
other third-generation cephalosporins exhibit slightly slower rates of acylation, including
cefotaxime (880 ± 120 M-1s-1), ceftazidime (780 ± 150 M-1s-1), cefixime (720 ± 60 M-1s-1),
and cefpodoxime (590 ± 90 M-1s-1). The remaining cephalosporins exhibit very slow
acylation rates; in fact, for four of these, cephalexin, cefazolin, cephalothin, and
cephaloridine, rates could not be measured.

Figure 3.11: Second-order rate of acylation of Bocillin-FL against tPBP2H041. A. Time-dependent
acylation of tPBP2H041 at various Bocillin-FL concentrations. Each curve was used to derive the
pseudo first-order rate constant, ka. B. Plot of ka against the concentration of Bocillin-FL, where the
slope is the second order acylation rate constant (k2/Ks). A minimum of three kinetics experiments
were completed for each concentration. Error bars are standard deviation.
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Table 3.1: Second-order acylation rates and minimum inhibitory concentrations for the selected
panel of cephalosporins. aThe acylation rate constant for each cephalosporin was derived from
kinetic measurements of the formation of the acyl-enzyme complex, as described in Chapter 2. The
rates were determined by a competition assay with Bocillin-FL. Values were derived from a
minimum of three separate determinations. Error is expressed as standard deviation. bThe
minimum inhibitory concentration (MIC) for each cephalosporin was determined using an agar
dilution protocol, as described in Chapter 2. Values were derived from a minimum of two separate
determinations. †Inhibition plot could not be fit due to lack of a plateau at the highest concentration
used; however, approximately 50% inhibition was seen at 10 mM. ‡Inhibition plot could not be fit
due to minimal inhibition seen at the highest concentration used. *Cephamycin – possesses a C7OMe group. All IC50 curves are shown in Appendix B.
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Examining the acylation data qualitatively, it appears that the R1 side chain has a
significant impact on tPBP2H041 acylation rate, as seen in pairwise comparisons of
compounds with identical R2 side chains (Table 3.2). These pairings exhibit up to 3,000fold differences in activity (e.g., cefoperazone versus cefmetazole). By contrast, the R2
side chain has a much lower impact on acylation rate, as evidenced by the narrow range
of values obtained for cephalosporins containing the 2-(2-aminothiazol-4yl)-2(alkoxyimino)acetyl (ATAO) moiety at R1.
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Table 3.2: Pairwise comparisons of cephalosporins with identical R2. aSecond-order acylation rate
constants taken from Table 1. bQuotient of second-order acylation rate constants for fast- versus
slow-acylating cephalosporin. †Cephamycin – possesses C7-OMe group. ‡Inhibition plot could not
be fit due to minimal inhibition seen at the highest concentration used.
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3.3.b. Antimicrobial activity against N. gonorrhoeae H041
Minimum inhibitory concentrations (MICs) were determined for the panel of
cephalosporins using agar dilution (Table 3.1). The tested compounds exhibit varying
degrees of antimicrobial potency against H041, ranging from 1 to >32 μg/mL. Consistent
with the acylation data, cefoperazone shows slightly more inhibition of bacterial growth
than ceftriaxone (1 vs 2 μg/mL), albeit within the error of dilution. Despite their rapid target
acylation rates against tPBP2H041, the MICs for ceftaroline and ceftobiprole are similar or
slightly higher compared to ceftriaxone. By contrast, cefdinir and cefoxitin, which both
exhibit relatively low acylation rates against tPBP2H041, inhibit the growth of H041 at
concentrations comparable to ceftriaxone (MIC = 1.5 and 3 μg/mL, respectively). The antigonococcal activity of the remaining cephalosporins is generally weaker, falling in the
range of 8 to 16 μg/mL. Cephalothin, ceftazidime, cefaclor, cefsulodin, and cephalexin are
exceptionally poor antimicrobials, and cannot inhibit growth of the H041 strain except at
concentrations of 32 μg/mL or more. In general, antimicrobial potency correlates relatively
poorly with acylation rate because MICs are also influenced by the degree of permeation
through porins and efflux rates, in addition to reactivity with the PBP target.

120

3.4. Quantitative structure-activity relationship for cephalosporins against N.
gonorrhoeae strain H041 and its PBP2
3.4.a. Partial least squares QSAR for second-order acylation rate constant against
tPBP2H041
Correlation of acylation data for the 18 cephalosporins with measurable acylation
rates with their molecular descriptors yielded a partial least squares model with an r2 of
0.995 and a cross-validated r2 of 0.957 (Fig. 3.12A). In addition to its high degree of
predictability within the training set, the model successfully predicts near-zero activity for
four cephalosporins not in the training set that have unmeasurable acylation rates against
tPBP2H041 (Table 3.3). To assess the probability of chance correlation, y-randomization
was performed, in which activity values were randomly assigned to a structure. This
yielded an r2 of 0.937 and a cross-validated r2 of 0.067 (Figure 3.12B), indicating that
correlations seen in the model are not random. Definitions of descriptors used in QSAR
models can be found in Appendix C.
From the PLS model, it can be seen that the second-order acylation rate of
tPBP2H041 by cephalosporins is greatly affected by the van der Waals surface area and
lipophilicity of the R1 substituent, with large, modestly lipophilic groups being favored.
Other features of the R1 substituent were also found to correlate with high activity,
including overall shape, connectivity, and topology. The contributions of these variables
indicate that active molecules possess a high degree of unsaturation and cyclicity, with
modest heteroatom counts and branching. The R2 side chain makes relatively less
contribution to acylation compared to R1 but does have some effect. R2 groups containing
a large number of hydrogen bond acceptors appear to confer higher acylation rates. The
model also points to partial positive charge and hydrophobicity of R2 as being favorable,
the former of which may be an indirect result of inductive effects by electronegative atoms
in R2 of highly active compounds.
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Figure 3.12: Partial least squares quantitative structure activity relationship of cephalosporins
against tPBP2H041. A. PLS QSAR model of tPBP2H041 acylation rate constant data, generated using
the physicochemical and structural descriptors shown in Table 3.3. The model exhibits high internal
validity by direct application to the training set (r2 = 0.995) and by leave-one-out cross validation
(X-r2 = 0.957). B. QSAR validation by y-randomization. Random assignment of second-order
acylation rate constants to physicochemical and structural descriptors shown in Table 3.3 yields a
poor PLS model of tPBP2H041-inhibitory activity (X-r2 = 0.067).

Table 3.3: Partial least squares QSAR model of tPBP2H041 acylation rate constant data. aDescriptor
definitions can be found in Appendix C.

Descriptora
vdw_area
Kier1
zagreb
KierA2
chi0v
BCUT_SLOGP_0
BCUT_SLOGP_1
a_ICM
SlogP_VSA7
BCUT_SLOGP_3
BCUT_SMR_3
a_acc
BCUT_PEOE_3
GCUT_PEOE_2
BCUT_PEOE_0
PEOE_VSA_FPNEG
Q_RPC+

Moiety
R1
R1
R1
R1
R1
R1
R1
R1
R2
R1
R1
R2
R1
R2
R1
R1
R2

Coefficient
+ 4.8926
- 4.5005
- 0.8829
+ 0.6690
+ 0.5917
- 0.5145
- 0.3783
+ 0.3723
+ 0.3679
- 0.3626
- 0.1991
+ 0.1939
- 0.1797
+ 0.1737
+ 0.1693
+ 0.1104
+ 0.0854

Importance
1
0.9198
0.1804
0.1367
0.1209
0.1052
0.0773
0.0761
0.0752
0.0741
0.0407
0.0396
0.0367
0.0355
0.0346
0.0226
0.0175
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Table 3.4: Application of PLS QSAR to a test set of null cephalosporins. aSecond-order acylation
rates for tPBP2H041, as reported in Table 3.1. bSecond-order acylation rates computed using the
model reported in Table 3.3 and Figure 3.12. Test set computations exhibit an overall root mean
square error of 12.4 M-1s-1 compared to true acylation rate.

Cephalosporin
cephalexin (LEX)
cefazolin (CFZ)
cephalothin (LOT)
cephaloridine (LOR)

k2/Ks (M-1s-1)a
~ 0.3†
~ 0‡
~ 0‡
~ 0‡

Predicted k2/Ks (M-1s-1)b
2.6
0.1
1.4
24.6

3.4.b. Classification QSAR for antimicrobial activity against Neisseria gonorrhoeae
H041
Since MIC values obtained were in discrete, two-fold increments, classification
QSAR was used to examine the relationship between MIC and the cephalosporin molecular
descriptors rather than PLS QSAR. Using a median MIC cut-off of ≤4 μg/mL, we defined 5
cephalosporins as active and 16 as inactive. The resulting model has an overall predictive
accuracy of 100% (p = 0.0005) and cross-predictive accuracy of 100% (p = 0.0005) (Figure
3.13A). As for the acylation-based QSAR, the validity of the model was checked by yrandomization to assess the probability of chance correlation (Figure 3.13B). While the
structural features driving acylation rate are largely the lipophilicity and topology of R1,
antimicrobial activity is enhanced by overall hydrophilicity of the molecule. Features shown
to contribute to greater activity include more hydrogen bonding elements, increased water
solubility, and formal charge. Similar to acylation, the model also indicates that antimicrobial
activity is enhanced by specific cephalosporin shape and topology, consistent with this
activity being dependent upon their inhibition of tPBP2H041.
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Figure 3.13: Classification quantitative structure activity relationship of cephalosporins against N.
gonorrhoeae H041. A. Classification QSAR model of antimicrobial activity against Neisseria
gonorrhoeae H041, generated using the descriptors shown in Table 3.5. The model exhibits high
predictive power (100% accuracy upon direct application to the test set, as well as cross-validation).
B. QSAR validation by y-randomization. Random assignment of MIC values to physicochemical
and structural descriptors shown in Table 3.5 yields a poor classification model of N. gonorrhoeae
H041 antimicrobial activity (X-A = 0.81).
Table 3.5: Classification QSAR model of Neisseria gonorrhoeae H041 antimicrobial activity data.
a
Descriptor definitions can be found in Appendix C.
Descriptora
PEOE_VSA+1
SlogP_VSA0
PEOE_VSA+0
zagreb
PEOE_VSA+4
SlogP_VSA1
PEOE_VSA-1
PEOE_VSA+3
PEOE_VSA+6
PEOE_VSA-4
SMR_VSA4
SMR_VSA3
PEOE_VSA-3
SlogP_VSA4
SlogP_VSA2
a_donacc
chi1v_C
GCUT_PEOE_1
h_logS
KierFlex
FCharge

Importance
0.402125
0.390994
0.376126
0.368061
0.363402
0.363401
0.356382
0.342549
0.332761
0.330928
0.301794
0.295544
0.293242
0.287767
0.280906
0.250032
0.249221
0.237011
0.233228
0.225164
0.219874
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3.5. Importance of Lys361 to tPBP2H041-cephalosporin complex formation
3.5.a. Homology modeling of class B PBPs and alignment with published crystal
structures
As noted above, the docking data reveal a potential hydrogen bond between K361
of α4 in tPBP2H041 and polar R2 side chains. Examination of crystal structures and
homology models of class B PBPs from several species shows that a positively charged
residue is highly conserved at this position in many Gram-negative pathogens (Figure
3.14, Table 3.5), including several belonging to the multi-drug resistant ESKAPE group,
suggesting that it may be important for the transpeptidase activity of class B PBPs. By
contrast, this residue is not conserved in class B PBPs of Gram-positive bacteria.

Figure 3.14: Alignment of ⍺4 of class B PBPs showing conservation of a lysine residue in several
important Gram negative pathogens. N. gonorrhoeae PBP2 shown in teal, E. coli PBP3 shown in
chartreuse, P. aeruginosa PBP3 shown in magenta, and A. baumanii PBP3 shown in orange.
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Table 3.6: Superimposition of class B PBPs. aResidues from rigid structural alignment that
generate a receptor surface analogous to the shallow cleft containing K361 in PBP2 of N.
gonorrhoeae. bPredominant formal charge of the cleft. *No structural data available – homology
model constructed using SWISS-MODEL.
Morphology

Gram negative

Gram
positive

Atypical

Organism
N. gonorrhoeae
N. gonorrhoeae
N. meningitidis
P. aeruginosa
P. aeruginosa
E. coli
A. baumanii
H. influenzae

Class B PBP
PBP2H041
PBP2WT (3EQU)
PBP2*
PBP3 (3PBN)
PBP3a*
PBP3 (4BJP)
PBP3 (3UE3)
PBP2*

H. influenzae
H. pylori

PBP3*
PBP2 (5LP4)

H. pylori
S. aureus
S. pneumoniae
S. pneumoniae
S. pneumoniae
S. pneumoniae
E. faecalis
E. faecium
B. subtilis
B. subtilis
B. subtilis
M. tuberculosis
B. burgdorferi

PBP3*
PBP2a (5M1A)
PBP2x (5OAU)
PBP2x (1PYY)
PBP2x (1QME)
PBP2b (2WAE)
PBP4 (6BSQ)
PBP5 (6MKA)
PBP2a*
PBP2b*
PBP3*
PBPA (3LO7)
PBP2*

Residuesa
H348, Y350, K361
H348, Y350, K361
V382, H386, V397
S334, K348
A329, R331, N342
A345, Y347, K358
H376, Y378, K389
W378, K379, H383,
E394
A365, R367, N378
W349, K350, H354,
E365
F367, Q381
E447, S461
W374, D375, H394
D375, E378, H394
W374, D375, H394
W424, Y425, Y442
K468, N481
S466, Y479
D398, E402, Y413
W352, R363, K493
E455, T468
G263, K280
W347, K348, H352,
H363

Chargeb
++
++
+
+
+
+
+
++/+
+/∅
+/+/+/∅
+
∅
-++
+
+++
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Table 3.7: Homology model template-target matching parameters for class B PBPs. aData
acquisition method and resolution for template molecule. bPrimary structure sequence identity
between template and target molecules, reported as a percentage. cGlobal Mean Quality Estimate
for the generated homology models.
Target
B. subtilis PBP2a
(SIQ60944.1)
B. subtilis PBP2b
(ARW31327.1)
B. subtilis PBP3
(KIU10857.1)
H. influenzae PBP2
(KPH67935.1)
H. influenzae PBP3
(BAF48352.1)
H. pylori PBP3
(CAX30260.1)
P. aeruginosa PBP3a
(CAA64770.1)
N. meningitidis PBP2
(RGB21187.1)
B. burdorferi PBP2
(ARS33437.1)

Template
S. aureus PBP2 (2olv.1)

Methoda
X-ray, 2.8 Å

Identityb
32.6

GMQEc
0.59

S. thermophilus PBP2x
(5u47.1.A)
E. faecium PBP2’
(5e31.1)
H. pylori PBP2/MreC
(5lp5.1)
P. aeruginosa PBP3
(4kqr.1)
P. aeruginosa PBP3
(4kqr.1)
P. aeruginosa PBP3
(4kqr.1)
H. pylori PBP2/MreC
(5lp5.1)
H. pylori PBP2/MreC
(5lp5.1)

X-ray, 2.0 Å

33.5

0.64

X-ray, 2.3 Å

38.7

0.70

X-ray, 2.7 Å

31.1

0.58

X-ray, 2.0 Å

41.4

0.63

X-ray, 2.0 Å

28.1

0.57

X-ray, 2.0 Å

49.8

0.74

X-ray, 2.7 Å

32.9

0.56

X-ray, 2.7 Å

27.0

0.58

Table 3.8: Homology model quality measures for class B PBPs. aPercent of residues with
geometries in favorable or acceptable regions of the Ramachandran plot. bPercent of residues with
geometries in favorable or acceptable regions of χ1- χ2 plot. cLog-odds score for overall homology
model geometry.
Model
B. subtilis PBP2a
B. subtilis PBP2b
B. subtilis PBP3
H. influenzae PBP2
H. influenzae PBP3
H. pylori PBP3
P. aeruginosa PBP3a
N. meningitidis PBP2
B. burdorferi PBP2

Ramachandran (%)a
96.8
97.9
97.9
99.2
99.1
98.4
99.5
99.0
97.5

χ1- χ2 (%)b
98.8
98.7
99.0
99.7
99.0
98.9
98.9
98.8
98.6

G-factorc
-0.14
-0.15
-0.12
-0.16
-0.09
-0.25
-0.11
-0.17
-0.23
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3.5.b. Second-order acylation rate constants of select cephalosporins against a
tPBP2H041-K361E mutant
To determine its influence on cephalosporin binding to tPBP2H041, Lys361 was
mutated to Glu, and the acylation rates of several cephalosporins with representative
electronegative or electropositive R2 side chains were determined. The second-order
acylation rate of Bocillin-FL against tPBP2H041-K361E is 57 ± 1 M-1s-1, a 5-fold decrease
compared to the native enzyme (Figure 3.15). The second-order acylation rates of
ceftriaxone (290 ± 70 M-1s-1) and cefoperazone (370 ± 60 M-1s-1) are both markedly lower
against the K361E mutant, with reductions of 83% and 97%, respectively (Table 3.8).
Ceftazidime (560 ± 180 M-1s-1) and cefepime (410 ± 130 M-1s-1) also exhibit lower acylation
rates, although less pronounced. These data indicate that in tPBP2H041, the R2 side chain
binds the shallow cleft between the β2c-β2d loop and the α10-β3 loop containing K361 in
the pre-covalent state.

Figure 3.15: Second-order rate of acylation of Bocillin-FL against tPBP2H041-K361E. A. Acylation
of tPBP2H041-K361E by Bocillin-FL was detected under pseudo-first order conditions using various
ligand concentrations to determine rate constant ka. B. The pseudo-first-order rates of acylation (ka)
were plotted against the concentration of Bocillin-FL to yield a plot whose slope is the second order
acylation rate constant (k2/Ks). A minimum of three kinetics experiments were completed for each
concentration. Error bars are standard deviation.
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Table 3.9: Second-order acylation rates for select cephalosporins against tPBP2H041-K361E.
a
Second order acylation rate constants against native tPBP2H041, as reported in Table 3.1. bThe
acylation rate constant for each cephalosporin was derived from kinetic measurements of the
formation of the acyl-enzyme complex, as described in Chapter 2. The rates were determined by a
competition assay with Bocillin-FL. Values were derived from a minimum of three separate
determinations. Error is expressed as standard deviation. cThe fractional acylation rate compared
to that with native tPBP2H041.

Ceph

R2
S

CFP

N
N
N N

S

CRO

CAZ
FEP

N

N+

N

N

O

N
H

O

k2/Ks
(M-1s-1)a

K361E k2/Ks
(M-1s-1)b

Fractional
Activityc

11,800 ± 1,300

370 ± 60

0.03

1,710 ± 320

290 ± 70

0.17

790 ± 150

560 ± 180

0.70

630 ± 50

410 ± 130

0.64

3.5.c. Docking of select cephalosporins to a tPBP2H041-K361E mutant
When this mutation is modeled in silico and the above docking protocol repeated,
the generated poses for ceftazidime and cefepime position R2 toward the mutated residue
due to electrostatic attraction, whereas the R2 side chains of ceftriaxone and cefoperazone
become oriented away from this region (Figure 3.16). The repulsion of electronegative R2
by E361 seen in these models may be the basis for differential effects of the mutant on
cefoperazone and ceftriaxone versus ceftazidime and cefepime.
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Figure 3.16: Pharmacophore-constrained induced fit docking of select cephalosporins to tPBP2H041-K361E.
Docking of the selected panel of cephalosporins against the K361E mutant lends insight into changes in the
compounds’ potential precovalent binding modes caused by the mutation. While interactions with S310 and T500
are conserved, interactions with residue 361 are seen more frequently for cephalosporins possessing positive
formal charge at R2 (ORCAZ,CFP = 21, p = 0.0002). A. Heat map of cephalosporin-tPBP2H041-K361E interactions
colored by number of poses interacting with a given residue. Key: cefoperazone (CFP), ceftriaxone (CRO),
ceftazidime (CAZ), cefepime (FEP). B. Heat map of cephalosporin-tPBP2H041-K361E interactions, colored by the
cephalosporin moiety interacting with a given residue. C. A representative pose of ceftriaxone shows the R2 group
occupying a different position. The native tPBP2H041 pose is shown in teal, and the tPBP2H041-K361E pose is
shown in magenta.

3.6. Further evaluation of cefoperazone as a potential antigonococcal agent
3.6.a. Crystallographic analysis of a tPBP2H041-CFP complex structure
The rapid acylation of tPBP2H041 by cefoperazone compared to ceftriaxone, as well
as its more favorable energetics of binding in the docked models, suggests it may bind
more favorably in the transpeptidase active site compared to other cephalosporins. To
examine this, the crystal structure of tPBP2H041 acylated by cefoperazone was determined
at 2.2 Å resolution, obtained by soaking crystals of tPBP2H041 with antibiotic (Table 3.9).
Overall, the structure is very similar to the reported tPBP2H041-CRO structure (C𝝰
rmsd = 0.123 Å), including the “outbent” conformation of the β3-β4 loop (Figure 3.17).
The unbiased |Fo|-|Fc| difference electron density map shows cefoperazone covalently
bound to Ser310 (Figure 3.18). Electron density is observed for a majority of the
cefoperazone molecule, with the exception of C3 of the dihydrothiazine ring, C6 of the 2,3dioxopiperazine ring, and the p-phenol substituent on R1. The lack of density at
dihydrothiazine C3 and 2,3-dioxopiperazine C6 is consistent with the presence of a
mixture of conformational states for these flexible ring systems. Cefoperazone forms a
number of polar contacts with active site residues of tPBP2H041 (Figure 3.18). These
include hydrogen bonds between the acyl carbonyl oxygen and the oxyanion hole
comprising the main chain amides of Ser310 and Thr500, and between the C7 acylamino
carbonyl oxygen and the side chain of Asn364 from the SxN motif. The C4 carboxylate
forms hydrogen bonds with the main chain of Ser545 and the side chain of Thr500. The
hydrophobic 2,3-dioxopiperazine ring system is positioned over the Y422 side chain, and
the p-phenol system is solvent exposed. The tPBP2H041-CFP structure does not show a
great deal of overlap with either the major or minor pose of cefoperazone from our docking
models (Figure 3.19).
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Table 3.10: X-ray diffraction data and model refinement statistics for a preliminary crystal structure
of tPBP2H041 in complex with cefoperazone.

Data collection:
Space group
Cell dimensions:
a, b, c (Å)
α, β, γ (o)
Resolution range (Å)
Rmerge* (%)
Completeness (%)
Redundancy
<I>/<σI>
No. of unique reflections
Refinement:
Resolution (Å)
No. of non-hydrogen protein
atoms
No. of antibiotic atoms
No. of water oxygen atoms
Rcryst/Rfree (%)
RMS deviations from ideal
stereochemistry
bond lengths (Å)
bond angles (o)
B factors:
Mean B factor (main chain)
(Å2)
RMS. deviation in main chain
B factors (Å2)
Mean B factor (side chains &
waters) (Å2)
RMS deviation in side chain
B factors (Å2)
Ramachandran plot:
Residues in most favored
region (%)
Residues is generously
allowed region (%)
Residues in additional
allowed region
Residues in disallowed
region

P212121
50.2, 60.6, 109.1
90.0, 90.0, 90.0
40.56 - 2.17
23.6 (60.9)
100 (99.8)
13.6 (13.9)
22.4 (6.1)
17,766 (1,688)
40.56 - 2.17
2,457
37
108
0.179/0.225
0.003
0.8
23.4
1.0
28.3
1.8
93.4
6.6
0.0
0.0
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Figure 3.17: Overlay of ceftriaxone- and cefoperazone-acylated structures of tPBP2H041.
Superimposition of tPBP2H041 in complex with ceftriaxone (aqua) and cefoperazone (pink) shows
that the structures are nearly identical. Ceftriaxone and cefoperazone are shown as teal and
magenta sticks, respectively. Note the ‟outbent” conformation of the β3-β4 loop in both complexes.
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Figure 3.18: Crystal structure of cefoperazone in complex with tPBP2H041. A. Unbiased |Fo|-|Fc| difference electron density
contoured at 2.3σ showing cefoperazone covalently bound to S310. B. Zoomed in view showing polar contacts between
cefoperazone and active site residues. Cefoperazone shown as orange sticks. Hydrogen bonds shown as dashed lines.

Figure 3.19: Overlay of docked cefoperazone poses with tPBP2H041-CFP complex structure.
Docked precovalent poses of cefoperazone (major in orange, minor in purple) show marked
differences from the acylated structure (green sticks). In the minor pose, in which the β-lactam ring
is well-positioned for attack by nucleophilic Oɣ of S310, the hydrophobic 2,3-dioxopiperazine ring
has moved quite far from its final position near α8.
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3.6.b. In vivo testing of cefoperazone in a gonococcal model of infection
As noted above, cefoperazone exhibits an acylation rate against tPBP2H041 higher
than ceftriaxone, suggesting it may have therapeutic potential to treat gonorrhea. To
examine this, cefoperazone (60 or 120 mg/kg TID) was administered intraperitoneally to
two groups of BALB/c mice infected with N. gonorrhoeae H041 (Figure 3.20). A 120 mg/kg
TID dosing regimen results in 100% culture negativity by day 3, with a mean time-toclearance of 2.1 days (n = 9), and shows equivalent efficacy to an identical regimen of
ceftriaxone (n = 10, mean time-to-clearance 1.6 days, log-rank p = 0.15). By contrast, a
gentamicin control regimen results in 100% culture negativity by day 4, with a mean timeto-clearance of 3.1 days (n = 8, log-rank p = 0.02 versus CFP, log-rank p = 0.0004 versus
CRO). Quantitative differences in colonization load are seen beginning at 1 day for
cefoperazone- and ceftriaxone-treated groups compared to vehicle control (two-way RM
ANOVA p < 0.01), while no such differences are seen until day 2 for the gentamicin-treated
group (two-way RM ANOVA p < 0.01). While a general trend toward decreased colonization
load is seen with administration of 60 mg/kg cefoperazone TID or 60 mg/kg ceftriaxone TID,
neither regimen is able to attain full infection clearance by day 8.
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Figure 3.20: Evaluation of cefoperazone in a murine model of gonococcal infection. A. KaplanMeier curve for culture positivity in mice treated with 120 mg/kg intraperitoneal (IP) cefoperazone
or ceftriaxone three times daily (TID). *Historical data from the Jerse laboratory. **Positive control
group was given 48mg/kg gentamicin IP once daily (QD). B. Colonization load by day for groups
treated with 120 mg/kg IP cefoperazone or ceftriaxone TID. C. Kaplan-Meier curve for culture
positivity in mice treated with 60 mg/kg IP cefoperazone or ceftriaxone TID. D. Colonization load
by day for groups treated with 60 mg/kg IP cefoperazone or ceftriaxone TID.
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3.7. Discussion
The goal of the current work is to elucidate which features of the cephalosporin
class of β-lactam antibiotics are important for antimicrobial activity against cephalosporinresistant Neisseria gonorrhoeae H041 through inhibition of PBP2. We find that the
structure of the R1 (C7 acylamino) side chain of cephalosporins has a profound effect on
the second-order rate of tPBP2H041 acylation, while the R2 (C3) side chain plays a subtler
role. Through molecular docking simulations of the precovalent ligand-receptor complex,
we show that aromatic and hydrophobic groups on R1 extend toward a hydrophobic patch
of the tPBP2H041 active site, and electronegative elements of R2 interact with K361. We
also show that antimicrobial activity correlates somewhat with tPBP2H041 inhibition, but is
complicated by a need to evade additional resistance mechanisms present in the
organism. Finally, we observe that cefoperazone acylates tPBP2H041 at a rate 7-fold faster
than ceftriaxone, and it exhibits comparable activity to ceftriaxone against N. gonorrhoeae
H041 both in vitro and in vivo.
3.7.a. Contributions of R1 to tPBP2H041-cephalosporin complex formation.
In this study, we found evidence of a key role for R1 structure and properties in the
second-order rate of acylation of tPBP2H041. The unfavorable contributions of several
atomic lipophilicity descriptors indicate that the R1-binding region of the PBP2H041 active
site is not tolerant of highly hydrophobic moieties. However, the atomic molar refractivity
descriptors show that this region cannot be extremely polar either. It therefore appears
that while there may be areas where hydrogen bonding is advantageous (e.g., interaction
of the acylamino moiety in mimicry of the peptide substrate), the R1 side chain should
contain groups of modest hydrophobicity, such as aromatic- and heteroaromatic ringcontaining systems. In addition, the total van der Waals surface area of the R1 group
contributes positively to acylation rate, suggesting a critical role for size of the
cephalosporin in tPBP2H041 acylation. Hence, while the ATAO side chains (van der Waals
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volume V ~ 200 Å3 , distribution coefficient logD7.4 = -0.7) seen in many third-generation
cephalosporins, as well as the chemically similar thiadiazolyl variants possessed by fifthgeneration agents, generally confer some activity, the larger (V > 400 Å3) and more
lipophilic (logD7.4 = 0.6) 2,3-dioxopiperazinyl moiety of cefoperazone dramatically
increases acylation rate.
Shape and topology also play critical roles, with high degrees of unsaturation and
cyclicity being associated with higher rates of acylation. Illustrating this trend is the vast
difference in acylation rates between cefmetazole, which has a negligible acylation rate
and is the only cephalosporin in our study lacking a ring system on R1, and cefoperazone,
which has two ring systems and exhibits the highest rate among the cephalosporins
tested. Also apparent in the R1 topological parameters is a preference for modest numbers
of heteroatoms, as well as a moderate degree of branching. The former is illustrated by
the low activity conferred by the tetrazolyl R1 of cefazolin, and the latter is apparent from
differences in acylation rates between compounds with 2-unsubstituted acylamino groups
(e.g., cephalothin and cephaloridine) and those with a single branch point at this position
(e.g., ceftriaxone and cefoperazone). The exception is that several compounds with 2substituted acylamino groups have very poor activity, including cephaloridine, cephalexin,
and cefaclor. These, however, are suboptimal for tPBP2H041 acylation because they
possess a small R1 with sulfonic acid or primary amine moieties. Energy score analysis of
docking data for R2-paired compounds suggests that these R1 groups impact precovalent
Michaelis complex formation by altering affinity for tPBP2H041 rather than acylation (Figure
3.21). With the exception of ceftizoxime and ceftibuten, the faster acylating compound of
each pair shows a more favorable binding energy with the tPBP2H041 active site.
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Figure 3.21: Energy score analyses for docking of cephalosporins against tPBP2H041. A. Overall
energy scores for the cephalosporins tested, rank ordered by second-order acylation rate (n = 10
poses), show a correlation of computational affinity with activity. B. Comparisons of energy scores
for cephalosporins with different R1 and identical R2. “High-affinity” indicates the molecule of the
pair exhibiting more rapid acylation (e.g., cefoperazone). “Low-affinity” indicates the molecule of
the pair exhibiting slower acylation (e.g., cefmetazole). N-methyltetrazole (NMTT), pyridyl (pyr). C.
Comparisons of energy scores for cephalosporins with similar R1 and different R2 show a
preference for negative electrostatics. 2-(2-aminothioazol-4-yl)-2-(alkoxyimino)acetyl (ATAO),
thiophen-2-ylacetyl (thioAc).
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Previous studies have also indicated that the R1 side chain may be an important
driver of affinity against PBPs. In a qualitative structure-activity relationship of penicillin
analogues against E. faecium PBP5, it was found that azlocillin (k2/Ks = 15 M-1s-1) exhibits
much more rapid acylation of the target than piperacillin (k2/Ks = 2.2 M-1s-1), ampicillin
(k2/Ks = 1.8 M-1s-1), or Bocillin-FL (k2/Ks = 1.1 M-1s-1).135 In a separate study of
Streptomyces R61 DD-peptidase, penicillin G (k2/Ks = 10,300 M-1s-1) was shown to be
manifold more potent than penicillin V (k2/Ks = 1,500 M-1s-1), carbenicillin (k2/Ks = 830 M1 -1

s ), and ampicillin (k2/Ks = 107 M-1s-1).136

Since the β-lactams examined in these

experiments are all penicillin analogues, which possess geminal dimethyl groups at the
R2 position, one can conclude that differences in activity are imparted by R1. This idea is
further supported by the differing specificities of compounds with identical R2 for various
transpeptidases. For example, in membrane preparations of E. coli, cefoperazone exhibits
very different apparent affinities for PBPs (PBP3 > PBP1b > PBP2 > PBP1a > PBP4) from
cefmetazole (PBP4 > PBP1a = PBP1b > PBP3 > PBP2).651,652
The strong influence of the R1 group on the activities of cephalosporins is important
to consider in light of recent new understanding of how PBP2 is acylated by ESCs. Structures
of tPBP2WT acylated by cefixime or ceftriaxone reveal significant movement of the β3-β4 loop
toward the active site, where several residues form a cluster around the aminothiazole ring,
and such interactions may contribute to the affinity of ESCs for PBP2 .113 The situation is very
different in tPBP2H041 because movement of the loop appears restricted by mutations
conferring resistance to ESCs, resulting in fewer interactions involving the aminothiazole in
the acylated complex.134 Interestingly, the electron density obtained for tPBP2H041 in
complex with ceftriaxone shows a potential dual conformation of R1, which can also be
seen in our docking data (Figure 3.3). Such a dual conformation indicates a lack of a
preferred, high-affinity binding mode for ceftriaxone with tPBP2H041. While the β3-β4 loop
is still locked in an “outbent” conformation in the tPBP2H041-CFP structure reported here,
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the modeled R1 assumes an unexpected position in the modeled binding mode that may
help to explain part of the increase in cefoperazone’s tPBP2H041 acylation rate. Instead of
the aromatic p-phenol group participating in π-π interactions with Y422, the 2,3dioxopiperazine moiety lies flat in the active site, making considerable van der Waals
contacts with Y422 and the surrounding residues (Figure 3.22). Perhaps, then, the ideal
cephalosporin for acylation of tPBP2H041 is one whose R1 can either 1) induce the hinging
in the β3-β4 loop to form more extensive contacts with the transpeptidase active site or 2)
create sufficient contacts in the absence of such hinging.

Figure 3.22: Contact of the 2,3-dioxopiperazine moiety of cefoperazone with tPBP2H041 in a
preliminary complex crystal structure. While the 2,3-dioxopiperazine does not make any polar
contacts with active site residues, it creates a large area of van der Waals contact with Y422 and
surrounding residues. tPBP2H041 and its surface are shown in cyan, and cefoperazone and its
surface mesh are shown in orange.
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3.7.b. Contributions of R2 to tPBP2H041-cephalosporin complex formation.
We also found that structural variations in R2 can have effects on tPBP2H041
acylation, albeit to a lesser extent than R1. First, planar R2 groups are correlated with faster
acylation rates. In fact, the four fastest acylating compounds (i.e., cefoperazone,
ceftaroline, ceftobiprole, and ceftriaxone) all have planar R2 groups with extended ring
systems, conferring several-fold increases in acylation when compared with compounds
of similar R1 group (e.g., ceftobiprole versus cefdinir). Second, the hydrogen bonding
capacity of R2 also appears to affect acylation, as exemplified by the thiotriazinone (TTN)
moiety conferring a 1.5- to 3-fold enhancement over other ATAO-containing
cephalosporins. Our docking data suggest that the electronegativity and hydrogen
bonding capability of R2 enhances affinity for the tPBP2H041 active site (Figure 3.21). In
addition to influencing precovalent ligand-receptor complex formation, the R2 group can
also participate in long-range inductive effects through the conjugated cephem
system.217,218 Thus, atoms in R2 may also exert an electron-withdrawing inductive effect,
thereby activating the β-lactam carbonyl for more rapid acylation. This is best illustrated
by the differences in acylation rate between cefaclor (29 ± 4 M-1s-1) and cephalexin (~0.3
M-1s-1), which have identical R1 groups but R2 groups with opposite inductive effects.
Finally, we found no correlation between the presence or absence of a C3 leaving
group on the dihydrothiazine ring of the cephalosporin and tPBP2H041 acylation. These C3
substituents are expelled by resonance upon acylation, and cephalosporins containing
leaving groups are thought to form more stable acyl-enzyme complexes, thereby
decreasing the rate of deacylation (k3) and regeneration of the PBP in apo form.653 Our
data are in keeping with the idea that departure of a C3 leaving group affects k3 but not
the rate of acylation. Nevertheless, given that tPBP2H041 has an enhanced rate of
deacylation compared to tPBP2WT,134 the leaving group should be taken into consideration
when selecting or designing antigonococcal therapeutics.
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In recent years, there have been several attempts to utilize the R2 side chain of
cephalosporins to reduce susceptibility to β-lactamases, and to enhance cell-wall
permeability and PBP-binding affinity.654-656 As an example, the planar vinylpyrrolidinone
side chain of ceftobiprole was designed to bind a narrow groove within the active site of
S. aureus PBP2a.656 Although there have been no design efforts of this nature against N.
gonorrhoeae PBP2 to date, our model can be used to make predictions about the structure
of an R2 side chain that would be expected to increase acylation rate. Generally,
tetravalent nitrogen-containing leaving groups lead to poor acylation against tPBP2H041,
as in the case of ceftolozane, cefsulodin, and cephaloridine. This is consistent with
previous studies showing that, although zwitterionic cephalosporins are distinguished by
their superior transport through porins and decreased affinity for β-lactamases, they suffer
from a loss of affinity for PBPs.266 By contrast, ceftaroline and ceftobiprole, which also
contain nitrogen cations, acylate tPBP2H041 rapidly. Their formal positive charges are more
distal to the bicyclic cephem core compared to others, suggesting a specific spatial
discrimination against such a feature.
In the docked models, larger heterocyclic R2 groups are shown to interact
predominantly with K361 and surrounding residues, a finding corroborated by
compromised acylation of a tPBP2H041-K361E mutant by cefoperazone and ceftriaxone.
By contrast, a crystal structure of tPBP2WT acylated by ceftriaxone with the C3 leaving
group intact shows R2 interacting with residues immediately prior to α11, similar to the
structure of S. aureus PBP2a in complex with ceftobiprole.657 Surprisingly, very few poses
from our docking studies adopt this conformation. These differences may indicate a
different binding mode between PBP2WT and PBP2H041, or they may suggest a shift in
position that accompanies the acylation reaction.
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3.7.c. Interactions of the C4 carboxylate with S483
In addition to providing structural insight into the trends above for R1 and R2, the
docking data also model how the bicyclic cephem scaffold might fit into the active site
during formation of the tPBP2H041-cephalosporin precovalent complex. In the docking
models, most of the cephalosporins interact directly with S483, which is mutated in
PBP2H041 compared to PBP2WT (from threonine) and contributes to cephalosporin
resistance.384 Previously, Tomberg et al. postulated that S483 is important for recognition
of the C4 carboxylate. In tPBP2H041, a small pocket comprising S362, T/S483, and K497
binds the carboxylate (Figure 3.23), orienting the cephem in a position where the β-lactam
carbonyl is inaccessible to the serine nucleophile (Figure 3.5). This binding mode differs
significantly from what is seen in acylated structures of either tPBP2WT or tPBP2H041. In
post-covalent crystal structures of tPBP2WT acylated by cefixime or ceftriaxone, the C4
carboxylate interacts instead with the Oɣ of T498, which has rotated to accommodate the
ligand, bringing the β-lactam ring into optimal position for reaction with S310.113 In the acylenzyme structure of tPBP2H041 with ceftriaxone, the C4 carboxylate interacts with S545 in
the post-covalent state to generate a binding mode distinct from that observed in
tPBP2WT.134
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Figure 3.23: Surface views of ceftriaxone and cefoperazone docked to tPBP2H041. A. In the major pose predicted
by the pharmacophore-constrained docking protocol, the C4 carboxylate of ceftriaxone (orange) fits into a small
pocket bordered by the side chains of S362, S483, and K497 (surface colorized by atom type). B. In the minor
pose, ceftriaxone is more extended, spanning the active site. C. Major pose for cefoperazone (orange). D. Minor
pose for cefoperazone. Y544 is shown with a transparent mesh surface to visualize the binding pocket.

Repetition of the cephalosporin docking analyses with tPBP2WT shows that the C4
carboxylate interacts with T483 in the apo form, occupying a very similar position to what
is seen in the major pose of our tPBP2H041 docking data. This suggests a similar initial
binding mode for both tPBP2WT and tPBP2H041 in which T/S483 plays a critical role in
carboxylate

recognition

(Figure

3.24).

Additional

experiments,

in

which

the

cephalosporins were docked against the T498-rotated form of tPBP2WT, yield binding
modes showing the carboxylate occupying a position closer to that seen in the acyl
structure (Figure 3.25). However, in tPBP2H041, the T498 side chain participates in a
hydrogen bonding interaction with the S545 side chain, preventing its rotation to contact
the β-lactam carboxylate during acylation.134 As a result, it appears that the cephalosporin
receives no enzymatic guidance toward a reactive position (represented in our dataset as
the minor pose) when bound to tPBP2H041, slowing the acylation rate. Our data do not
explain the final position of the carboxylate in acylated structure of tPBP2H041, however.
Although this final position may be achieved during the course of the acylation reaction,
more work is needed to confirm the importance residue 483 in initial carboxylate
recognition.
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Figure 3.24: Overlay of ceftriaxone docked to apo tPBP2WT with the major pose of ceftriaxone
docked to tPBP2H041. Docked precovalent poses of ceftriaxone with apo tPBP2WT (orange) are very
similar to the major pose reported from docking with tPBP2H041 (teal).
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Figure 3.25: Overlay of ceftriaxone docked to T498-rotated tPBP2WT with the minor pose of
ceftriaxone docked to tPBP2H041. T498 rotation toward the active site in response to carboxylate
binding orients the β-lactam ring in preparation for acylation, and also orients the aromatic thiazole
toward its final position near α8 (tPBP2WT complex shown in orange). In the absence of this rotation,
the ligand receives no enzymatic guidance toward a reactive position (tPBP2H041 shown in teal).
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3.7.d. Correlations between acylation rate and antimicrobial activity
There is some correlation between acylation rate and antimicrobial activity for the
set of cephalosporins. For example, cefoperazone and ceftriaxone, which acylate
tPBP2H041 rapidly, exhibit the most potent antimicrobial activity, while cefaclor, cefsulodin,
cephalexin, and cephalothin, which do not acylate tPBP2H041, exhibit the least. Some
cephalosporins, however, deviate significantly from this trend. One reason for these
discrepancies can be seen in the antimicrobial activity model, the descriptors of which
reflect the ability of a molecule to access the periplasm by traversing the predominant porin
in N. gonorrhoeae PorB1b , as well as their propensity to be substrates for efflux by the
MtrCDE system. In fact, the same amphipathic features of cephalosporins that favor rapid
acylation of tPBP2H041 (i.e., large, lipophilic R1 and polar R2) also result in decreased
diffusion through porins and increased efflux.317,318 Examples of cephalosporins susceptible
to such factors include ceftaroline and ceftobiprole, whose rapid acylation rates contrast
with relatively weak antimicrobial potency. This is especially the case for ceftaroline, which
is relatively hydrophobic compared to other cephalosporins (logD7.4 = 1.03), and is
relatively ineffective against H041 in vitro.444 The picture is less clear for ceftobiprole,
whose relative hydrophilicity (logD7.4 = -2.33) suggests it less likely to be removed from
the gonococcal cell by efflux pumps. However, MtrCDE confers resistance to a number of
cationic species and may also transport ceftobiprole.312 Strategic addition of anionic
groups to cephalosporins exhibiting rapid tPBP2H041 acylation may therefore increase
antimicrobial activity by increasing aqueous solvation and avoiding efflux mechanisms.
Another reason for the weak correlation between k2/Ks and antimicrobial activity is
that some cephalosporins may acylate PBP1 more rapidly than PBP2. For example,
cefdinir and cefoxitin exhibit very slow acylation rates versus tPBP2H041, but high
antimicrobial activity (MICs are 1.5 and 3 μg/mL, respectively), consistent with them
targeting PBP1 rather than PBP2. In fact, cefdinir and cefoxitin generally show preferential
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binding to class A and class C PBPs from a number of bacterial species,658-665 and early
studies of PBPs from N. gonorrhoeae show that cefoxitin acylates PBP1 more rapidly than
PBP2 in penicillin-susceptible and -resistant strains.666
3.7.e. The potential of cefoperazone to treat ESC-resistant gonorrhea
This work has revealed the third-generation compound cefoperazone is nearly 7fold more active against tPBP2H041 than ceftriaxone, is comparably potent against the
H041 strain, and performs similarly in a mouse model of infection. This is consistent with
previous studies of gonococcal PBPs that showed cefoperazone bound to PBP2 in
membrane preparations at concentrations of less than 10-3 µg/mL.666 It is also consistent
with the high activity of ureido penicillins and cephalosporins against class B PBPs from
several Gram negative pathogens.589,651,667-669 To date, cefoperazone has been reported
as being highly effective against infections by both penicillin-susceptible and -resistant
gonococci.670-672 Its activity against the H041 strain reported here suggests cefoperazone
has potential to address ESC-resistant N. gonorrhoeae conferred by mosaic penA due to
its higher acylation activity against PBP2 compared to ceftriaxone. Cefoperazone is FDAapproved and safe for use in most patients, with tolerated daily doses up to multiple grams
and a similar side effect profile to other β-lactam antimicrobials.673 Cephalosporins with Nmethyltetrazole (NMTT) leaving groups at R2, such as cefoperazone, have been
associated with an increase in prothrombin time (PT) via the inhibition of vitamin K
dependent ɣ-carboxylases by NMTT and its symmetric disulfide oxidation product;
however, the IC50 is quite high for each species (~200 and 600 µM, respectively).674
Generally, this inhibition results in increases in PT without increases in clinically significant
bleeding.675 One study shows increased risk with cefoperazone specifically, but cases and
controls are poorly matched (i.e., the exposed group had many more comorbidities
associated with bleeding).676 While the pharmacokinetics of cefoperazone may be less
favorable than ceftriaxone for treating urogenital infections, with a t1/2 of 1-2 hours (versus
151

6-8 hours for CRO) and primarily biliary excretion (versus primarily renal for CRO),677 it
may have utility in the treatment of mucosal infections due to its relative lipophilicity. In the
murine model of gonococcal infection, 120 mg/kg cefoperazone administered TID
exhibited similar efficacy to an identical regimen of ceftriaxone. With optimized dosing
guided by pharmacokinetics, cefoperazone may offer another clinical option for highly
resistant gonococcal infections in a relatively barren therapeutic landscape.
3.7.f. Significance
The overall picture emerging from our studies is that rapid tPBP2H041 acylation is
promoted by a large R1 (C7 acylamino side chain) with modestly lipophilic properties, and
an electronegative R2 (C3 side chain) with a planar structure. Unfortunately, these
properties render cephalosporins less permeable to the Gram negative outer membrane
and more prone to efflux, but strategic placement of anionic groups may help to overcome
these barriers. Finally, we have shown that cefoperazone holds promise as an
antigonococcal agent for strains harboring mosaic penA alleles.
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CHAPTER 4: Discovery of Novel PBP-Inhibitory Chemotypes as Potential
Antigonococcal Agents
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4.1. Introduction
Due to their status as critical antibacterial targets, and given the rising number of
bacteria resistant to existing β-lactams, the PBPs have become the subjects of numerous
drug discovery ventures. Many efforts have centered on the modification of the β-lactam
or lactivicin framework, adding novel side chains predicted to show enhanced interaction
with the active site. Others have focused on tetrahedral intermediate mimicry via the
reaction of phosphonates, boronates, and cyclobutanones with the serine nucleophile.
However, if the mutations in PBP2 conferring cephalosporin resistance do so in part by
decreasing reactivity to electrophiles, these strategies may prove fruitless.
Another, perhaps more urgent, reason to explore non-β-lactam agents as PBP
inhibitors is the emergence of highly efficient hydrolytic enzymes. Nearly 1,000 unique βlactamases have been identified in clinical isolates across species, and extendedspectrum β-lactamases (ESBLs) have emerged in many Gram negative bacteria,
including the highly resistant ESKAPE pathogens (Enterococcus, Staphylococcus,
Klebsiella,

Acinetobacter,

Pseudomonas,

and

Enterobacter),

necessitating

the

identification of alternatives to the current therapies.345 While strains of Neisseria
gonorrhoeae capable of producing β-lactamases have been isolated, they are rarer than
strains harboring chromosomal resistance determinants. Moreover, only penicillinases have
been reported in the gonococcus to date.18,19,349 Recently, however, plasmids containing
blaTEM-135 have been identified,350-352 several of which possess an M182T mutation seen in
many ESBL.351 It is proposed that this mutation stabilizes the active site and may allow
additional mutations to the encoded TEM-135 penicillinase that broaden its spectrum.
For these reasons, high throughput methods (e.g., in silico and physical screening)
have been employed with the goal of discovering novel chemotypes that inhibit PBPs
noncovalently. Although several investigations have identified a number of chemical
scaffolds as inhibitors of various class B PBPs, such molecules tend to lack potency and
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require a great deal of optimization by medicinal chemistry. The identification of new PBPinhibitory scaffolds should be continued, as it may increase the number of eventual
successful molecules against the target by affording diverse candidates for development.
While the specific QSAR models developed in Chapter 3 were constructed using activity
data from cephalosporins, the general trends they reveal about features necessary for
PBP2 inhibition can be applied to the identification of novel inhibitors. In this chapter, the
discovery of two novel N. gonorrhoeae PBP2 inhibitors (JEK-42 and JMT-1) possessing
a common 1,1’-biphenyl moiety is described. These compounds are capable of inhibiting
PBP2 of both β-lactam-susceptible (tPBP2WT) and -resistant (tPBP2H041) strains, and they
show antimicrobial activity against N. gonorrhoeae FA19 and H041 in disc diffusion
assays. Interestingly, they also show inhibition of P. aeruginosa PBP3. Through modeling
of their PBP2 binding modes by docking and molecular dynamics, we show the potential
for interaction with a number of residues conserved across class B PBPs, as well as
possible β-lactam mimicry. Finally, we present a three-point pharmacophore model
constructed from the structural similarities between these molecules and β-lactams to aid
in the identification of additional scaffolds. Overall, our data reveal that JEK-42 and JMT-1
are attractive initial hits for medicinal chemical optimization.
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4.2. Identification of 2-(biphenylamido)benzoic acids and isosteres as PBP2 inhibitors
4.2.a. Physical screen of (biphenylamido)benzoic acids against tPBP2WT
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Figure 4.1: Structures of compounds reported by Kirkpatrick et al. (coded JEK-XX).
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From the ligand binding data (i.e., cephalosporin docking data and structureactivity relationships) described in Chapter 3, we found that large, somewhat lipophilic
groups of high cyclicity are favored in the direction of the cephalosporin R1 side chain. This
information, in combination with the knowledge that active β-lactam antimicrobials require
a specific spatial arrangement of their carboxylate and carbonyl groups for binding to
PBPs,142 led to the selection of a group of (biphenylamido)benzoic acids as possible PBP2
binders (Figure 4.1), 24 of which were synthesized and provided by Joy Kirkpatrick.
Testing of these compounds against tPBP2WT revealed 2-(4’-methyl-[1,1'-biphenyl]-4amido)-5-fluorobenzoic

acid

(JEK-42)

and

2-(4’-methyl-[1,1'-biphenyl]-3-amido)-5-

fluorobenzoic acid (JEK-45) as active in a competition assay with Bocillin-FL, exhibiting
89 ± 5% and 86 ± 4% inhibition at 100 μM, respectively (Figure 4.2A). The beginnings of
a structure-activity relationship can be seen from comparisons within this dataset (Figure
4.2B). First, a switch from anthranilic acid to its meta- or para-benzoic acid analogues
results in little to no PBP2 inhibition. The substitution pattern of the anthranilic acid moiety
also affects inhibition, with 3-substituted and fully unsubstituted systems showing greatly
diminished activity compared to 4- and 5-substituted analogues. Next, a [1,1'-biphenyl]-4amido or [1,1'-biphenyl]-3-amido structure is preferred, as [1,1'-biphenyl]-2-amido
analogues of these compounds suffer a stark loss of potency. Finally, a 4’-methyl
substitution appears to enhance inhibition considerably, as the only 4’-desmethyl
analogue with any activity is the weak inhibitor JEK-30 (27 ± 10% inhibition). Due to its
reasonable inhibition of tPBP2WT at the concentration assayed, as well as the commercial
availability of its building blocks, JEK-42 was selected as a hit compound for further testing
and derivatization.
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Figure 4.2: Inhibition data for JEK compounds against tPBP2WT. A. Values were determined in a
purified protein assay in which tPBP2WT was preincubated with 100 µM compound, followed by
addition of 1 µM Bocillin-FL. Data are presented as a fraction of DMSO control. Error bars are
standard deviation. B. Structural features of PBP2-inhibitory (green) and -noninhibitory (red)
compounds.
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JEK-42 was resynthesized from 4'-methyl-[1,1'-biphenyl]-4-carboxylic acid and
methyl 5-fluoroanthranilate using the method shown in Scheme 4.1. The compound was
tested for inhibition of tPBP2H041 at 100 µM and showed 99 ± 1% suppression of activity
(Figure 4.3A). Further evaluation in a disc diffusion assay against N. gonorrhoeae FA19
and H041 revealed that JEK-42 inhibits growth of these strains with 18.0 ± 0.9 mm and
15.3

± 0.4 mm zones of inhibition, respectively (Figure 4.3B). This inhibition is

comparable to a ceftriaxone control disc, which shows zones of inhibition measuring 19.3
± 1.3 mm against FA19 and 14.6 ± 3.8 mm against H041. To assess the possibility for
broad-spectrum activity, the compound was also assayed against Pseudomonas
aeruginosa PBP3, against which it showed 74 ± 1% inhibition (Figure 4.3A).

F
O

O
OH

H 2N
Cl

(COCl)2

O OMe

a

b

F

O
N
H

LiOH
O

OMe

F

O

c

N
H
O

OH

JEK-42

Scheme 4.1: Synthesis of JEK-42 from 4’-methyl-[1,1’-biphenyl]-4-carboxylic acid. a. DMF, DCE,
N2, RT, 12 h. b. pyridine, DCM, N2, RT, 8 h. c. 1:1 THF/H2O, RT, 12 h.
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Figure 4.3: Activity data for JEK-42. A. PBP inhibition was determined in a purified protein assay
in which a given PBP was preincubated with 100 µM compound, followed by addition of 1 µM
Bocillin-FL. Data are presented as a fraction of DMSO control. B. Antimicrobial activity was
determined in a disc diffusion assay against susceptible reference gonococcal strain FA19 and
multi-drug resistant H041 at 10 µg per disc. Data for a ceftriaxone control disc (CRO) are shown.
Error bars are standard deviation.

4.2.b. Synthesis and testing of a sulfonamide derivative of JMT-1
To examine the effect of modifications to the carbonyl group of JEK-42, simple
isosteric substitution of the amide with a sulfonamide was performed to give 5-fluoro-2(4'-methyl-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-1), obtained from 4'-methyl[1,1'-biphenyl]-4-sulfonyl chloride and methyl 5-fluoroanthranilate using the synthetic
method shown in Scheme 4.2. JMT-1 was screened at 100 µM against both tPBP2WT and
tPBP2H041, against which it showed 93 ± 7% and 84 ± 2% inhibition, respectively (Figure
4.4A). The compound was found to have antimicrobial activity as well, albeit slightly less
than that of JEK-42. In disc diffusion assays, JMT-1 exhibits a 16.7 ± 1.2 mm zone of
inhibition against N. gonorrhoeae FA19 and a 10.8 ± 0.4 mm zone of inhibition against N.
gonorrhoeae H041 (Figure 4.4B). The compound is also active against P. aeruginosa
PBP3, showing 70 ± 2% inhibition at 100 µM (Figure 4.4A).
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Scheme 4.2: Synthesis of JMT-1 from 4’-methyl-[1,1’-biphenyl]-4-sulfonyl chloride. a. pyridine,
DCM, N2, RT, 12 h. b. 1:1 THF/H2O, RT, 12 h.

Figure 4.4: Activity data for sulfonamide derivative JMT-1. A. PBP inhibition was determined in a
purified protein assay in which a given PBP was preincubated with 100 µM compound, followed by
addition of 1 µM Bocillin-FL. Data are presented as a fraction of DMSO control. B. Antimicrobial
activity was determined in a disc diffusion assay against susceptible reference gonococcal strain
FA19 and multi-drug resistant H041 at 10 µg per disc. Data for a ceftriaxone control disc (CRO)
are shown. Error bars are standard deviation.
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4.3. Prediction of the binding modes of JEK-42 and JMT-1
4.3.a. In tandem docking and molecular dynamics against tPBP2WT and tPBP2H041
Important for inhibition by the amides and sulfonamides is the presence of an
anthranilic acid motif, and not its meta- or para-aminobenzoic acid analogues. This is
perhaps due to the same constraints placed on β-lactam antimicrobials for their mimicry
of the D-Ala-D-Ala substrate of peptidoglycan. Depending upon the C1-C2-N-C dihedral
(or C1-C2-N-S in the case of sulfonamides), the distance between the carboxylate carbon
and the amide oxygen in these molecules (analogous to the Cohen distance in β-lactams)
ranges from 2.5 Å to 5.0 Å. Thus, in certain conformations, the reported scaffolds may be
capable of mimicking β-lactams in their binding to PBPs. A comparison of the structural
similarities among cephems, JEK-42, and JMT-1 is shown in Figure 4.5.

Figure 4.5: Structural similarities between cephems and the base scaffolds of JEK-42 and JMT-1.
The examined PBP2 inhibitors share a triad of features, including an acidic group, a hydrogen bond
acceptor, and a hydrophobic/aromatic group.
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Initial attempts to crystallize these compounds in complex with tPBP2 variants
were unsuccessful, perhaps due to their limited affinity and aqueous solubility. For this
reason, in silico tools were employed to model their potential binding modes. Using
constraints informed by structures of PBP2 variants in complex with ceftriaxone, ligands
JEK-42 and JMT-1 were flexibly docked into the active sites of tPBP2WT and tPBP2H041,
followed by 5 ns molecular dynamics simulations to assess the stability of the generated
poses. While substantial movement of the ligand anionic group is observed in the first 500
ps for simulations of JEK-42 and JMT-1 in complex with tPBP2WT (Figures 4.6 and 4.7),
the modeled complexes are stable for the remaining 4.5 ns according to measurements
of ligand-tPBP2 interaction energy, ligand internal energy, and root mean square deviation
(rmsd) of the ligand from its initial position (Figures 4.6 and 4.9). The tPBP2H041 complexes
are stable for the entirety of the simulation by these same measures (Figures 4.6, 4.8,
and 4.10). Overall, the consistency of energy scores and ligand positions indicate that the
in silico analyses generated reasonable hypotheses for the ligands’ true binding modes at
equilibrium.
In the modeled poses, JMT-1 shows a more favorable interaction energy with both
tPBP2WT and tPBP2H041 compared to JEK-42, due in large part to improved electrostatics
(Table 4.1). However, while the sulfonamide may provide better contact with the active
site, it appears to do so at the expense of ligand internal energy, as JMT-1 must assume
a higher energy conformation for binding to the transpeptidase active site. A majority of
this energy comes from angle bending and intramolecular electrostatic repulsion.
Interestingly, while JMT-1 exhibits a significant reduction in interaction energy with
tPBP2H041 compared to tPBP2WT, there is no such reduction for JEK-42. This is a possible
explanation for the relative activities of the compounds against tPBP2H041 in the in vitro
competition assay with Bocillin-FL.
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Table 4.1: Summary data for molecular dynamics simulations of JEK-42 and JMT-1 in complex
with tPBP2. aAverage energy calculated from the state of the system in intervals of 500 ps (n = 11).
b
Overall variation in tPBP2 complex structure, as calculated by the alignment and superimposition
of 11 states representing the system at 500 ps intervals. cTotal ligand displacement from its initial
position.

Receptor
Ligand
LigandReceptor
Interaction
Energies
(kcal mol-1)a

tPBP2WT
JEK-42
JMT-1

Overall

-155.3 ± 11.8

-234.7 ± 9.8

van der
Waals

-26.1 ± 4.3

-26.4 ± 4.6

Electrostatics

-129.0 ± 16.4

Overall
Strain
Angle Bend
Ligand
Internal
Out of Plane
Energy
Torsion
(kcal mol-1)a
van der
Waals
Electrostatics
Complex rmsd (Å)b
Ligand rmsd (Å)c

60.5 ± 7.2
8.1 ± 3.7
21.6 ± 4.3
3.7 ± 1.8
29.2 ± 4.0

-208.5 ±
16.2
131.9 ± 6.4
10.1 ± 4.5
37.8 ± 5.3
2.8 ± 1.5
21.9 ± 3.9

11.0 ± 2.1
-16.1 ± 4.0
0.920
2.4

tPBP2H041
JEK-42
JMT-1
-158.4 ±
-123.2 ± 4.9
12.6
-29.1 ± 3.7

-32.2 ± 3.7

56.0 ± 8.2
9.1 ± 4.3
19.5 ± 3.7
4.2 ± 1.6
23.4 ± 3.8

-125.9 ±
13.8
152.4 ± 4.7
9.9 ± 4.5
41.3 ± 3.3
5.0 ± 1.9
27.0 ± 4.3

11.6 ± 2.2

13.4 ± 2.5

9.1 ± 1.3

47.4 ± 4.7
1.114
1.5

-15.0 ± 6.4
0.554
1.3

57.7 ± 3.4
1.013
1.9

-123.2 ± 4.9
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Figure 4.6: Energy and position analyses for molecular dynamics simulations of JEK-42 and JMT1 in complex with tPBP2WT and tPBP2H041. A. Potential energy of interaction was calculated for the
tPBP2WT-JMT complexes at intervals of 250 ps. Data beyond 500 ps were fit to linear regressions
to determine change in attractive/repulsive forces in the active site over time. All slopes are
statistically insignificant. B. Ligand potential energy was calculated for poses in complex with
tPBP2WT at intervals of 250 ps. Data beyond 500 ps were fit to linear regressions to determine
change in pose energetic favorability over time. All slopes are statistically insignificant. C. Ligand
displacement from its initial pose was calculated at intervals of 500 ps. Data beyond 500 ps were
fit to linear regressions to determine ligand movement over time. All slopes are statistically
insignificant. D. Potential energy of interaction analysis for tPBP2H041-JMT complexes. All slopes
are statistically insignificant. E. Ligand potential energy analysis for tPBP2H041-JMT complexes. All
slopes are statistically insignificant. F. Ligand displacement analysis for tPBP2H041-JMT complexes.
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Figure 4.7: Change in positions of JEK-42 (A) and JMT-1 (B) in the active site of tPBP2WT over the
first 500 ps of molecular dynamics simulations. A. In the first 500 ps of the molecular dynamics
simulation, JEK-42 moves to an rmsd of 2.4 Å, much of which is accounted for by the flipping of
the anthranilic acid moiety. At the start of the simulation (ligand and receptor shown in yellow), the
carboxylic acid faces T498, and the aromatic ring is angled such that it faces S310. At the end of
the initial phase of the simulation (ligand shown in purple, receptor shown in pink), it has rotated
approximately 90° such that the carboxylic acid now faces S310 and S362. B. JMT-1 moves to an
rmsd of 1.5 Å in the first phase of the simulation. Like JEK-42, its carboxylic acid faces T498 at the
start of the simulation (shown in orange), and by 500 ps (ligand shown in teal, receptor shown in
cyan), the aromatic ring has rotated approximately 60° such that the carboxylic acid faces S310
and S362.
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Figure 4.8: Change in positions of JEK-42 (A) and JMT-1 (B) in the active site of tPBP2H041 over the first 500 ps
of molecular dynamics simulations. A. In the first 500 ps of the molecular dynamics simulation, JEK-42 does not
experience much movement (rmsd of 1.3 Å). The carboxylic acid faces S545 both at the beginning (shown in
yellow) and at the end of this period (ligand shown in purple, receptor shown in pink). B. JMT-1 also shows very
little positional change over the initial phase of the simulation, moving to an rmsd of 1.6 Å. Like JEK-42, its
carboxylic acid faces S545 both at the start (shown in orange), and at 500 ps (ligand shown in teal, receptor
shown in cyan).
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Figure 4.9: Molecular dynamics simulations of JEK-42 (A) and JMT-1 (B) in complex with tPBP2WT. A. In the
later stages of the molecular dynamics simulation, JEK-42 (purple) does not experience significant movement
in the active site of tPBP2WT. States isolated at 500-ps intervals are indicated by transparent sticks. In its final
position (solid sticks), the carboxylic acid interacts with the side chains of S310, S362, and K497, and the
amide carbonyl oxygen projects into the oxyanion hole created by S310 and T500. B. JMT-1 (teal) also shows
very little positional change in the later stages of the simulation (timepoints represented as transparent sticks,
final position represented as solid sticks). In its final position, the carboxylic acid interacts with the side chains
of K313, T483, K497, and T498, and one sulfonyl oxygen projects into the oxyanion hole.
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Figure 4.10: Molecular dynamics simulations of JEK-42 (A) and JMT-1 (B) in complex with tPBP2H041. A. In the later stages of the
molecular dynamics simulation, JEK-42 (purple) does not experience significant movement in the active site of tPBP2H041. States
isolated at 500-ps intervals are indicated by transparent sticks. In its final position (solid sticks), the carboxylic acid interacts with the
side chains of T500 and S545, and the amide carbonyl oxygen projects into the oxyanion hole created by S310 and T500. B. JMT-1
(teal) also shows very little positional change in the later stages of the simulation (timepoints represented as transparent sticks, final
position represented as solid sticks). In its final position, the carboxylic acid interacts with the side chains of T500 and S545, and one
sulfonyl oxygen projects into the oxyanion hole.

For all complexes examined, a carbonyl or sulfonyl oxygen is positioned within the
oxyanion hole created by the main chain nitrogens of Ser310 and Thr500, a position that
is well-maintained throughout all molecular dynamics simulations (Figure 4.11A). An
additional hydrogen bond is observed between the second sulfonyl oxygen of JMT-1 and
the side chain of Thr500. Also consistent across models is the position of the 1,1’-biphenyl
system, which projects into a hydrophobic patch comprising Phe420 and Tyr422 (Figure
4.11B). In the distribution of states seen over the course of the simulations, these 1,1’biphenyl systems assume two predominant positions related by rotation: one in which the
secondary aromatic ring forms H-π interactions with Asn364, and one in which it
participates in π-stacking with Phe420. There is another less abundant state in which the
ring participates in π-stacking with Tyr422.

Figure 4.11: Common interactions of JEK-42 and JMT-1 with tPBP2. A. The carbonyl or sulfonyl
oxygens of the ligands fits into the oxyanion hole created by the main chain nitrogens of S310 and
T500 over the course of the molecular dynamics simulations. Polar contacts with the main chain
are shown as black dashed lines. B. The biphenyl moieties of all three ligands sit in a hydrophobic
patch of tPBP2 surface created by the side chains of F420 and T422 and can participate in either
π-π interactions with these residues, or in H-π interactions with the N364 side chain.
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Differences among the modeled complexes are apparent in the positioning of the
acidic moieties of the ligands. For models of JEK-42 and JMT-1 in complex with tPBP2WT,
the anthranilic acid moieties adopt different orientations, perhaps due to differences in the
geometries of their carbonyl (sp2) and sulfonyl (sp3) functional groups (Figure 4.9). JEK42 is positioned such that the anthranilic acid ring is angled toward β3 and α11, with its
carboxylate contacting the side chains of Ser310, Ser362, and Lys497. In the JMT-1
complex, the anthranilic acid moiety occupies a more central position in the active site,
and its carboxylate makes contacts with the side chains of Lys313, Thr483, Lys497, and
Thr498. By contrast, in tPBP2H041-bound poses, the anthranilic acid moieties of JEK-42
and JMT-1 are nearly identical (Figure 4.10). In the absence of Thr498 rotation toward a
bound acidic group, the carboxylate participates in hydrogen bonding with Ser545 and
Thr500, and the aromatic ring lies flat along the floor of the active site.
4.3.b. Homology modeling and rigid alignment of class B PBPs
As noted above, the docking and molecular dynamics data reveal potential
interactions of the 1,1’-biphenyl systems of JEK-42 and JMT-1 with N364 and F420 of
PBP2. As part of the SxN motif, N364 is highly conserved in bacterial transpeptidases.
Examination of crystal structures and homology models of class B PBPs (model statistics
for which are shown in Chapter 3) reveals that F420 is also highly conserved, with an
aromatic residue being present at this position in many Gram-negative and Gram-positive
pathogens (Figure 4.12, Table 4.2). If the proposed binding modes for JEK-42 and JMT1 are correct, conservation of both N364 and F420 indicates promise for inhibition of a
variety of class B PBPs and, thus, potential for broad spectrum antimicrobial activity.
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Figure 4.12: Alignment of ⍺8 of class B PBPs showing conservation of an aromatic residue in
several important Gram negative and Gram positive pathogens. A. In Gram negative pathogens,
aromatic residues are conserved at the positions of F420 and Y422, creating an aro-x-aro motif. N.
gonorrhoeae PBP2 (teal), E. coli PBP3 (chartreuse), P. aeruginosa PBP3 (magenta), P. aeruginosa
PBP3a (pink), A. baumanii PBP3 (light orange), H. influenzae PBP3 (blue), H. pylori PBP3 (grey).
B. In Gram positive pathogens, an aromatic residue at the position of F420 is frequently conserved,
but there is generally a glutamine at the position of Y422. S. aureus PBP2a (green), S. pneumoniae
PBP2x (purple), E. faecalis PBP4 (maroon), E. faecium PBP5 (pink), B. subtilis PBP2b (yellow), B.
subtilis PBP3 (orange).
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Table 4.2: Superimposition of class B PBPs. aResidues from rigid structural alignment that occupy
the same position as F420 in PBP2 of N. gonorrhoeae. bResidue type. *No structural data available
– homology model constructed using SWISS-MODEL.

Morphology

Gram
negative

Gram
positive

Atypical

Organism
N. gonorrhoeae
N. gonorrhoeae
N. meningitidis
P. aeruginosa
P. aeruginosa
E. coli
A. baumanii
H. influenzae
H. influenzae
H. pylori
H. pylori
S. aureus
S. pneumoniae
S. pneumoniae
S. pneumoniae
S. pneumoniae
E. faecalis
E. faecium
B. subtilis
B. subtilis
B. subtilis
M. tuberculosis
B. burgdorferi

Class B PBP
PBP2-H041
PBP2-WT (3EQU)
PBP2*
PBP3 (3PBN)
PBP3a*
PBP3 (4BJP)
PBP3 (3UE3)
PBP2*
PBP3*
PBP2 (5LP4)
PBP3*
PBP2a (5M1A)
PBP2x (5OAU)
PBP2x (1PYY)
PBP2x (1QME)
PBP2b (2WAE)
PBP4 (6BSQ)
PBP5 (6MKA)
PBP2a*
PBP2b*
PBP3*
PBPA (3LO7)
PBP2*

F420a
F420
F420
I462
Y407
F401
F417
Y448
I461
Y438
I432
Y441
Y519
F450
F450
F450
F450
Y540
Y538
I523
Y420
Y526
I337
I431

Typeb
aromatic
aromatic
hydrophobic
aromatic
aromatic
aromatic
aromatic
hydrophobic
aromatic
hydrophobic
aromatic
aromatic
aromatic
aromatic
aromatic
aromatic
aromatic
aromatic
hydrophobic
aromatic
aromatic
hydrophobic
hydrophobic
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4.4. Virtual screen of a molecular fragment library for putative PBP2 inhibitors.
The design of compounds applying the 4’-methyl-[1,1’-biphenyl] system to other
C-terminal peptidomimetic functionalities may yield additional, more potent inhibitors of N.
gonorrhoeae PBP2. To this end, a three-point pharmacophore comprising the common
characteristics of bicyclic β-lactams (i.e., penams, carbapenems, and cephalosporins)
together with JEK-42 and JMT-1 was generated from a flexible alignment of the scaffolds
using a stochastic conformational search (Figure 4.13). This pharmacophore was then
employed to search an ~800,000-ligand fragment-like subset of the ZINC virtual database
for putative inhibitors of N. gonorrhoeae PBP2, yielding 139,444 matching conformers
(Figure 4.14).

Figure 4.13: Pharmacophore model developed from the flexible alignment of JEK-42 and JMT-1
with bicyclic β-lactam scaffolds. Common features were identified using a threshold of 100% and a
tolerance of 1.0 Å. The resulting model consists of three features: anionic (red mesh, radius = 0.7
Å), hydrophobic/aromatic (green mesh, radius = 0.9 Å), hydrogen bond acceptor (cyan mesh,
radius = 1.0 Å). JEK-42 is shown in purple, JMT-1 is shown in teal, and β-lactams are shown in
grey.
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Figure 4.14: Pharmacophore search of a virtualized library of molecular fragments. A. A threepoint pharmacophore consisting of one anionic feature (radius = 0.7 Å), one hydrophobic/aromatic
feature (radius = 0.9 Å), and one hydrogen bond accepting feature (radius = 1.0 Å) was used to
search a virtual library of molecular fragment structures, yielding 139,444 matching conformations.
B. Example 2-(1,2,4-oxadiazol-5-yl)benzoic acid fragment shown in a pharmacophore-matching
conformation (rmsd = 0.1 Å). C. Example 2-(1,2,4-oxadiazol-5-yl)benzoic acid (green) fragment
modeled into the active site of tPBP2WT. Polar contacts are indicated by black dashed lines.

Predictably, while the screen revealed a few structures that diverge significantly
from known inhibitors, it predominantly yielded matches that represent simple derivatives
of the above scaffolds. A majority of the putative hits can be divided into four structural
categories. The first grouping is the most β-lactam-like, consisting of polycyclic carbonylcontaining structures substituted at the β-position with a carboxylic acid (Figure 4.15).
The carbonyl groups are varied and include lactams, lactones, and acyclic amides.
Because β-lactams generally form low-affinity Michaelis complexes with PBPs, fragments
i through iv are likely not the best starting points for the design of potent inhibitors. More
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interesting are the bridged structures v through viii, which can be used to investigate the
effects of bulk and volume of the hydrophobic feature, in comparison to monocyclic
systems that are flat, flexible, or both. The second grouping (ix-xi) consists of saturated
carbocyclic carboxylic acids substituted at the 2-position with an amide, similar to JEK-42
but with more conformational flexibility at the position of the hydrophobic feature (Figure
4.16). The third grouping contains benzoic acid analogues substituted at the 2-position
with various amide isosteres, including esters (xii, acetyl salicylic acid), ketones (xiii),
ureas (xiv and xv), and 5-membered heterocycles (i.e., 1,3,4-oxadiazole xvi,1,2,4oxadiazole xvii, thiazoles xviii and xix, imidazole xx, and 1,3,4-triazole xxi) (Figure 4.17).
Incorporation of these types of functional groups in place of the amide seen in JEK-42 or
the sulfonamide seen in JMT-1 would help to explore specific requirements of shape and
conformational flexibility at the hydrogen bond accepting feature. The fourth grouping
(xxii-xxvi) contains fragments that combine the structural modifications of the first three
(Figure 4.18). In all, the results from this experiment provide multiple avenues for the
discovery of additional PBP-inhibitory molecules.
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4.5. Discussion
In this work, we report the discovery of prototype PBP2 inhibitors and the creation
of models for the identification or design of others. First, we show that JEK-42 and its
isosteric derivative JMT-1 are PBP2-inhibitory scaffolds with antimicrobial activity against
N. gonorrhoeae FA19 and H041. We also show that they are capable of inhibiting PBP3
from ESKAPE pathogen P. aeruginosa. With this cross-inhibition in mind, we present
models for the binding of these compounds in which they resemble β-lactam
antimicrobials, presumably mimicking the C-terminal D-Ala-D-Ala motif of peptidoglycan in
a similar manner. Finally, we present a pharmacophore model used in the identification of
putative PBP2 inhibitors through screening of a fragment library, putative hits from which
serve as a source of guidance for future analogue design.
4.5.a. Arylamides and arylsulfonamides
To date, two studies have reported inhibition of PBPs by arylamides: a small
physical screen followed by a structural similarity search for inhibitors of S. aureus PBP2a
and S. pneumoniae PBP2x,627 and subsequent combinatorial chemistry to explore the
scaffold, conducted in the Gobec laboratory.628 Their best hit was 5-bromo-2-(3propoxybenzamido)benzoic acid, with an IC50 of 230 μM against PBP2a and 155 μM
against PBP2x (Figure 4.19). They also observed that only amides of anthranilic acids
(i.e., o-aminobenzoic acids) exhibit significant inhibition of either PBP2a or PBP2x,
consistent with the results of our initial screen. The structures explored previously were
limited to substituted phenyl systems, so the 1,1’-biphenyl system reported in JEK-42
represents a departure into novel chemical space for PBP inhibition. In the same
publications from the Gobec laboratory, arylsulfonamides derived from anthranilic acid
were also shown to possess PBP-inhibitory activity.627,628 Around the same time, in a highthroughput physical screen conducted by Fedarovich et al., additional arylsulfonamides
were identified as inhibitors of N. gonorrhoeae PBP2.621 The best hits from those studies
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were 5-bromo-2-(naphthalene-2-sulfonamido)benzoic acid (IC50 = 80 μM against
SauPBP2a) and N-(4-hydroxynaphthalen-1-yl)naphthalene-1-sulfonamide (IC50 = 50 μM
against NgPBP2), respectively (Figure 4.19). Notably, this scaffold, unlike its carboxamide
isostere, does not seem to require a carboxylic acid for inhibition. However, the active
compounds lacking a carboxylic acid do possess an ionizable phenolic OH situated para
to the sulfonamide. The chemical space examined in previous studies was limited largely
to naphthyl moieties, so again, the 1,1’-biphenyl system reported in JMT-1 is novel.
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Figure 4.19: Structures of reported arylamide and arylsulfonamide PBP inhibitors.
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While there are many available compounds belonging to these chemotypes for
testing, future studies focusing on synthetic and medicinal chemistry may prove more
useful. Amide synthesis from acyl chlorides is generally facile, and its broad functional
group tolerance allows access to molecules with a variety of topologic and electronic
structures. Most simple derivatives can be attained from their corresponding carboxylic
acids and amines in two steps in excellent yield, as shown in Scheme 4.3. Fortunately,
similar to the amides, the synthesis of sulfonamides from their corresponding sulfonyl
chlorides and anthranilic acids can also be achieved in few steps in the presence of a
variety of functional groups. In cases of derivatives for which the sulfonyl chloride is
unavailable, other methods employing dediazotization or organometallic agents provide
access to this functional group, as shown in Scheme 4.4.
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4.5.b. Molecular dynamics and cross-inhibition of other class B PBPs – evidence
for broad specificity
Due to key structural similarities between cephalosporins and the described
scaffolds, we propose that JEK-42 and JMT-1 may bind the transpeptidase active site in
a manner similar to cephalosporins, where the 1,1’-biphenyl system corresponds to R1
and the anthranilic acid substitution corresponds to R2. Docking and molecular dynamics
of JEK-42 and JMT-1 yield poses similar to acylenzyme complexes of ceftriaxone with
tPBP2WT and tPBP2H041 113,134 (Figure 4.20). In poses of both ligands in both receptors,
the carbonyl or sulfonyl oxygen occupies the same position as the acyl oxygen of
ceftriaxone within the oxyanion hole. While the positions of anionic groups are variable
due to the different geometric constraints of each scaffold, they are generally in the same
region of the active site in comparisons of the same tPBP2 variant. Moreover, the 1,1’biphenyl system projects in the same direction as the 2-aminothiazol-4-yl group of
ceftriaxone. There is better overlap with the tPBP2H041-ceftriaxone structure, with the
aromatic rings fitting into the hydrophobic area of PBP2 surface created by F420 and
Y422. The basis for inhibition of both tPBP2WT and tPBP2H041 by JEK-42 and JMT-1 may,
therefore, be that they 1) mimic the peptide C-terminus in a manner similar to β-lactams,
and 2) avoid the requirement for β3-β4 hinging proposed to enhance contacts of the
cephalosporin thiazole with the tPBP2WT active site. This, in combination with their
predicted interactions with highly conserved residues, suggests that JEK-42 and JMT-1
may be capable of inhibiting a variety of class B PBPs. This hypothesis is further
strengthened by the compounds’ abilities to inhibit P. aeruginosa PBP3, another class B
PBP with only 40% sequence identity.
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Figure 4.20: Overlay of ceftriaxone (CRO) acyl structures with JEK-42 and, JMT-1. A. Published
tPBP2WT-CRO complex superimposed on final positions of ligands from molecular dynamics
simulations with tPBP2WT (receptor shown in grey, CRO shown as orange sticks, JEK-42 shown
as purple sticks, JMT-1 shown as teal sticks). B. Published tPBP2H041-CRO complex superimposed
on final positions of ligands from molecular dynamics simulations with tPBP2H041 (same color
scheme as above).
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4.5.d. Guidance for further derivatization
The three-point pharmacophore screen of fragments proposes a number of
changes that can be made to the anthranilic acid moiety, including replacement of the
aromatic system with bridged polycyclic or flexible saturated carbocycles. The more
interesting aspect of the fragment screen, however, is perhaps the variety of amide
isosteres that emerged, including the 1,2,4-oxadiazoles. Many 1,2,4-oxadiazoles have
now been reported with activity against S. aureus PBP2a,633-636 and the class is discussed
in detail in Chapter 1. Briefly, shown in Figure 4.21 is the current lead compound from this
series, exhibiting an MIC of 4 µg/mL against MRSA, low in vitro cytotoxicity, favorable
murine pharmacokinetics, and efficacy in a murine model of staphylococcal peritonitis.635
Another amide isostere emerging from the pharmacophore screen with precedent in the
literature is urea. The 2-ureidobenzenesulfonic acids, also discussed in Chapter 1, were
reported as inhibitors of S. pneumoniae PBP2x.630 The reported IC50 for the ureido
compound shown in Figure 4.21 against PBP2x is 71 µM. Application of these isosteres,
and others from the screen results, to our system will provide important information about
the steric and electronic requirements of the PBP2 active site at the location occupied by
the amide and sulfonamide of JEK-42 and JMT-1, respectively.
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Figure 4.21: 1,2,4-oxadiazole and 2-ureidobenzenesulfonic acid PBP inhibitors.

4.5.e. Significance
Here we report the identification and initial characterization of two novel inhibitors
of

PBP2

from

N.

gonorrhoeae:

2-(arylamido)benzoic

acid

JEK-42

and

2-

(arylsulfonamido)benzoic acid JMT-1. The overall picture emerging from studies of these
compounds is that they are not susceptible to the PBP2 modifications that result in
cephalosporin resistance, and that they may be capable of inhibiting a number of other
class B PBPs due to 1) their structural resemblance to β-lactams and 2) predicted
interactions with highly conserved residues.
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CHAPTER 5: Derivatization of Identified PBP-Inhibitory Chemotypes
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5.1 Introduction
Chapter 4 outlines the discovery of novel PBP2-inhibitory chemotypes proposed
to mimic the binding of β-lactams and, thus, the bacterial peptidoglycan D-Ala- D-Ala motif.
The next phase of our investigation is the derivatization of these molecules, with the goal
of enhancing in vitro potency against N. gonorrhoeae PBP2 and against the pathogen
itself. In this chapter, the synthesis of 127 analogues of JMT-1, as well as their PBP2inhibitory and antigonococcal activity, is described.

F

O
N
H
O

OH

JEK-42

F

O O
S
N
H
O

OH

JMT-1

Figure 5.1: Structures of prototype compounds JEK-42 and JMT-1.
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5.2. Derivatization of JMT-1 sulfonamides
Sulfonamide synthesis is achievable in two simple steps from commercially
available sulfonyl chloride starting materials, shown in Scheme 5.1. The first step is
substitution of the sulfonyl chloride (a) with either a methyl anthranilate or 2aminobenzonitrile. The methyl benzoate products are treated with lithium hydroxide (b) to
afford the corresponding carboxylic acid, and benzonitrile products undergo a 1,3-dipolar
cycloaddition with sodium azide under copper (II) sulfate catalysis (c) to generate the
corresponding tetrazole. All JMT-1 derivatives reported herein were prepared using this
route.

O
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R
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S
Ar
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N
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Scheme 5.1: Synthesis of JMT-1 derivatives. a. pyridine, DCM, N2, RT, 12 h. b. 1:1 THF/H2O, RT,
8 h. c. CuSO4·5H20, DMSO, 150°C, 1 h.
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5.2.a. Modifications to the anthranilic acid moiety I: Substitution at positions 4
through 6

R1
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N
H

R3
O
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R1 = H
R1 = F
R1 = F
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R2 = H
R2 = H
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R3 = H
R3 = H
R3 = H
R3 = H
R3 = H
R3 = H
R3 = H
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13:
14:
15:

OH

R1 = Me
R1 = H
R1 = H
R1 = CF3
R1 = H
R1 = OMe
R1 = H

R2 = H
R2 = Me
R2 = H
R2 = H
R2 = CF3
R2 = H
R2 = OMe

R3 = H
R3 = H
R3 = Me
R3 = H
R3 = H
R3 = H
R3 = H

Figure 5.2: Structures of compounds JMT-2 through JMT-15, which possess substitutions on the
anthranilic acid moiety of JMT-1.

To begin, we surveyed each position on the anthranilic acid moiety of JMT-1 to
determine functional groups and substitution patterns that increase inhibition of PBP2. For
all compounds synthesized, inhibition of tPBP2WT and tPBP2H041 was determined at 100
µM using the previously described competition assay with Bocillin-FL. Compounds
showing >80% inhibition of both variants at 100 µM were tested at 10 µM. Data for this
initial series are shown in Figure 5.3 and Figure 5.4. Examining the compound set from
Kirkpatrick et al. screened earlier (as described in Chapter 4), substitution at the 3-position
was already found to abolish activity of carboxamido compounds related to JEK-42, so
under the assumption that JEK-42 and its sulfonamide isostere JMT-1 bind similarly to
PBP2, this position was not examined. The data show that the fully unsubstituted version
(JMT-2) is less active at 100 µM than JMT-1, with 71 ± 4% inhibition of tPBP2WT compared
to 93 ± 7% for JMT-1. A switch of the 5-fluoro moiety to the 4-position (JMT-3) did not
change activity significantly; however, the 4,5-difluoro compound JMT-4 exhibits a sharp
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increase in potency, inhibiting tPBP2WT and tPBP2H041 fully at 100 µM and showing 87 ±
6% inhibition against tPBP2H041 at 10 µM. Note the 6-fluoro product was not obtained in
sufficient yield and purity for testing.
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Figure 5.3: Inhibition data for JMT-2 through JMT-15 against tPBP2WT and tPBP2H041 at 100 µM.
Values were determined in a purified protein assay in which tPBP2 was preincubated with 100 µM
compound, followed by addition of 1 µM Bocillin-FL. Data are presented as a fraction of activity of
the DMSO control. Error bars are standard deviation.
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Figure 5.4: Inhibition data for selected anthranilic acid-substituted derivatives of JMT-1 against
tPBP2H041 at 10 µM. Compounds exhibiting greater than 80% inhibition of both tPBP2WT and
tPBP2H041 activity at 100 µM (Figure 5.3) were tested. Values were determined in a purified protein
assay in which tPBP2H041 was preincubated with 10 µM compound, followed by addition of 1 µM
Bocillin-FL. Data are presented as a fraction of activity of the DMSO control. Error bars are standard
deviation.
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To examine the effects of increasing atomic radius at the 4- and 5-positions,
analogues with additional halogens were synthesized. Analogues chlorinated (JMT-5 &
JMT-6) or brominated (JMT-7 & JMT-8) at 4- and 5-positions are active at 100 µM, with
the 5-bromo compound JMT-8 exhibiting 96 ± 2% inhibition of tPBP2H041 at 10 µM. The 5iodo product could not be synthesized in sufficient yield for testing. Further increases in
bulk were explored with a series of methyl substitutions at the 4- and 5-positions, revealing
the 4-methyl analogue JMT-9 to be the more active. Interestingly, while JMT-9 exhibits 85
± 9% inhibition of tPBP2H041 at 10 µM, the 5-methyl analogue JMT-10 fails to inhibit
tPBP2H041 fully at 100 µM. The 6-position was also surveyed by testing 6-methyl analogue
JMT-11, whose relatively weak inhibition indicates that substitution at this position is not
favored.
Given the lesser activity of methyl compounds compared to their halogenated
analogues, it can be inferred that either activity is dependent upon a very specific van der
Waals radius of substituents to the anthranilic acid, or upon the polarizability of these
substituents. To answer this question, analogues possessing a trifluoromethyl group at
the 4- (JMT-12) or 5-position (JMT-13) were synthesized and potently inhibited both
tPBP2WT and tPBP2H041. The relative potencies of compounds JMT-12 and JMT-13 (97 ±
1% and 99 ± 1% inhibition, respectively, of tPBP2H041 at 10 µM) suggest that both van der
Waals radius and polarizability of substituents correlate positively with PBP2 inhibition.
All generated compounds discussed to this point possess anthranilic acid moieties
substituted with hydrophobic functional groups. In order to assess the effects of polarity,
4- (JMT-14) and 5-methoxy (JMT-15) compounds were generated. JMT-14 is more active
than JMT-15 against tPBP2H041 but not more than the prototype JMT-1, indicating
tolerance of modestly polar groups at this position rather than any preference for them. To
explore polarity further, synthesis of a 5-nitro analogue was also attempted, but the
desired product was not found on mass spectrometric analysis of the crude reaction
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mixture. In all, the pattern emerging from these initial derivatization studies suggests the
following in terms of tPBP2 inhibition:
4-CF3 ~ 5-CF3 ~ 5-Br > 4-Cl ~ 4,5-diF ~ 4-Br ~ 4-Me >
5-Cl > 4-OMe > 5-OMe ~ 4-F > H > 6-Me
Compounds exhibiting >75% inhibition of tPBP2H041 at 10 µM were tested in disc
diffusion assays against N. gonorrhoeae FA19 and H041 (Figure 5.5). Consistent with
their enzymatic inhibition, compounds JMT-12, and JMT-13 exhibit the most potent
antimicrobial activity against both strains. JMT-12, a 4-trifluoromethyl analogue of
prototype JMT-1, inhibits growth of N. gonorrhoeae FA19 and H041 up to 20.5 ± 0.7 mm
and 15.5 ± 1.8 mm, respectively, from the edge of a disc impregnated with 10 µg
compound. JMT-13, the 5-trifluoromethyl analogue, shows a 19.0 ± 1.0 mm zone of
inhibition against FA19 and a 16.3 ± 1.1 mm zone of inhibition against H041. JMT-5 also
shows good antimicrobial activity against both strains, in contrast with JMT-8, which
shows a stark reduction in potency against H041.
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Figure 5.5: Disc diffusion data for potent anthranilic acid-substituted derivatives of JMT-1 against
N. gonorrhoeae FA19 and H041. Compounds exhibiting greater than 75% inhibition of tPBP2H041
activity at 10 µM were tested against susceptible reference gonococcal strain FA19 and multi-drug
resistant H041 at 10 µg per disc.
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5.2.b. Modifications to the anthranilic acid moiety II: Isosteric replacement of the
carboxylic acid for a 1H-tetrazol-5-yl moiety
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R3 = H
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R3 = H
R3 = H
R3 = H
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R1 = H
R1 = CF3
R1 = H
R1 = OMe
R1 = H

R2 = Me
R2 = H
R2 = CF3
R2 = H
R2 = OMe

R3 = H
R3 = H
R3 = H
R3 = H
R3 = H

Figure 5.6: Structures of compounds JMT-16 through JMT-25, which possess a 1H-tetrazol-5-yl
moiety at C1 in place of the carboxylic acid seen in JMT-1.

Next, we examined the effect of isosteric replacement of the carboxylic acid group
of the anthranilic acid moiety on PBP2 inhibition. The 1H-tetrazol-5-yl system was chosen
for these derivatives, as it confers favorable drug-like properties (e.g., improved
membrane permeability and resistance to some forms of xenobiotic metabolism) and is
easily accessed from nitriles using a copper(II)-catalyzed 1,3-dipolar cycloaddition.
Inhibition data for this initial set of phenyltetrazoles against tPBP2 are shown in Figure
5.7 and Figure 5.8. The generated tetrazoles JMT-16 through JMT-25 generally show
similar activity to their carboxylic acid analogues against tPBP2WT and tPBP2H041. Modest
improvements in tPBP2 inhibition are seen in several cases of 5-substitution, including 5fluoro (JMT-17), 5-chloro (JMT-18), 5-methyl (JMT-21), and 5-methoxy (JMT-25)
compounds. Consistent with results for the anthranilic acid compounds, substitution with
a trifluoromethyl group yields excellent tPBP2 inhibition, with 4- (JMT-22) and 5substituted (JMT-23) molecules showing 89 ± 4% and 83 ± 12% inhibition, respectively,
of tPBP2H041 at 10 µM.
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Figure 5.7: Inhibition data for JMT-16 through JMT-25 against tPBP2WT and tPBP2H041 at 100 µM.
Values were determined in a purified protein assay in which tPBP2 was preincubated with 100 µM
compound, followed by addition of 1 µM Bocillin-FL. Data are presented as a fraction of activity of
the DMSO control. Error bars are standard deviation.
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Figure 5.8: Inhibition data for 1H-tetrazol-5-yl derivatives of JMT-1 against tPBP2H041 at 10 µM.
Compounds exhibiting greater than 80% inhibition of both tPBP2WT and tPBP2H041 activity at 100
µM (Figure 5.7) were tested against tPBP2H041 at 10 µM. Values were determined in a purified
protein assay in which tPBP2 was preincubated with 10 µM compound, followed by addition of 1
µM Bocillin-FL. Data are presented as a fraction of activity of the DMSO control. Error bars are
standard deviation.
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As for the anthranilic acid compounds, the antimicrobial activity of the tetrazoles
was tested against N. gonorrhoeae strains FA19 and H041. Overall, antimicrobial activity
is weaker than for the carboxylic acid parent compounds (Figure 5.9). Trifluoromethyl
compounds JMT-22 and JMT-23 inhibit growth of N. gonorrhoeae within less than 15 mm
of the disc. Interestingly, whereas the 5-bromo carboxylic acid JMT-8 exhibits excellent
activity against FA19 but only modest activity against H041, its tetrazole analogue JMT19 seems to show very little difference between strains. JMT-19 is the most potent of this
series, exhibiting 17.3 ± 1.8 mm and 16.0 ± 1.4 mm zones of inhibition against FA19 and
H041, respectively.
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Figure 5.9: Disc diffusion data for potent 1H-tetrazol-5-yl derivatives of JMT-1 against N.
gonorrhoeae FA19 and H041. Compounds exhibiting greater than 75% inhibition of tPBP2H041
activity at 10 µM were tested against susceptible reference gonococcal strain FA19 and multi-drug
resistant H041 at 10 µg per disc.
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5.2.c. Modifications to the anthranilic acid moiety III: Replacement of aromatic ring
with heterocyclic carboxylic acids
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X = CH2
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X=S
X = CH2
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n=0
n=0
n=0
n=1
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Figure 5.10: Structures of compounds JMT-26 through JMT-30, which possess nitrogen-containing
heterocyclic carboxylic acids in place of the anthranilic acid seen in JMT-1.

A series of sulfonamides synthesized from nitrogen-containing heterocycles were
attempted to create scaffolds more closely resembling β-lactam antimicrobials. Inhibition
data for this series against tPBP2 are shown in Figure 5.11. Pyrrolidine (JMT-26) and
thiazolidine (JMT-27) compounds inhibit tPBP2WT only weakly at 100 µM. Next, the 5,5dimethylthiazolidine analogue JMT-28 was tested. Although this has a structure very
similar to most penams, it fails to show any inhibition at 100 µM. Cephem-like 6-membered
ring systems were also examined, but the incorporation of neither piperidine (JMT-29) nor
tetrahydro-1,3-thiazine (30) improves activity.
To determine if loss of the anthranilic acid moiety abolishes PBP2 binding fully, the
compounds were also tested at 1 mM. At this concentration, compounds JMT-26 through
JMT-30 all inhibit tPBP2WT, indicating a severe reduction in affinity, but not a complete
loss. Because of their low inhibition, none of these analogues was tested against N.
gonorrhoeae.
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Figure 5.11: Inhibition data for JMT-26 through JMT-30 against tPBP2WT and tPBP2H041 at 100 µM.
Values were determined in a purified protein assay in which tPBP2 was preincubated with 100 µM
compound, followed by addition of 1 µM Bocillin-FL. Data are presented as a fraction of activity of
the DMSO control. Error bars are standard deviation.
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5.2.d. Modifications to the biphenyl ring system I: Replacement of the 4’-methyl
group
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Figure 5.12: Structures of compounds JMT-31 through JMT-39, which lack the biphenyl 4’-methyl
group seen in JMT-1.

To determine the importance of the 4’-substituent to PBP2 inhibition, a series of
4’-desmethyl analogues (JMT-31 through JMT-39) were synthesized. Inhibition data for
this series against tPBP2 are shown in Figure 5.13 and Figure 5.14. The first of these,
JMT-31 through JMT-35, possess entirely unsubstituted biphenyl secondary aromatic
systems. These compounds are generally much less active than their 4’-methylated
counterparts, showing minimal inhibition of tPBP2WT at 100 µM. However, the 5-bromo
analogue JMT-35 inhibits both tPBP2WT and tPBP2H041 fully at this concentration, and it
retains some activity against tPBP2H041 upon dose reduction to 10 µM (66 ± 17%
inhibition). Its relative potency among compounds of this series supports the assertion that
a large, polarizable, hydrophobic group at C5 enhances inhibition.
To survey other positions on the biphenyl secondary aromatic ring, a small number
of 3’-methyl analogues (JMT-36 through JMT-39) were generated, which are marginally
less active than their 4’-methyl parent compounds. The most active of those synthesized
and tested is the 5-bromo analogue JMT-38, which exhibits 71 ± 8% inhibition of tPBP2H041
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at 10 µM, again supporting the requirement for a large, polarizable group at C5. Overall,
the lesser activity of 4’-desmethyl compounds indicates that substitution at the 4’-position
enhances PBP2-inhibitory potency.
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Figure 5.13: Inhibition data for JMT-31 through JMT-39 against tPBP2WT and tPBP2H041 at 100 µM.
Values were determined in a purified protein assay in which tPBP2 was preincubated with 100 µM
compound, followed by addition of 1 µM Bocillin-FL. Data are presented as a fraction of activity of
the DMSO control. Error bars are standard deviation.
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Figure 5.14: Inhibition data for 4’-desmethyl derivatives of JMT-1 against tPBP2H041 at 10 µM.
Compounds exhibiting greater than 80% inhibition of both tPBP2WT and tPBP2H041 activity at 100
µM (Figure 5.13) were tested against tPBP2H041 at 10 µM. Values were determined in a purified
protein assay in which tPBP2 was preincubated with 10 µM compound, followed by addition of 1
µM Bocillin-FL. Data are presented as a fraction of activity of the DMSO control. Error bars are
standard deviation.
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Figure 5.15: Structures of compounds JMT-40 through JMT-58, which possess a 4’-methoxy in
place of the 4’-methyl group seen in JMT-1. TTZ: 1H-tetrazol-5-yl

Since the 4’-substituent appears to be important for inhibition of PBP2, compounds
with various 4’-substituents were synthesized to explore physicochemical requirements at
this position. First, the influence of polarity was assessed by incorporation of a 4’-methoxy
group (JMT-40 through JMT-58). Inhibition data for this series against tPBP2 are shown
in Figure 5.16 and Figure 5.17. In general, this change yields less active compounds by
direct comparison with 4’-methyl analogues, indicating that a polar group at this position
is not favored. However, there are a few in the series that inhibit PBP2 relatively well. For
example, 4- (JMT-46, JMT-55) and 5-trifluoromethyl (JMT-47, JMT-56) compounds are
active, as well as 5-bromophenyl tetrazole JMT-52. In fact, JMT-46 and JMT-56 exhibit
94 ± 0% and 91 ± 2% inhibition of tPBP2H041, respectively, at 10 µM. Again, the activity
conferred by these hydrophobic, polarizable 4- and 5-substitutions to the anthranilic acid
or phenyltetrazole moiety further emphasizes the benefit of such groups at these positions.
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Figure 5.16: Inhibition data for JMT-40 through JMT-58 against tPBP2WT and tPBP2H041 at 100 µM.
Values were determined in a purified protein assay in which tPBP2 was preincubated with 100 µM
compound, followed by addition of 1 µM Bocillin-FL. Data are presented as a fraction of activity of
the DMSO control. Error bars are standard deviation.
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Figure 5.17: Inhibition data for 4’-methoxy derivatives of JMT-1 against tPBP2H041 at 10 µM.
Compounds exhibiting greater than 80% inhibition of both tPBP2WT and tPBP2H041 activity at 100
µM (Figure 5.16) were tested against tPBP2H041 at 10 µM. Values were determined in a purified
protein assay in which tPBP2 was preincubated with 10 µM compound, followed by addition of 1
µM Bocillin-FL. Data are presented as a fraction of activity of the DMSO control. Error bars are
standard deviation.
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Figure 5.18: Structures of compounds JMT-59 through JMT-83, which possess a halogen in place
of the 4’-methyl group seen in JMT-1. TTZ: 1H-tetrazol-5-yl

The next parameter to be examined was a change in van der Waals radius at the
4’-position. To this end, a series of 4’-halogenated molecules was synthesized, and
inhibition data are shown in Figure 5.19 and Figure 5.20. While the 4’-fluoro (JMT-59
through JMT-67) analogues are among the least active compounds reported in these
studies, large hydrophobic substitutions on the anthranilic acid moiety again enhance
PBP2-inhibitory activity. The 5-bromoanthranilic acid and 4-methylanthranilic acid
analogues JMT-62 and JMT-63 are the only compounds of this group to fully inhibit both
tPBP2WT and tPBP2H041 at 100 µM. They exhibit 45 ± 14% and 54 ± 18% inhibition of
tPBP2H041, respectively, at 10 µM. In all cases, the 4’-chloro compounds (JMT-68 through
JMT-83) are more potent than their 4’-fluoro analogues. However, the 4’-chloro
substitution still appears to confer less activity than the 4’-methyl parent structure. Taken
together, these data suggest that increasing van der Waals radius at the 4’-position is
associated with increased inhibition, but potential effects of 4’-substituent polarizability
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cannot be dismissed. Consistent with data from other series, the 4- (JMT-74) and 5trifluoromethylanthranilic acid (JMT-75) compounds are still quite active, inhibiting
tPBP2H041 89 ± 4% and 86 ± 6%, respectively, at 10 µM.
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Figure 5.19: Inhibition data for JMT-59 through JMT-83 against tPBP2WT and tPBP2H041 at 100 µM.
Values were determined in a purified protein assay in which tPBP2 was preincubated with 100 µM
compound, followed by addition of 1 µM Bocillin-FL. Data are presented as a fraction of activity of
the DMSO control. Error bars are standard deviation.
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Figure 5.20: Inhibition data for 4-fluoro and 4-chloro derivatives of JMT-1 against tPBP2H041 at 10
µM. Compounds exhibiting greater than 80% inhibition of both tPBP2WT and tPBP2H041 activity at
100 µM (Figure 5.19) were tested against tPBP2H041 at 10 µM. Values were determined in a purified
protein assay in which tPBP2 was preincubated with 10 µM compound, followed by addition of 1
µM Bocillin-FL. Data are presented as a fraction of activity of the DMSO control. Error bars are
standard deviation.
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Figure 5.21: Structures of compounds JMT-84 through JMT-100, which possess a 4’trifluoromethyl group in place of the 4’-methyl group seen in JMT-1. TTZ: 1H-tetrazol-5-yl

To examine the effects of polarizability at the 4’-position further, a series of 4’trifluoromethyl analogues was synthesized. Inhibition data for this series against tPBP2
are shown in Figure 5.22 and Figure 5.23. Analogues JMT-84 through JMT-100 are the
most active series of compounds from the collection of biphenyl 4’-position modifications,
with nearly all exhibiting full inhibition of both tPBP2WT and tPBP2H041 at 100 µM. Their
potent activity in the context of a variety of 4- and 5-substituted anthranilic acid and
phenyltetrazole moieties suggests a role for both van der Waals radius and polarizability
at the 4’-position. From the combined data on compounds derivatized at the 4’-position,
the following pattern has emerged with respect to tPBP2 inhibition:
CF3 > CH3 > Cl ~ OMe > F > H
As in other series, the most active compounds from the 4’-trifluoromethyl series are the 4and 5-trifluoromethylanthranilic acid analogues JMT-90 and JMT-91, which exhibit full
inhibition of tPBP2H041 at 10 µM. By contrast with other series, however, there are several
other promising molecules among the 4’-trifluoromethyl analogues. For example, JMT-86
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JMT-88

and

JMT-98

(4((5-

methylphenyl)tetrazole) all show greater than 90% inhibition of tPBP2H041 at 10 µM.
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Figure 5.22: Inhibition data for JMT-84 through JMT-100 against tPBP2WT and tPBP2H041 at 100
µM. Values were determined in a purified protein assay in which tPBP2 was preincubated with 100
µM compound, followed by addition of 1 µM Bocillin-FL. Data are presented as a fraction of activity
of the DMSO control. Error bars are standard deviation.
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Figure 5.23: Inhibition data for 4’-trifluoromethyl derivatives of JMT-1 against tPBP2H041 at 10 µM.
Compounds exhibiting greater than 80% inhibition of both tPBP2WT and tPBP2H041 activity at 100
µM (Figure 5.22) were tested against tPBP2H041 at 10 µM. Values were determined in a purified
protein assay in which tPBP2 was preincubated with 10 µM compound, followed by addition of 1
µM Bocillin-FL. Data are presented as a fraction of activity of the DMSO control. Error bars are
standard deviation.
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Several of the most active compounds from the 4’-derivatized collection, defined
as exhibiting greater than 75% inhibition against tPBP2H041 at 10 µM, were tested against
N. gonorrhoeae FA19 and H041 in disc diffusion assays (Figure 5.24). The most potent
antigonococcal yet, JMT-84, is seen in this group. This anthranilic acid analogue with 4fluoro and 4’-trifluoromethyl substitutions inhibits the growth of N. gonorrhoeae FA19 and
H041 up to 21.2 ± 1.9 mm and 17.5 ± 0 mm, respectively, from discs imbued with 10 µg
compound. Consistent with what was seen for the initial derivatives, phenyltetrazole
compounds appear to perform worse than their anthranilic acid analogues in measures of
antimicrobial potency. Data for JMT-47, JMT-56, JMT-74, JMT-90, JMT-91, and JMT-96
are pending.
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Figure 5.24: Disc diffusion data for potent 4’-substituted derivatives of JMT-1 against N.
gonorrhoeae FA19 and H041. Compounds exhibiting greater than 75% inhibition of tPBP2H041
activity at 10 µM were tested against susceptible reference gonococcal strain FA19 and multi-drug
resistant H041 at 10 µg per disc.
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5.2.e. Modifications to the biphenyl ring system II: Changes to the secondary
aromatic system
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Figure 5.25: Structures of compounds JMT-101 through JMT-118, which possess a 4cyclohexylphenyl group in place of the 1,1’-biphenyl system seen in JMT-1. TTZ: 1H-tetrazol-5-yl

Next, we wanted to observe the effect of increased flexibility at the distal ring
system on PBP2-inhibitory activity. Inhibition data for this series against tPBP2 are shown
in Figure 5.26 and Figure 5.27. Somewhat surprisingly, replacement of the secondary
biphenyl aromatic ring with a cyclohexyl group (JMT-101 through JMT-118) yields active
compounds despite the absence of a 4’-substituent. This indicates that flexibility at this
position may allow a conformation that involves more or better contacts with the PBP2
active site. The most active compound of the cyclohexylphenyl series is the 5trifluoromethylanthranilic acid JMT-108, which inhibits tPBP2H041 fully at 10 µM. Other
potent inhibitors include 4,5-difluoroanthranilic acid JMT-103, (5-fluorophenyl)tetrazole
JMT-112, and (5-methylphenyl)tetrazole JMT-115, all of which exhibit greater than 90%
inhibition of tPBP2H041 at 10 µM.
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Figure 5.26: Inhibition data for JMT-101 through JMT-118 against tPBP2WT and tPBP2H041 at 100
µM. Values were determined in a purified protein assay in which tPBP2 was preincubated with 100
µM compound, followed by addition of 1 µM Bocillin-FL. Data are presented as a fraction of activity
of the DMSO control. Error bars are standard deviation.
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Figure 5.27: Inhibition data for 4-cyclohexylphenyl derivatives of JMT-1 against tPBP2H041 at 10
µM. Compounds exhibiting greater than 80% inhibition of both tPBP2WT and tPBP2H041 activity at
100 µM (Figure 5.26) were tested against tPBP2H041 at 10 µM. Values were determined in a purified
protein assay in which tPBP2 was preincubated with 10 µM compound, followed by addition of 1
µM Bocillin-FL. Data are presented as a fraction of activity of the DMSO control. Error bars are
standard deviation.

209

R1

B

R2

O O
S
N
H
O

119:
120:
121:
122:
123:
124:
125:
126:
127:
128:

R1 = F
R1 = H
R1 = H
R1 = F
R1 = H
R1 = H
R1 = H
R1 = F
R1 = H
R1 = H

R2 = H
R2 = F
R2 = Me
R2 = H
R2 = F
R2 = Me
R2 = H
R2 = H
R2 = F
R2 = Me

OH

B = CH=CHCH=CH
B = CH=CHCH=CH
B = CH=CHCH=CH
B = CH2CH2CH2CH2
B = CH2CH2CH2CH2
B = CH2CH2CH2CH2
B = OCH2CH2O
B = OCH2CH2O
B = OCH2CH2O
B = OCH2CH2O

Figure 5.28: Structures of compounds JMT-119 through JMT-128, which possess a bicyclo[4.4.0]
ring system in place of the 1,1’-biphenyl system seen in JMT-1.

Less conservative changes were also made to the 1,1’-biphenyl system, including
fusion to naphth-2-yl (JMT-119 through JMT-121), 5,6,7,8-tetrahydronaphth-2-yl (JMT122 through JMT-124), and 1,4-benzodioxan-6-yl (JMT-125 through JMT-128) systems.
Inhibition data for this series against tPBP2 are shown in Figure 5.29 and Figure 5.30.
Each of these changes substantially decreases inhibition. The most active among this
series of bicyclo[4.4.0] compounds are the 5,6,7,8-tetrahydronaphth-2-yl analogues, with
4-fluoro compound JMT-122 exhibiting 97 ± 1% and 84 ± 2% inhibition of tPBP2WT and
tPBP2H041, respectively, at 100 μM. JMT-122 was further tested against tPBP2H041 at 10
µM but showed minimal inhibition at this concentration.
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Figure 5.29: Inhibition data for JMT-119 through JMT-128 against tPBP2WT and tPBP2H041 at 100
µM. Values were determined in a purified protein assay in which tPBP2 was preincubated with 100
µM compound, followed by addition of 1 µM Bocillin-FL. Data are presented as a fraction of activity
of the DMSO control. Error bars are standard deviation.
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Figure 5.30: Inhibition data for bicyclo[4.4.0] derivatives of JMT-1 against tPBP2H041 at 10 µM.
Compounds exhibiting greater than 80% inhibition of both tPBP2WT and tPBP2H041 activity at 100
µM were tested against tPBP2H041 at 10 µM. Values were determined in a purified protein assay in
which tPBP2 was preincubated with 10 µM compound, followed by addition of 1 µM Bocillin-FL.
Data are presented as a fraction of activity of the DMSO control. Error bars are standard deviation.
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Potent PBP2 inhibitors from the final set of biphenyl modifications were tested
against N. gonorrhoeae FA19 and H041 in disc diffusion assays, revealing the second
most potent antigonococcal to emerge from these studies (Figure 5.31). JMT-108, a 5trifluoromethylanthranilic acid analogue from the cyclohexylphenyl series, exhibits large
zones of inhibition against both FA19 (20.0 ± 0 mm) and H041 (16.0 ± 0.7 mm). Other
compounds showing good antimicrobial activity include JMT-103, JMT-107, and JMT113, all of which show zones of inhibition greater than 15 mm against both strains. No
bicyclo[4.4.0] compounds were tested due to their poor performance in PBP2 inhibition
assays.
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Figure 5.31: Disc diffusion data for potent cyclohexylphenyl derivatives of JMT-1 against N.
gonorrhoeae FA19 and H041. Compounds exhibiting greater than 75% inhibition of tPBP2H041
activity at 10 µM were tested against susceptible reference gonococcal strain FA19 and multi-drug
resistant H041 at 10 µg per disc.
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5.3. Prediction of the binding modes of the most potent JMT-1 derivatives
The most potent PBP2 inhibitors (JMT-13 and JMT-108) and the most potent
antigonococcal (JMT-84) were docked to the active sites of tPBP2WT and tPBP2H041 with
guidance from the molecular dynamics simulations of JEK-42 and JMT-1 reported in
Chapter 4. In the modeled complexes, a sulfonyl oxygen is positioned within the oxyanion
hole created by the main chain nitrogens of Ser310 and Thr500, and the 1,1’-biphenyl
system extends toward N364 and F420 (Figure 5.32). In the tPBP2WT complexes, the
carboxylic acid forms hydrogen bonds with the side chains of S362, S483, K497 and T498,
and in the tPBP2H041 complexes, it forms hydrogen bonds with the side chain of T500 and
S545. Because the changes to JMT-1 represented in these molecules do not add
opportunities for strong hydrogen bonding, the resulting increases in potency likely have
to do with enhanced van der Waals interactions with the active site. Computationally, this
appears to be the case. On the anthranilic acid moiety of the molecule, the 5trifluoromethyl groups of JMT-13 and JMT-108 contribute 2-fold more van der Waals
interaction energy to ligand-receptor complex formation than the 5-fluoro group of JMT-1
(-0.7 kcal·mol-1 v -1.7 kcal·mol-1) (Figures 5.33 & 5.34), while the 4-fluoro group of JMT86 augments interaction only marginally (-0.9 kcal·mol-1). With respect to the secondary
ring of the 1,1’-biphenyl system, the cyclohexyl system seen in JMT-108 show similar
receptor interactions to the methylphenyl group of JMT-1 and JMT-13 (-8.8 kcal·mol-1 v 8.6 kcal·mol-1). However, the trifluoromethylphenyl system of JMT-84 makes more
extensive contact with the active site surface (-10.5 kcal·mol-1).
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Figure 5.32: Docked poses of compounds showing potent tPBP2 inhibition and antigonococcal
activity. A. When docked to tPBP2WT with guidance from the predicted JMT-1 binding mode, potent
compounds show similar interactions with the transpeptidase active site. The docked structure of
JMT-13 is shown in green, JMT-84 is shown in orange, and JMT-108 is shown in purple. Predicted
hydrogen bonds are shown as dashed lines. B. Potent compounds docked to tPBP2H041 with
guidance from the predicted JMT-1 binding mode show similar interactions with the transpeptidase
active site. The docked structure of JMT-13 is shown in green, JMT-84 is shown in orange, and
JMT-108 is shown in purple. Predicted hydrogen bonds are shown as dashed lines.
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Figure 5.33: Surface rendering of modeled JMT-1 derivatives in complex with tPBP2WT. A. The
trifluoromethyl group seen on the anthranilic acid moiety of JMT-13 and JMT-108 (ligand shown as
teal sticks, surface shown as teal mesh) and the 4-fluoro group of JMT-84 (ligand shown as
magenta sticks, surface shown as magenta mesh) create more surface contact with the active site
of tPBP2WT than the 5-fluoro group of JMT-1 (ligand shown as orange sticks, surface shown as
orange mesh). B. The trifluoromethylphenyl group of JMT-84 (ligand shown as magenta sticks,
surface shown as magenta mesh) exhibits a closer contour to the tPBP2WT surface (shown in grey)
than the methylphenyl group of JMT-1 and JMT-13 (ligand shown as teal sticks, surface shown as
teal mesh), while the cyclohexyl group of JMT-108 (ligand shown as yellow sticks, surface shown
as yellow mesh) shows only marginally increased contact with the active site surface.
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Figure 5.34: Surface rendering of modeled JMT-1 derivatives in complex with tPBP2H041. A. As in
tPBP2WT, the trifluoromethyl group seen on the anthranilic acid moiety of JMT-13 and JMT-108
(ligand shown as teal sticks, surface shown as teal mesh) and the 4-fluoro group of JMT-84 (ligand
shown as magenta sticks, surface shown as magenta mesh) create more surface contact with the
active site of tPBP2H041 than the 5-fluoro group of JMT-1 (ligand shown as orange sticks, surface
shown as orange mesh). B. The trifluoromethylphenyl group of JMT-84 (ligand shown as magenta
sticks, surface shown as magenta mesh) exhibits a closer contour to the tPBP2H041 surface (shown
in grey) than the methylphenyl group of JMT-1 and JMT-13 (ligand shown as teal sticks, surface
shown as teal mesh), while the cyclohexyl group of JMT-108 (ligand shown as yellow sticks, surface
shown as yellow mesh) shows only marginally increased contact with the active site surface.
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5.4. Discussion
In this work, we present the derivatization of the prototype N. gonorrhoeae PBP2
inhibitor JMT-1 with the goal of identifying modifications that enhance or diminish in vitro
activity against both PBP2 and gonococci. First, we show that substitution of the JMT-1
anthranilic acid moiety with hydrophobic groups at C4 or C5 is preferred for PBP2
inhibition, and that isosteric replacement of the C1 carboxylic acid with a 1H-tetrazol-5-yl
group results in compounds with similar activity. Next, we show that 4’-substitution of the
1,1’-biphenyl system is required for potent inhibition, but that this requirement is eliminated
if the structure is changed to a more flexible 4-cyclohexylphenyl system. Modeling of the
most potent compounds suggest the modifications to JMT-1 responsible for increasing
tPBP2 inhibition do so through augmented van der Waals interactions with the
transpeptidase active site.
5.4.a. Summary of potent antigonococcal compounds and structure-activity
relationships
Compounds showing potent tPBP2 inhibition and antigonococcal activity are
shown in Table 5.1. Overall, the most potent JMT-1 derivatives possess lipophilic
polarizable groups at the 4- and 5-positions of an anthranilic acid moiety. Increasing van
der Waals radius at C4 or C5 appears to be correlated with greater activity as well, with
six of the ten best compounds possessing a trifluoromethyl or bromo substituent. High
activity is also observed in compounds 4,5-disubstituted with fluorine atoms, suggesting
that there is a preference for a somewhat large area of hydrophobic surface at these
positions. Phenyltetrazoles are generally less active against gonococci, and especially
against H041, than their anthranilic acid analogues despite similar inhibition of tPBP2. This
is perhaps due to the relative lipophilicity of the tetrazole-containing molecules (5-methyl1H-tetrazole logD7.4 = -2.2) compared to corresponding carboxylic acids (acetic acid
logD7.4 = -3.0). In both FA19 and H041, compounds must traverse the outer membrane
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through porins that select for highly solvated, hydrophilic molecules. In H041, not only are
these porins mutated to restrict entry,306 but there is also an overexpressed MtrCDE efflux
system with the ability to extrude hydrophobic xenobiotics.317.318 Exceptions to this trend
are the 5-bromophenyltetrazoles, which show improved antigonococcal activity compared
to their 5-bromoanthranilic acid analogues and have a very narrow difference in activities
between FA19 and H041.
Modifications to the 1,1’-biphenyl end of the JMT-1 scaffold also result in some
improvements in activity. Overall, compounds with larger hydrophobic groups at the 4’position (i.e., 4’-methyl and 4’-trifluoromethyl) tend to have better activity compared to
smaller or more hydrophilic derivatives. Interestingly, while elimination of the 4’-substituent
greatly diminishes activity of 1,1’-biphenyl compounds, incorporation of a 4’-unsubstituted
cyclohexyl group causes no such decrease in activity and in fact, yields some of the most
potent antigonococcal compounds resulting from these studies.
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Table 5.1: Summary data for the JMT-1 derivatives showing the most potent antigonococcal
activity. aPurified protein assay in which PBP2 is pre-incubated with compound or DMSO for 1 hour,
followed by the addition of 1 µM Bocillin-FL. Value reported is percent inhibition. bDisc diffusion
assay performed with 10 µg compound per disc. Value reported is zone of inhibition. Errors are
standard deviation.
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The most active compounds identified in the course of these studies were flexibly
aligned using a stochastic conformational search, yielding an eight-point pharmacophore
shown in Figure 5.35. This pharmacophore is generally supported by previous data on
the inhibition of S. aureus PBP2a and S. pneumoniae by similar compounds,627,628 with
the unique addition of the 1,1’-biphenyl system. Representation of the 1,1’-biphenyl
system with two hydrophobic features, where only one is required to be aromatic,
increases design capabilities by allowing the incorporation of a variety of 4-substituted
phenyl systems like in the 4-cyclohexylphenyl series.

Figure 5.35: Flexible alignment and consensus pharmacophore based on the JMT-1 derivatives
with the most potent antigonococcal activity.

Experiments published by other laboratories have determined zones of inhibition
by several FDA-approved antimicrobials against N. gonorrhoeae strains with varied
susceptibility profiles63,678

(Table 5.2). For example, with 0.5 µg penicillin G, the

susceptible reference strain WHO F is inhibited with a 13.2 mm zone of inhibition, while
neither penicillin-resistant strain (WHO K and H041) is inhibited at all. Similarly, a 0.5 µg
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ceftriaxone disc inhibits the growth of WHO F with a 14.2 mm zone of inhibition, while it
displays a decrease in potency against WHO K (6.7 mm) and fails to inhibit H041. By
contrast, the reported JMT-1 derivatives inhibit both FA19 and H041 to similar degrees. It
should be noted that the masses of compound used in each disc is slightly different in the
assays reported, as each takes into account the pharmacokinetic and pharmacodynamic
factors determining efficacy, as well as epidemiologic values for susceptibility versus
resistance. Since the reported JMT-1 analogues represent a novel, experimental class,
no such data exists. Thus, the 10 µg quantity used in these studies is not calibrated for
direct comparisons of potency. Nonetheless, the large zones of inhibition seen against
both reference strain FA19 and multidrug resistant H041 indicate real antimicrobial activity
that is quite promising for the early development of a new class of compounds.
Table 5.2: Calibrated dichotomous sensitivity disc diffusion literature values for FDA-approved
antimicrobials against N. gonorrhoeae with varied susceptibility profiles. †Taken from Mal et al.,
2016.678 ‡Taken from Ohnishi et al., 2011.63

Compound
(mass, µg)
penicillin G (0.5)
ceftriaxone (0.5)
ciprofloxacin (1)
spectinomycin (100)

WHO F†
(PenSCephS)
13.2 mm
14.2 mm
15 mm
11 mm

WHO K†
(PenRCephDS)
0 mm
6.7 mm
0 mm
16 mm

H041‡
(PenRCephR)
0 mm
1 mm
1 mm
9 mm

5.4.b. Future testing of potent antigonococcal compounds
We have only just begun the hit-to-lead optimization and overall development
processes for the reported scaffolds, and much more foundational work needs to be
completed toward their biochemical and biological characterization. This includes more
precise measures of potency against both the target (i.e., IC50 determinations against
tPBP2WT and tPBP2H041) and pathogen (i.e., MIC determinations against N. gonorrhoeae
strains), as well as measures of selectivity (i.e., cytotoxicity experiments against hepatic
and renal lines). Additional experiments are needed to ensure the antigonococcal activity
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results from transpeptidase inhibition. Such experiments include macromolecular
synthesis assays measuring the incorporation of [14C]-diaminopimelate, microscopy for
the observation of filament formation, and peptidoglycan cross-link formation assays
measuring D-Ala release. If compounds are identified that show potent, on-target,
selective antigonococcal activity, these compounds can be tested in the murine infection
model described in Chapter 3.
Despite their lesser antigonococcal activity in vitro, tetrazole-containing derivatives
should not yet be abandoned due to their potentially favorable properties in vivo.
Xenobiotic carboxylic acids are commonly conjugated by phase II metabolic enzymes to
acyl glucuronides and acyl coenzyme A thioesters.679,680 These modifications mask the
acidic group critical to PBP2 inhibition, and the resulting acyl metabolites are reactive
species implicated in hepatotoxicity. Tetrazoles, by contrast, are resistant to coenzyme A
conjugation and form nonreactive N-glucuronide conjugates.681,682 Moreover, as
mentioned above, tetrazole compounds are more lipophilic (5-methyl-1H-tetrazole logD7.4
= -2.2) than analogous carboxylic acids (acetic acid logD7.4 = -3.0), potentially improving
their lipid bilayer permeability and bodily distribution.683 This property may be
advantageous in the treatment of gonococcal cervicitis and pharyngitis by increasing
accumulation at the site of infection. Taking into account the modest losses in activity seen
in JMT-1 analogues upon replacement of the carboxylic acid with a tetrazole, the potential
for improved pharmacokinetics could ultimately outweigh such losses.
5.4.c. Future design strategies
In addition to biological characterization of the most potent compounds from these
experiments, another immediate goal is further derivatization of the scaffolds, especially
since the anthranilic acid moiety of JMT-1 provides ample opportunity to explore additional
chemical space. First, there is a need for data on the 6-fluoroanthranilic acid compound.
While the 6-methyl analogue exhibited poor activity, substitution with a smaller fluorine
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may better approximate the shape of the post-covalent cephalosporin complex after
elimination of the C3 leaving group (Figure 5.36). Thus, the potency of such an analogue
will provide insight into whether these compounds adopt a binding mode similar to the βlactams after acylation. There is also a need for the investigation of less conservative
substitutions on the anthranilic acid moiety, as the current dataset does not contain a great
deal of structural diversity. Some modifications that can be incorporated to develop more
comprehensive structure-activity relationships are the following: 1) polar hydrogen
bonding substituents, including hydroxy and amino functionalities; 2) extended and
branched aliphatics, such as ethyl and isopropyl groups; 3) bulkier 4,5-disubstitutions,
including methylenedioxy and fused cyclopentyl groups; and 4) additional carboxylic acid
isosteres, including those shown in Figure 5.37.684

Figure 5.36: Overlay of ceftriaxone after leaving group departure and 2-(4’-methyl-[1,1'-biphenyl]4-amido)-6-fluorobenzoic acid.
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Figure 5.37: Carboxylic acid bioisosteres. HA: hydroxamic acid, HIT: 3-hydroxyisothiazole, HIO:
3-hydroxyisoxazole, TZD: thiazolidinedione, OZD: oxazolidinedione, CPD: 1,3-cyclopentanedione,
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There is also opportunity to explore the 1,1’-biphenyl moiety of JMT-1. In our
dataset, it was observed that incorporation of a methyl or trifluoromethyl group at the 4’position enhances PBP2-inhibitory activity compared to substituents with smaller van de
Waals radii (i.e., H, F, and Cl). In this vein, the effects of shape and bulk should be
assessed further by the incorporation of larger, more diverse groups, including branched
aliphatics (e.g., isopropyl and t-butyl) and small carbocycles (e.g., cyclopropyl and
cyclobutyl). The effect of 2’-substitution, as well as disubstitution, should also be
examined. Finally, replacement of one or both rings with various aromatic or saturated
heterocycles and carbocycles should be attempted. Sulfonyl chloride starting materials
can be obtained through Suzuki cross-coupling reactions with thioacetate compounds,
followed by oxidation with N-chlorosuccinimide685,686 (Scheme 5.2).
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Scheme 5.2: Proposed synthesis of 4’-methyl[1,1’-biphenyl]-4-sulfonyl chloride from S-acetyl 4bromothiophenol. a. Pd(dppf)2Cl2·CH2Cl2, Cs2CO3, 10:1 THF/H2O, 100°C. b. 1:5 2 M HCl / MeCN,
RT.

Amide analogues similar to JEK-42 should be made for the most active JMT-1
derivatives as well. Fortunately, benzoic acid starting materials can be obtained from
similar syntheses using Suzuki cross-coupling reactions with methyl esters, followed by
alkaline hydrolysis (Scheme 5.3). For a discussion of other possible changes to the
sulfonamide functionality, see Chapter 4.
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Scheme 5.3: Proposed synthesis of 4’-methyl[1,1’-biphenyl]-4-carboxylic acid from methyl 4bromobenzoate. a. Pd(dppf)2Cl2·CH2Cl2, Cs2CO3, 10:1 THF/H2O, 100°C. b.1:1 THF/H2O, RT.

5.4.d. Significance
Here we describe the synthesis 127 novel structures and their testing for inhibition
of N. gonorrhoeae PBP2. We found that larger hydrophobic substitutions at C4 and C5 of
the anthranilic acid moiety (e.g., bromo, trifluoromethyl) improve PBP2 inhibition, as does
a trifluoromethyl substitution at C4’ of the 1,1’-biphenyl system. Interestingly, we also
found that while lack of substitution at the C4’ position results in decreased inhibition,
modification of the secondary aromatic ring to a conformationally flexible cyclohexyl group
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yields strong inhibition. Docked models predict the increased potency imparted by these
substitutions is due to more favorable van der Waals interactions with the PBP2 active site
compared to prototype JMT-1. Overall, the activity data coming from these early hit-tolead optimization studies show the promise of this scaffold. It is capable of inhibiting PBP2
variants derived from both β-lactam-susceptible and -resistant strains and shows
antigonococcal activity against both reference strain FA19 and multidrug resistant H041.
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CHAPTER 6: Conclusion
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6.1. Summary
Over the last several decades, N. gonorrhoeae has developed resistance to
sulfonamides, penicillin, spectinomycin, tetracyclines, macrolides, fluoroquinolones, and
now cephalosporins. With this proclivity for resistance development in mind, the CDC
began recommending dual antimicrobial regimens of ceftriaxone with azithromycin or
doxycycline, but patterns of increasing resistance to these agents globally have raised
concerns of a future in which gonorrhea is untreatable. Therefore, continued efforts to
identify antigonococcal compounds using all avenues of drug discovery are necessary to
keep pace with the development of resistance. The body of work coming out of our
laboratory has focused for several years on the structural biology of the penicillin-binding
proteins, and more recently on the mechanisms of β-lactam resistance conferred by
mutations in PBP2 of N. gonorrhoeae. In this project, emphasis was placed on ligand
structure, specifically on the identification of features enhancing PBP2 inhibition, with the
ultimate goal of designing novel antigonococcal agents. We report three studies to this
end.
In Chapter 3, we outlined structure-activity relationships (SAR) for the
cephalosporin class of β-lactams against cephalosporin-resistant Neisseria gonorrhoeae
H041. We found that structural features of the C7 acylamino side chain (R1) correlate
highly with the second-order rate of tPBP2H041 acylation, with larger groups of modest
lipophilicity containing multiple ring systems (e.g., the 2,3-dioxopiperazine side chain of
cefoperazone) conferring greater activity. While the data suggest that the C3 side chain
(R2) plays a less obvious role, a combination of electronegative elements and planarity
(e.g., the pyridylthiazole side chain of ceftaroline) can enhance tPBP2H041 acylation
considerably.
Through molecular docking simulations of the precovalent ligand-receptor
complex, we gained insight into how these features may enhance inhibition. In the docked
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models, aromatic and hydrophobic groups on R1 are shown extending toward a
hydrophobic patch of the tPBP2H041 active site, and in a preliminary crystal structure of
cefoperazone in complex with tPBP2H041, the 2,3-dioxopiperazine moiety lies flat in this
hydrophobic patch against the side chain of Y422. The models also show electronegative
elements of R2 interacting with K361. The importance of this residue for cephalosporin
binding is supported by a stark reduction in the rate of acylation by ceftriaxone upon its
mutation to a glutamate. We also found that many of the features enhancing target
inhibition (e.g., lipophilicity, aromaticity, etc.) diminish antimicrobial activity against the
H041 strain, perhaps due to decreased accumulation in the periplasm. Finally, we
observed that cefoperazone acylates tPBP2H041 much more rapidly than most other
cephalosporins, and it exhibits comparable activity to ceftriaxone against N. gonorrhoeae
H041 both in vitro and in vivo.

Figure 6.1: Features of cephalosporins enhancing the second-order rate of tPBP2H041 acylation,
illustrated by cefoperazone.
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In Chapter 4, we applied qualitative trends emerging from the cephalosporin SAR
to identify novel noncovalent PBP2 inhibitors possessing a 1,1’-biphenyl system. JEK-42
and its isosteric derivative JMT-1 inhibit both tPBP2WT and tPBP2H041, and are capable of
inhibiting growth of both β-lactam-susceptible (FA19) and -resistant (H041) gonococcal
strains. Their cross-inhibition of P. aeruginosa PBP3 provides evidence of their potential
for broader activity against class B PBPs. Models of their binding modes show that these
molecules may bind in a way that mimics the precovalent complex formed by β-lactam
antimicrobials. These models also show the 1,1’-biphenyl system interacting with highly
conserved residues N364 and F420. Using the structural similarities between JEK-42,
JMT-1, and bicyclic β-lactam scaffolds (i.e., penam, carbapenem, and cephem), a threepoint pharmacophore was generated that was then used to screen a virtual library of
molecular fragments, yielding many structures for testing against PBP2 and N.
gonorrhoeae as potential inhibitors.
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Figure 6.2: Predicted tPBP2 binding mode of antigonococcal prototypes. JEK-42 is shown in its
predicted binding mode with tPBP2WT. Areas of interaction for the shared acidic (red), hydrophobic
(green) and hydrogen bond accepting (cyan) features of JEK-42 and JMT-1 are shown.
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In Chapter 5, we began the process of hit-to-lead optimization by exploring the
chemical space surrounding the prototype molecules to determine the effects of specific
substitutions on PBP2 inhibition and antigonococcal activity. In all, 127 derivatives of JMT1 were synthesized and tested. First, PBP2 inhibition by the JMT-1 sulfonamide scaffold is
improved by the presence of hydrophobic, polarizable groups (e.g., bromo, trifluoromethyl)
at C4 or C5 of the anthranilic acid moiety. Second, replacement of the C1 carboxylic acid
with a bioisosteric 1H-tetrazol-5-yl group results in compounds with similar target inhibition
but lesser antimicrobial activity. Third, a substitution at the 4’-position of the 1,1’-biphenyl
system promotes potent inhibition, but is not required when the secondary aromatic ring is
modified to a more flexible cyclohexyl group. In all, 10 molecules show promise as
antigonococcal agents from in vitro measures of target inhibition and antimicrobial activity
and will be tested further. These structures will also serve as the basis for future inhibitor
design.
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Figure 6.3: Structures of JMT-1 derivatives. A. JMT-13 and JMT-108 are the most potent inhibitors
of N. gonorrhoeae PBP2. Both show 99 ± 1% inhibition of tPBP2H041 at 10 µM. JMT-84 shows
slightly lesser target inhibition but is the most potent antigonococcal agent, yielding 21.2 ± 1.9 mm
and 17.5 ± 0 mm zones of inhibition against N. gonorrhoeae FA19 and H041, respectively. B. There
is additional space in the tPBP2 active site that can be explored by derivatization of the JMT series.
Composite surface for superimposed inhibitors shown in orange mesh. Receptor surface of
tPBP2WT shown in grey.
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6.2. Common features among published PBP-inhibitory compounds
Returning to the literature with additional insight and sharper focus provided by
these studies, pervasive trends become apparent in reported inhibitors of diverse PBPs
from a variety of bacterial species. Many inhibitors are structurally similar to the JMT series
(Figure 6.4). In combination with the inhibition of P. aeruginosa PBP3 reported for JMT-1
and JMT-2 in Chapter 4, these similarities suggest that JMT compounds may be capable
of inhibiting the growth of a variety of pathogens. What is novel about the molecules
reported in this work is the incorporation of the 1,1’-biphenyl system, whose secondary
aromatic ring is uniquely capable of interacting with highly conserved N364 (of the SxN
motif) and F420 of N. gonorrhoeae PBP2 according to the modeling data presented in
Chapters 4 and 5. The predicted interactions with highly conserved residues provide
further support for the hypothesis that these compounds may exhibit broad spectrum
activity beyond N. gonorrhoeae.
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Figure 6.4: Flexible alignment of JMT-84 with published noncovalent PBP inhibitors.
Commonalities among the compounds examined include acidic (red), aromatic (orange) and
hydrogen bond accepting (cyan) features.

6.3. Future Directions
The data presented on cephalosporin activity against N. gonorrhoeae H041 and
its PBP2 provide a means of identifying cephalosporins with high activity against ESCR
strains harboring mosaic penA alleles. First, cefoperazone should be investigated further
for its application to gonococcal infections through the determination of murine
pharmacokinetic parameters and subsequent dose optimization. Second, the generated
QSAR models can also be applied to additional cephalosporins reported in the literature,
including experimental compounds that were never developed, as well as those currently
used solely in veterinary medicine. Finally, because the QSAR has been constructed using
features of R1 and R2 separately, it can be used to computationally evaluate a series of
carboxylic

acids

(R1)

and

sulfur

nucleophiles

(R2)

for

attachment

to

7-

aminocephalosporanic acid according to Scheme 6.1.
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Scheme 6.1: Proposed synthesis of novel cephalosporins from 7-aminocephalosporanic acid.

Hit-to-lead optimization for JEK-42 and JMT-1 is underway, and many additional
substitutions have been proposed for the scaffolds in Chapter 5, including less
conservative modifications of the anthranilic acid and 1,1’-biphenyl moieties. Importantly,
more biochemical and biological characterization is needed for the most potent molecules,
including the determination of half-maximal inhibitory concentrations (IC50) against PBP2,
minimum inhibitory concentrations (MIC) against N. gonorrhoeae strains, and halfmaximal eukaryotic cytotoxic doses (TD50). Macromolecular synthesis assays,
microscopic observation of gonococcal morphology, or peptidoglycan cross-linking assays
should also be conducted to confirm the compounds are on-target. If potent, on-target,
selective antigonococcal compounds emerge, these compounds can be tested in the
murine infection model described in Chapter 3. Potent antigonococcal compounds should
also be tested for inhibition of additional class B PBPs, as well as for antimicrobial activity
against a variety of pathogens.
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Figure 6.5: Model for early antimicrobial discovery

6.4. Overall impact
Together, these studies lay the groundwork for an antimicrobial discovery program
targeted against the PBPs, with possibilities ranging from β-lactams to derivatives of the
JMT series to entirely new, as yet unidentified chemotypes. The structure-activity
relationships for cephalosporins against N. gonorrhoeae H041 provide mathematical
models for in silico prediction of cephalosporin potency that can be employed in selecting
semisynthetic cephalosporins from the literature, or in the design of entirely novel
structures. In the latter case, such a model helps to reduce attrition by guiding the
synthesis of molecules that are likely to be active in both enzymatic assays against
tPBP2H041 and antimicrobial assays against N. gonorrhoeae H041. The synthesis and
testing of JEK-42 and JMT-1 marks the discovery of two novel antimicrobial scaffolds that
act through the inhibition of PBPs. These scaffolds are likely not susceptible to βlactamases, and based on preliminary data, it appears they are not vulnerable to the same
PBP2 modifications that result in resistance to cephalosporins. Finally, the creation of
pharmacophore models from structural similarities in PBP inhibitors allows the in silico
discovery of yet other scaffolds to pursue, opening the possibilities for chemically diverse
leads and, thus, greater odds of generating a successful drug candidate.
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Appendix A. Pharmacophore-constrained cephalosporin docking parameters

Figure A.1: Placement constraints for docking of cephalosporins to tPBP2H041. Criteria for
placement in the docking protocol include: 1) a carboxylate centroid near proposed electrostatic
anchor K497 and 2) a lactam ring adjacent S310 and projecting toward the oxyanion hole defined
by S310 and T500. A. Full receptor view. B. Detailed view.

Figure A.2: Energy scores for pharmacophore-constrained docking of penams (A) and
carbapenems (B). AMX: amoxicillin, AMP: ampicillin, MZC: mezlocillin, PNG: penicillin G, PNV:
penicillin V, PPC: piperacillin, TCC: ticarcillin, IMI: imipenem, DORI: doripenem, MERO:
meropenem, ERTA: ertapenem.
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Appendix B. Untransformed activity data (IC50) for cephalosporins against
tPBP2H041
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Figure B.1: tPBP2H041 IC50 curves for cephalosporins reported in Chapter 3. CFP: cefoperazone
(2.5 ± 0.3 µM, r2 = 0.966), CPT: ceftaroline (2.6 ± 0.4 µM, r2 = 0.987), BPR: ceftobiprole (0.9 ± 0.1
µM, r2 = 0.990), CRO: ceftriaxone (1.8 ± 0.3 µM, r2 = 0.977), ZOX: ceftizoxime (2.9 ± 0.8 µM, r2 =
0.974), CTX: cefotaxime (3.0 ± 0.5 µM, r2 = 0.993). BOC10x: co-incubation with 10 µM Bocillin-FL,
BOC-100x: co-incubation with 100 µM Bocillin-FL. n ≥ 3 determinations for each. Error bars are
standard deviation.
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Figure B.2: tPBP2H041 IC50 curves for cephalosporins reported in Chapter 3, continued. CAZ:
ceftazidime (3.6 ± 0.6 µM, r2 = 0.991), CFM: cefixime (3.8 ± 0.4 µM, r2 = 0.983), FEP: cefepime
(4.4 ± 0.4 µM, r2 = 0.966), CPD: cefpodoxime (4.7 ± 1.0 µM, r2 = 0.979), TOL: ceftolozane (14.7 ±
1.8 µM, r2 = 0.985), CDR: cefdinir (33.8 ± 2.9 µM, r2 = 0.968). BOC10x: co-incubation with 10 µM
Bocillin-FL. n ≥ 3 determinations for each. Error bars are standard deviation.
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Figure B.3: tPBP2H041 IC50 curves for cephalosporins reported in Chapter 3, continued. CEC:
cefaclor (97.0 ± 16.5 µM, r2 = 0.908), CTB: ceftibuten (144 ± 1 µM, r2 = 0.932), CXM: cefuroxime
(400 ± 10 µM, r2 = 0.931), FOX: cefoxitin (840 ± 130 µM, r2 = 0.878), CMZ: cefmetazole (770 ± 10
µM, r2 = 0.959), CFS: cefsulodin (3.7 ± 0.5 mM, r2 = 0.911). BOC10x: co-incubation with 10 µM
Bocillin-FL. n ≥ 3 determinations for each. Error bars are standard deviation.
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Figure B.4: tPBP2H041 inhibition data for cephalosporins classified in Chapter 3 as inactive. LOT:
cefelothin (13 ± 4% inhibition), LEX: cephalexin (54 ± 8% inhibition), CFZ: cefazolin (26 ± 4%
inhibition), LOR: cephaloridine (12 ± 9% inhibition). 1,000x Ceph:BOC: co-incubation of 10 mM
cephalosporin with 10 µM Bocillin-FL. Error bars are standard deviation.
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Figure B.5: tPBP2H041-K361E IC50 curves for cephalosporins reported in Chapter 3. CFP:
cefoperazone (1.6 ± 0.2 µM, r2 = 0.975), CRO: ceftriaxone (2.0 ± 0.5 µM, r2 = 0.984), CAZ:
ceftazidime (11.1 ± 3.6 µM, r2 = 0.950), FEP: cefepime (13.4 ± 5.1 µM, r2 = 0.955). BOC10x: coincubation with 10 µM Bocillin-FL, BOC-100x: co-incubation with 100 µM Bocillin-FL. n ≥ 3
determinations for each. Error bars are standard deviation.
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Appendix C. Quantitative structure-activity relationship descriptors
Table C.1: Definitions of physicochemical descriptors using the quantitative structure-activity
relationships developed in Chapter 3.

Descriptor
a_acc

a_donacc

a_ICM

BCUT_PEOE_0

BCUT_PEOE_3

BCUT_SLOGP_0

BCUT_SLOGP_1

BCUT_SLOGP_3

BCUT_SMR_3

Definition
Number of hydrogen bond acceptor atoms
(excluding acidic atoms, but including
atoms that function as both hydrogen bond
donors and acceptors)
Number of hydrogen bond donor atoms
plus number of hydrogen bond acceptors
atoms
Mean atom information content / entropy of
element distribution. Sum of pilogpi for all i,
where pi = ni/n, ni is the number of
occurrences of atomic number i in the
molecule, and n is the total number of
atoms.
Smallest eigenvalue of a modified
adjacency matrix in which each ij entry
takes the value 1/sqrt(bij), where bij is the
formal bond order between bonded atoms i
and j. The diagonal takes the value of
PEOE partial charges.
Largest eigenvalue of a modified adjacency
matrix in which each ij entry takes the value
1/sqrt(bij), where bij is the formal bond order
between bonded atoms i and j. The
diagonal takes the value of PEOE partial
charges.
Smallest eigenvalue of a modified
adjacency matrix in which each ij entry
takes the value 1/sqrt(bij), where bij is the
formal bond order between bonded atoms i
and j. The diagonal takes the value of
atomic contribution to logP(o/w).
Second eigenvalue of a modified adjacency
matrix in which each ij entry takes the value
1/sqrt(bij), where bij is the formal bond order
between bonded atoms i and j. The
diagonal takes the value of atomic
contribution to logP(o/w).
Largest eigenvalue of a modified adjacency
matrix in which each ij entry takes the value
1/sqrt(bij), where bij is the formal bond order
between bonded atoms i and j. The
diagonal takes the value of atomic
contribution to logP(o/w).
Largest eigenvalue of a modified adjacency
matrix in which each ij entry takes the value
1/sqrt(bij), where bij is the formal bond order
between bonded atoms i and j. The
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diagonal takes the value of atomic
contribution to molar refractivity.
Atomic valence connectivity index (order 0)
from Hall, calculated as the sum of 1/sqrt(vi)
over all heavy atoms i with vi > 0.
chi0v

chi1v_C

FCharge

GCUT_PEOE_1

GCUT_PEOE_2

h_logS

Kier1

KierA2
KierFlex

PEOE_VSA_FPNEG

PEOE_VSA-1

For heavy atom i, let vi = (pi-hi)/(Zi-pi-1)
where pi is the number of s and p valence
electrons.
Carbon valence connectivity index (order
1), calculated as the sum of 1/sqrt(vivj) over
all bonds between carbon atoms i and j
where i < j.
For heavy atom i, let vi = (pi-hi)/(Zi-pi-1)
where pi is the number of s and p valence
electrons.
Total formal charge.
Second eigenvalue of a modified distance
adjacency matrix in which each ij entry
takes the value 1/sqrt(dij), where dij is the
graph distance between atoms i and j. The
diagonal takes the value of PEOE partial
charges.
Third eigenvalue of a modified distance
adjacency matrix in which each ij entry
takes the value 1/sqrt(dij), where dij is the
graph distance between atoms i and j. The
diagonal takes the value of PEOE partial
charges.
log of aqueous solubility (mol/L) using a 7parameter model based on Hueckel Theory
with r2 = 0.83, RMSE 0.85 on 1,708
molecules.
First kappa shape index: (n-1)2/m2, where n
is the number of atoms in a hydrogensuppressed molecular graph and m is the
number of bonds.
Second alpha modified shape index: s(s1)2/m2 where s = n+a, where a is a
correction factor derived from the covalent
radii of bonded atoms.
Kier molecular flexibility index:
(KierA1)(KierA2)/n.
Fractional negative polar van der Waals
surface area: sum of approximate van der
Waals surface area vi (Å2) for each atom i
with partial charge qi < -0.2, divided by the
total van der Waals surface area.
Sum of approximate van der Waals surface
area vi (Å2) for each atom i whose
contribution to PEOE qi is in the range [-0.1,
0.05).
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PEOE_VSA-3

PEOE_VSA-4

PEOE_VSA+0

PEOE_VSA+1

PEOE_VSA+3

PEOE_VSA+4

PEOE_VSA+6
Q_RPC+
SlogP_VSA0

SlogP_VSA1

SlogP_VSA2

SlogP_VSA4

SlogP_VSA7

SMR_VSA3

Sum of approximate van der Waals surface
area vi (Å2) for each atom i whose
contribution to PEOE qi is in the range [-0.2,
-0.15).
Sum of approximate van der Waals surface
area vi (Å2) for each atom i whose
contribution to PEOE qi is in the range [0.25, -0.2).
Sum of approximate van der Waals surface
area vi (Å2) for each atom i whose
contribution to PEOE qi is in the range [0,
0.05).
Sum of approximate van der Waals surface
area vi (Å2) for each atom i whose
contribution to PEOE qi is in the range
[0.05, 0.1).
Sum of approximate van der Waals surface
area vi (Å2) for each atom i whose
contribution to PEOE qi is in the range
[0.15, 0.2).
Sum of approximate van der Waals surface
area vi (Å2) for each atom i whose
contribution to PEOE qi is in the range [0.2,
0.25).
Sum of approximate van der Waals surface
area vi (Å2) for each atom i whose
contribution to PEOE qi > 0.3.
Relative positive partial charge: the largest
positive qi divided by the sume of positive
qi.
Sum of approximate van der Waals surface
area vi (Å2) for each atom i whose
contribution to logP(o/w) Li ≤ -0.4.
Sum of approximate van der Waals surface
area vi (Å2) for each atom i whose
contribution to logP(o/w) Li is in the range (0.4, 0.2].
Sum of approximate van der Waals surface
area vi (Å2) for each atom i whose
contribution to logP(o/w) Li is in the range (0.2, 0].
Sum of approximate van der Waals surface
area vi (Å2) for each atom i whose
contribution to logP(o/w) Li is in the range
(0.1, 0.15]
Sum of approximate van der Waals surface
area vi (Å2) for each atom i whose
contribution to logP(o/w) Li is in the range
(0.25, 0.30].
Sum of approximate van der Waals surface
area vi (Å2) for each atom i whose
contribution to molar refractivity Ri is in the
range (0.35, 0.39].
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SMR_VSA4

vdw_area
zagreb

Sum of approximate van der Waals surface
area vi (Å2) for each atom i whose
contribution to molar refractivity Ri is in the
range (0.4, 0.44].
area of van der Waals surface (Å2)
calculated using connection table
approximation.
Zagreb index: the sum of squares of heavy
atom degree di over all heavy atoms i.
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Appendix D. Characterization of synthesized compounds by ESI-MS and 1HNMR
5-fluoro-2-(4'-methyl-[1,1'-biphenyl]-4-carboxamido)benzoic acid (JEK-42). The reaction
of 4'-methyl-[1,1'-biphenyl]-4-carboxylic acid afforded JEK-42 as a white powder. 1H NMR
(600 MHz, D3COCD3): δ = 12.19 (s, 1H), 9.00 (dd, J = 5.2, 9.3 Hz, 1H), 8.09 (d, J = 8.4
Hz, 2H), 7.84 (d, J = 8.5 Hz, 2H), 7.86 (m, 1H), 7.64 (d, J = 8.2 Hz, 2H), 7.50 (dq, J = 3.2,
9.3 Hz, 1H), 7.32 (d, J = 7.9 Hz, 2H), 3.08 (s, 3H). ESI-MS for C21H16FNO3: [M-H]calculated 348.1, found 348.2
5-fluoro-2-(4'-methyl-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-1). The reaction of
4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I afforded
JMT-1 as a beige powder. 1H NMR (600 MHz, D3COCD3): δ = 10.73 (s, 1H), 7.87 (d, J =
8.5 Hz, 2H), 7.80 (m, 1H), 7.79 (d, J = 8.6 Hz, 2H), 7.67 (dd, J = 3.1, 9.1 Hz, 1H), 7.57 (d,
J = 8.1 Hz, 2H), 7.43 (dq, J = 3.0, 10.3 Hz, 1H), 7.29 (d, J = 8.0 Hz, 2H), 2.35 (s, 3H). ESIMS for C20H16FNO4S: [M-H]- calculated 384.1, found 384.2
2-(4'-methyl-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-2). The reaction of 4'methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I afforded JMT2 as a white powder. ESI-MS for C20H17NO4S: [M-H]- calculated 366.1, found 366.2
4-fluoro-2-(4'-methyl-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-3). The reaction of
4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I afforded
JMT-2 as a beige powder. ESI-MS for C20H16FNO4S: [M-H]- calculated 384.1, found 384.2
4,5-difluoro-2-(4'-methyl-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-4). The
reaction of 4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I
afforded JMT-4 as a beige powder. ESI-MS for C20H15F2NO4S: [M-H]- calculated 402.1,
found 402.2
4-chloro-2-(4'-methyl-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-5). The reaction of
4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I afforded
JMT-5 as a white powder. 1H NMR (600 MHz, D3COCD3): δ = 11.27 (s, 1H), 8.02 (d, J =
8.5 Hz, 1H), 7.96 (d, J = 8.6 Hz, 2H), 7.84 (d, J = 8.5 Hz, 2H), 7.74 (d, J = 2.0 Hz, 1H),
7.58 (d, J = 8.2 Hz, 2H), 7.29 (d, J = 8.0 Hz, 2H), 7.26 (dd, J = 2.0, 8.5 Hz, 1H), 2.35 (s,
3H). ESI-MS for C20H16ClNO4S: [M-H]- calculated 400.0, found 400.2, 402.2
5-chloro-2-(4'-methyl-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-6). The reaction of
4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I afforded
JMT-6 as a white powder. ESI-MS for C20H16ClNO4S: [M-H]- calculated 400.0, found
400.2, 402.2
4-bromo-2-(4'-methyl-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-7). The reaction of
4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I afforded
JMT-7 as a white powder. ESI-MS for C20H16BrNO4S: [M-H]- calculated 444.0, found
444.1, 446.1
5-bromo-2-(4'-methyl-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-8). The reaction of
4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I afforded
JMT-8 as a white powder. ESI-MS for C20H16BrNO4S: [M-H]- calculated 444.0, found
444.2, 446.1
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4-methyl-2-(4'-methyl-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-9). The reaction of
4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I afforded
JMT-9 as a white powder. ESI-MS for C21H19NO4S: [M-H]- calculated 380.1, found 380.2
5-methyl-2-(4'-methyl-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-10). The reaction
of 4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I afforded
JMT-10 as a white powder. ESI-MS for C21H19NO4S: [M-H]- calculated 380.1, found 380.2
6-methyl-2-(4'-methyl-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-11). The reaction
of 4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I afforded
JMT-11 as a white powder. ESI-MS for C21H19NO4S: [M-H]- calculated 380.1, found 380.3
4-(trifluoromethyl)-2-(4'-methyl-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-12). The
reaction of 4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I
afforded JMT-12 as a white powder. 1H NMR (600 MHz, D3COCD3): δ = 11.29 (s, 1H),
8.23 (d, J = 8.2 Hz, 1H), 8.02 (d, J = 0.6 Hz, 1H), 7.95 (d, J = 8.6 Hz, 2H), 7.84 (d, J = 8.7
Hz, 2H), 7.58 (d, J = 8.2 Hz, 2H), 7.46 (dd, J = 1.1, 8.2 Hz, 1H), 7.29 (d, J = 7.8 Hz, 2H),
2.35 (s, 3H). ESI-MS for C21H16F3NO4S: [M-H]- calculated 434.1, found 434.2
5-(trifluoromethyl)-2-(4'-methyl-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-13). The
reaction of 4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I
afforded JMT-13 as a white powder. 1H NMR (600 MHz, D3COCD3): δ = 11.39 (s, 1H),
8.29 (s, 1H), 8.02 (d, J = 8.5 Hz, 1H), 7.91 (m, 2H), 7.84 (d, J = 8.3 Hz, 2H), 7.58 (d, J =
7.9 Hz, 2H), 7.29 (d, J = 8.0 Hz, 2H), 2.35 (s, 3H). ESI-MS for C21H16F3NO4S: [M-H]calculated 434.1, found 434.2
4-methoxy-2-(4'-methyl-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-14). The
reaction of 4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I
afforded JMT-14 as an off-white powder. ESI-MS for C21H19NO5S: [M-H]- calculated 396.1,
found 396.2
5-methoxy-2-(4'-methyl-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-15). The
reaction of 4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I
afforded JMT-15 as an off-white powder. ESI-MS for C21H19NO5S: [M-H]- calculated 396.1,
found 396.3
N-(2-(1H-tetrazol-5-yl)-5-fluorophenyl)-4'-methyl-[1,1'-biphenyl]-4-sulfonamide (JMT-16).
The reaction of 4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General
Procedure II afforded JMT-16 as a white powder. ESI-MS for C20H16FN5O2S: [M-H]calculated 408.1, found 408.3
N-(2-(1H-tetrazol-5-yl)-4-fluorophenyl)-4'-methyl-[1,1'-biphenyl]-4-sulfonamide (JMT-17).
The reaction of 4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General
Procedure II afforded JMT-17 as a white powder. ESI-MS for C20H16FN5O2S: [M-H]calculated 408.1, found 408.2
N-(2-(1H-tetrazol-5-yl)-4-chlorophenyl)-4'-methyl-[1,1'-biphenyl]-4-sulfonamide (JMT-18).
The reaction of 4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General
Procedure II afforded JMT-18 as a white powder. ESI-MS for C20H16ClN5O2S: [M-H]calculated 424.1, found 424.2, 426.3
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N-(2-(1H-tetrazol-5-yl)-4-bromophenyl)-4'-methyl-[1,1'-biphenyl]-4-sulfonamide (JMT-19).
The reaction of 4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General
Procedure II afforded JMT-19 as a white powder. 1H NMR (600 MHz, D3COCD3): δ = 10.70
(s, 1H), 8.15 (d, J = 2.3, 1H), 8.03 (d, J = 8.6 Hz, 1H), 7.79 (m, 1H), 7.73 (dd, J = 2.3, 8.9
Hz, 1H), 7.53 (d, J = 8.2 Hz, 2H), 7.27 (d, J = 7.9 Hz, 2H), 7.03 (d, J = 8.6 Hz, 2H) 2.35
(s, 3H). ESI-MS for C20H16BrN5O2S: [M-H]- calculated 468.0, found 468.2, 470.2
N-(2-(1H-tetrazol-5-yl)-5-methylphenyl)-4'-methyl-[1,1'-biphenyl]-4-sulfonamide
(JMT20). The reaction of 4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General
Procedure II afforded JMT-20 as a white powder. ESI-MS for C21H19N5O2S: [M-H]calculated 404.1, found 404.3
N-(2-(1H-tetrazol-5-yl)-4-methylphenyl)-4'-methyl-[1,1'-biphenyl]-4-sulfonamide
(JMT21). The reaction of 4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General
Procedure II afforded JMT-21 as a white powder. ESI-MS for C21H19N5O2S: [M-H]calculated 404.1, found 404.3
N-(2-(1H-tetrazol-5-yl)-5-(trifluoromethyl)phenyl)-4'-methyl-[1,1'-biphenyl]-4-sulfonamide
(JMT-22). The reaction of 4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to
General Procedure II afforded JMT-22 as a white powder. ESI-MS for C21H16F3N5O2S: [MH]- calculated 458.1, found 458.2
N-(2-(1H-tetrazol-5-yl)-4-(trifluoromethyl)phenyl)-4'-methyl-[1,1'-biphenyl]-4-sulfonamide
(JMT-23). The reaction of 4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to
General Procedure II afforded JMT-23 as a white powder. ESI-MS for C21H16F3N5O2S: [MH]- calculated 458.1, found 458.2
N-(2-(1H-tetrazol-5-yl)-5-methoxyphenyl)-4'-methyl-[1,1'-biphenyl]-4-sulfonamide (JMT24). The reaction of 4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General
Procedure II afforded JMT-24 as a beige powder. ESI-MS for C21H19N5O3S: [M-H]calculated 420.1, found 420.3
N-(2-(1H-tetrazol-5-yl)-4-methoxyphenyl)-4'-methyl-[1,1'-biphenyl]-4-sulfonamide (JMT25). The reaction of 4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General
Procedure II afforded JMT-25 as an off-white powder. ESI-MS for C21H19N5O3S: [M-H]calculated 420.1, found 420.3
((4'-methyl-[1,1'-biphenyl]-4-yl)sulfonyl)proline (JMT-26). The reaction of 4'-methyl-[1,1'biphenyl]-4-sulfonyl chloride according to General Procedure I afforded JMT-26 as a white
powder. ESI-MS for C18H19NO4S: [M-H]- calculated 344.1, found 344.2
3-((4'-methyl-[1,1'-biphenyl]-4-yl)sulfonyl)thiazolidine-4-carboxylic acid (JMT-27). The
reaction of 4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I
afforded JMT-27 as a white powder. ESI-MS for C17H17NO4S2: [M-H]- calculated 362.1,
found 362.2
5,5-dimethyl-3-((4'-methyl-[1,1'-biphenyl]-4-yl)sulfonyl)thiazolidine-4-carboxylic
acid
(JMT-28). The reaction of 4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to
General Procedure I afforded JMT-28 as a white powder. ESI-MS for C19H21NO4S2:
calculated 390.1, found 390.2
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1-((4'-methyl-[1,1'-biphenyl]-4-yl)sulfonyl)piperidine-2-carboxylic acid (JMT-29). The
reaction of 4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I
afforded JMT-29 as a white powder. ESI-MS for C19H21NO4S: [M-H]- calculated 358.1,
found 358.3
3-((4'-methyl-[1,1'-biphenyl]-4-yl)sulfonyl)-1,3-thiazinane-4-carboxylic acid (JMT-30). The
reaction of 4'-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I
afforded JMT-30 as a white powder. ESI-MS for C18H19NO4S2: [M-H]- calculated 376.1,
found 376.2
2-([1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-31). The reaction of [1,1'-biphenyl]-4sulfonyl chloride according to General Procedure I afforded JMT-31 as a white powder.
ESI-MS for C19H15NO4S: [M-H]- calculated 352.1, found 352.2
4-fluoro-2-([1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-32). The reaction of [1,1'biphenyl]-4-sulfonyl chloride according to General Procedure I afforded JMT-32 as a beige
powder. ESI-MS for C19H14FNO4S: [M-H]- calculated 370.1, found 370.2
5-fluoro-2-([1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-33). The reaction of [1,1'biphenyl]-4-sulfonyl chloride according to General Procedure I afforded JMT-33 as an offwhite powder. ESI-MS for C19H14FNO4S: [M-H]- calculated 370.1, found 370.2
5-bromo-2-([1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-34). The reaction of [1,1'biphenyl]-4-sulfonyl chloride according to General Procedure I afforded JMT-34 as a white
powder. ESI-MS for C19H14BrNO4S: [M-H]- calculated 430.0, found 430.0, 432.1
5-methyl-2-([1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-35). The reaction of [1,1'biphenyl]-4-sulfonyl chloride according to General Procedure I afforded JMT-35 as a white
powder. ESI-MS for C20H17NO4S: [M-H]- calculated 366.1, found 366.2
4-fluoro-2-(3'-methyl-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-36). The reaction
of 3’-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I afforded
JMT-36 as an off-white powder. ESI-MS for C20H16FNO4S: [M-H]- calculated 384.1, found
384.2
5-fluoro-2-(3'-methyl-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-37). The reaction
of 3’-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I afforded
JMT-37 as an off-white powder. ESI-MS for C20H16FNO4S: [M-H]- calculated 384.1, found
384.2
5-bromo-2-(3'-methyl-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-38). The reaction
of 3’-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I afforded
JMT-38 as a white powder. ESI-MS for C20H16BrNO4S: [M-H]- calculated 444.0, found
444.1, 446.2
5-methyl-2-(3'-methyl-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-39). The reaction
of 3’-methyl-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I afforded
JMT-39 as a white powder. ESI-MS for C21H19NO4S: [M-H]- calculated 380.1, found 380.3
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4-fluoro-2-(4'-methoxy-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-40). The reaction
of 4’-methoxy-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I
afforded JMT-40 as a beige powder. ESI-MS for C20H16FNO5S: [M-H]- calculated 400.1,
found 400.2
5-fluoro-2-(4'-methoxy-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-41). The reaction
of 4’-methoxy-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I
afforded JMT-41 as an off-white powder. ESI-MS for C20H16FNO5S: [M-H]- calculated
400.1, found 400.3
4,5-difluoro-2-(4'-methoxy-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-42). The
reaction of 4’-methoxy-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure
I afforded JMT-42 as a beige powder. ESI-MS for C20H15F2NO5S: [M-H]- calculated 418.1,
found 418.2
5-bromo-2-(4'-methoxy-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-43). The
reaction of 4’-methoxy-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure
I afforded JMT-43 as a beige powder. ESI-MS for C20H16BrNO5S: [M-H]- calculated 460.0,
found 460.0, 462.1
4-methyl-2-(4'-methoxy-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-44). The
reaction of 4’-methoxy-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure
I afforded JMT-44 as an off-white powder. ESI-MS for C21H19NO5S: [M-H]- calculated
396.1, found 396.3
5-methyl-2-(4'-methoxy-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-45). The
reaction of 4’-methoxy-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure
I afforded JMT-45 as a white powder. ESI-MS for C21H19NO5S: [M-H]- calculated 396.1,
found 396.3
4-(trifluoromethyl)-2-(4'-methoxy-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-46).
The reaction of 4’-methoxy-[1,1'-biphenyl]-4-sulfonyl chloride according to General
Procedure I afforded JMT-46 as a white powder. ESI-MS for C21H16F3NO5S: [M-H]calculated 450.1, found 450.2
5-(trifluoromethyl)-2-(4'-methoxy-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-47).
The reaction of 4’-methoxy-[1,1'-biphenyl]-4-sulfonyl chloride according to General
Procedure I afforded JMT-47 as a white powder. ESI-MS for C21H16F3NO5S: [M-H]calculated 450.1, found 450.1
4-methoxy-2-(4'-methoxy-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-48). The
reaction of 4’-methoxy-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure
I afforded JMT-48 as a beige powder. ESI-MS for C21H19NO6S: [M-H]- calculated 412.1,
found 412.3
5-methoxy-2-(4'-methoxy-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-49). The
reaction of 4’-methoxy-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure
I afforded JMT-49 as an off-white powder. ESI-MS for C21H19NO6S: [M-H]- calculated
412.1, found 412.3
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N-(2-(1H-tetrazol-5-yl)-5-fluorophenyl)-4'-methoxy-[1,1'-biphenyl]-4-sulfonamide (JMT50). The reaction of 4’-methoxy-[1,1'-biphenyl]-4-sulfonyl chloride according to General
Procedure II afforded JMT-50 as a white powder. ESI-MS for C20H16FN5O3S: [M-H]calculated 424.1, found 424.3
N-(2-(1H-tetrazol-5-yl)-4-fluorophenyl)-4'-methoxy-[1,1'-biphenyl]-4-sulfonamide (JMT51). The reaction of 4’-methoxy-[1,1'-biphenyl]-4-sulfonyl chloride according to General
Procedure II afforded JMT-51 as a white powder. ESI-MS for C20H16FN5O3S: [M-H]calculated 424.1, found 424.2
N-(2-(1H-tetrazol-5-yl)-4-bromophenyl)-4'-methoxy-[1,1'-biphenyl]-4-sulfonamide (JMT52). The reaction of 4’-methoxy-[1,1'-biphenyl]-4-sulfonyl chloride according to General
Procedure II afforded JMT-52 as a white powder. ESI-MS for C20H16BrN5O3S: [M-H]calculated 484.0, found 484.2, 486.2
N-(2-(1H-tetrazol-5-yl)-5-methylphenyl)-4'-methoxy-[1,1'-biphenyl]-4-sulfonamide (JMT53). The reaction of 4’-methoxy-[1,1'-biphenyl]-4-sulfonyl chloride according to General
Procedure II afforded JMT-53 as a white powder. ESI-MS for C21H19N5O3S: [M-H]calculated 420.1, found 420.3
N-(2-(1H-tetrazol-5-yl)-4-methylphenyl)-4'-methoxy-[1,1'-biphenyl]-4-sulfonamide (JMT54). The reaction of 4’-methoxy-[1,1'-biphenyl]-4-sulfonyl chloride according to General
Procedure II afforded JMT-54 as a white powder. ESI-MS for C21H19N5O3S: [M-H]calculated 420.1, found 420.3
N-(2-(1H-tetrazol-5-yl)-5-(trifluoromethyl)phenyl)-4'-methoxy-[1,1'-biphenyl]-4sulfonamide (JMT-55). The reaction of 4’-methoxy-[1,1'-biphenyl]-4-sulfonyl chloride
according to General Procedure II afforded JMT-55 as a white powder. ESI-MS for
C21H16F3N5O3S: [M-H]- calculated 474.1, found 474.3
N-(2-(1H-tetrazol-5-yl)-4-(trifluoromethyl)phenyl)-4'-methoxy-[1,1'-biphenyl]-4sulfonamide (JMT-56). The reaction of 4’-methoxy-[1,1'-biphenyl]-4-sulfonyl chloride
according to General Procedure II afforded JMT-56 as a white powder. ESI-MS for
C21H16F3N5O3S: [M-H]- calculated 474.1, found 474.3
N-(2-(1H-tetrazol-5-yl)-5-methoxyphenyl)-4'-methoxy-[1,1'-biphenyl]-4-sulfonamide (JMT57). The reaction of 4’-methoxy-[1,1'-biphenyl]-4-sulfonyl chloride according to General
Procedure II afforded JMT-57 as an off-white powder. ESI-MS for C21H19N5O4S: [M-H]calculated 436.1, found 436.2
N-(2-(1H-tetrazol-5-yl)-4-methoxyphenyl)-4'-methoxy-[1,1'-biphenyl]-4-sulfonamide (JMT58). The reaction of 4’-methoxy-[1,1'-biphenyl]-4-sulfonyl chloride according to General
Procedure II afforded JMT-58 as an off-white powder. ESI-MS for C21H19N5O4S: [M-H]calculated 436.1, found 436.3
4-fluoro-2-(4'-fluoro-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-59). The reaction of
4’-fluoro-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I afforded
JMT-59 as a beige powder. ESI-MS for C19H13F2NO4S: [M-H]- calculated 388.1, found
388.2
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5-fluoro-2-(4'-fluoro-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-60). The reaction of
4’-fluoro-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I afforded
JMT-60 as a beige powder. ESI-MS for C19H13F2NO4S: [M-H]- calculated 388.1, found
388.1
4,5-difluoro-2-(4'-fluoro-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-61). The
reaction of 4’-fluoro-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I
afforded JMT-61 as a beige powder. ESI-MS for C19H12F3NO4S: [M-H]- calculated 406.0,
found 406.2
5-bromo-2-(4'-fluoro-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-62). The reaction of
4’-fluoro-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I afforded
JMT-62 as a white powder. ESI-MS for C19H13FBrNO4S: [M-H]- calculated 448.0, found
448.0, 450.0
4-methyl-2-(4'-fluoro-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-63). The reaction
of 4’-fluoro-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I afforded
JMT-63 as an off-white powder. ESI-MS for C20H16FNO4S: [M-H]- calculated 384.1,
found 384.2
5-methyl-2-(4'-fluoro-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-64). The reaction
of 4’-fluoro-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I afforded
JMT-64 as an off-white powder. ESI-MS for C20H16FNO4S: [M-H]- calculated 384.1, found
384.2
5-methoxy-2-(4'-fluoro-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-65). The reaction
of 4’-fluoro-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I afforded
JMT-65 as an off-white powder. ESI-MS for C20H16FNO5S: [M-H]- calculated 400.1, found
400.2
N-(2-(1H-tetrazol-5-yl)-4-fluorophenyl)-4'-fluoro-[1,1'-biphenyl]-4-sulfonamide (JMT-66).
The reaction of 4’-fluoro-[1,1'-biphenyl]-4-sulfonyl chloride according to General
Procedure II afforded JMT-66 as a white powder. ESI-MS for C19H13F2N5O2S: [M-H]calculated 412.1, found 412.2
N-(2-(1H-tetrazol-5-yl)-4-methylphenyl)-4'-fluoro-[1,1'-biphenyl]-4-sulfonamide (JMT-67).
The reaction of 4’-fluoro-[1,1'-biphenyl]-4-sulfonyl chloride according to General
Procedure II afforded JMT-67 as a white powder. ESI-MS for C20H16FN5O2S: [M-H]calculated 408.1, found 408.3
4-fluoro-2-(4'-chloro-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-68). The reaction of
4’-chloro-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I afforded
JMT-68 as an off-white powder. ESI-MS for C19H13ClFNO4S: [M-H]- calculated 404.0,
found 404.1, 406.1
5-fluoro-2-(4'-chloro-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-69). The reaction of
4’-chloro-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I afforded
JMT-69 as a white powder. ESI-MS for C19H13ClFNO4S: [M-H]- calculated 404.0, found
404.1, 406.1
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4,5-difluoro-2-(4'-chloro-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-70). The
reaction of 4’-chloro-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I
afforded JMT-70 as an off-white powder. ESI-MS for C19H12ClF2NO4S: [M-H]- calculated
422.0, found 422.2, 424.1
5-bromo-2-(4'-chloro-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-71). The reaction
of 4’-chloro-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I afforded
JMT-71 as a white powder. ESI-MS for C19H13BrClNO4S: [M-H]- calculated 463.9, found
464.1, 466.1
4-methyl-2-(4'-chloro-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-72). The reaction
of 4’-chloro-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I afforded
JMT-72 as a white powder. ESI-MS for C20H16ClNO4S: [M-H]- calculated 400.0, found
400.2, 402.1
5-methyl-2-(4'-chloro-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-73). The reaction
of 4’-chloro-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I afforded
JMT-73 as a white powder. ESI-MS for C20H16ClNO4S: [M-H]- calculated 400.1, found
400.1, 402.2
4-(trifluoromethyl)-2-(4'-chloro-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-74). The
reaction of 4’-chloro-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I
afforded JMT-74 as a white powder. ESI-MS for C20H13ClF3NO4S: [M-H]- calculated 454.0,
found 454.1
5-(trifluoromethyl)-2-(4'-chloro-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-75). The
reaction of 4’-chloro-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I
afforded JMT-75 as a white powder. ESI-MS for C20H13ClF3NO4S: [M-H]- calculated 454.0,
found 454.2, 456.0
4-methoxy-2-(4'-chloro-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-76). The
reaction of 4’-chloro-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I
afforded JMT-76 as an off-white powder. ESI-MS for C20H16ClNO5S: [M-H]- calculated
416.0, found 416.2, 418.2
5-methoxy-2-(4'-chloro-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-77). The
reaction of 4’-chloro-[1,1'-biphenyl]-4-sulfonyl chloride according to General Procedure I
afforded JMT-77 as an off-white powder. ESI-MS for C20H16ClNO5S: [M-H]- calculated
416.0, found 416.2, 418.2
N-(2-(1H-tetrazol-5-yl)-5-fluorophenyl)-4'-chloro-[1,1'-biphenyl]-4-sulfonamide (JMT-78).
The reaction of 4’-chloro-[1,1'-biphenyl]-4-sulfonyl chloride according to General
Procedure II afforded JMT-78 as a white powder. ESI-MS for C19H13ClFN5O2S: [M-H]calculated 428.0, found 428.2, 430.3
N-(2-(1H-tetrazol-5-yl)-4-fluorophenyl)-4'-chloro-[1,1'-biphenyl]-4-sulfonamide (JMT-79).
The reaction of 4’-chloro-[1,1'-biphenyl]-4-sulfonyl chloride according to General
Procedure II afforded JMT-79 as a white powder. ESI-MS for C19H13ClFN5O2S: [M-H]calculated 428.0, found 428.2, 430.2
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N-(2-(1H-tetrazol-5-yl)-5-methylphenyl)-4'-chloro-[1,1'-biphenyl]-4-sulfonamide (JMT-80).
The reaction of 4’-chloro-[1,1'-biphenyl]-4-sulfonyl chloride according to General
Procedure II afforded JMT-80 as a white powder. ESI-MS for C20H16ClN5O2S: [M-H]calculated 424.1, found 424.3, 426.2
N-(2-(1H-tetrazol-5-yl)-4-methylphenyl)-4'-chloro-[1,1'-biphenyl]-4-sulfonamide (JMT-81).
The reaction of 4’-chloro-[1,1'-biphenyl]-4-sulfonyl chloride according to General
Procedure II afforded JMT-81 as a white powder. ESI-MS for C20H16ClN5O2S: [M-H]calculated 424.1, found 424.2, 426.2
N-(2-(1H-tetrazol-5-yl)-5-methoxyphenyl)-4'-chloro-[1,1'-biphenyl]-4-sulfonamide (JMT82). The reaction of 4’-chloro-[1,1'-biphenyl]-4-sulfonyl chloride according to General
Procedure II afforded JMT-82 as a beige powder. ESI-MS for C20H16ClN5O3S: [M-H]calculated 440.1, found 440.2, 442.2
N-(2-(1H-tetrazol-5-yl)-4-methoxyphenyl)-4'-chloro-[1,1'-biphenyl]-4-sulfonamide (JMT83). The reaction of 4’-chloro-[1,1'-biphenyl]-4-sulfonyl chloride according to General
Procedure II afforded JMT-83 as an off-white powder. ESI-MS for C20H16ClN5O3S: [M-H]calculated 440.1, found 440.2, 442.2
4-fluoro-2-(4'-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-84). The
reaction of 4’-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonyl chloride according to General
Procedure I afforded JMT-84 as a beige powder. 1H NMR (600 MHz, D3COCD3): δ = 11.60
(s, 1H), 8.11 (dd, J = 6.5, 8.9 Hz, 1H), 8.06 (d, J = 8.5 Hz, 2H), 7.95 (d, J = 8.7 Hz, 2H),
7.93 (d, J = 8.5 Hz, 2H), 7.83 (d, J = 8.2 Hz, 2H), 7.47 (dd, J = 2.5, 11.1 Hz, 1H), 6.93 (dt,
J = 2.5, 8.1 Hz, 1H). ESI-MS for C20H13F4NO4S: [M-H]- calculated 438.0, found 438.2
5-fluoro-2-(4'-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-85). The
reaction of 4’-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonyl chloride according to General
Procedure I afforded JMT-85 as an off-white powder. 1H ESI-MS for C20H13F4NO4S: [MH]- calculated 438.0, found 438.2
4,5-difluoro-2-(4'-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-86).
The reaction of 4’-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonyl chloride according to General
Procedure I afforded JMT-86 as a beige powder. 1H NMR (600 MHz, D3COCD3): δ = 11.14
(s, 1H), 8.02 (d, J = 8.6 Hz, 2H), 7.93 (m, 5H), 7.83 (d, J = 8.3 Hz, 2H), 7.67 (dd, J = 7.1,
12.4 Hz, 1H). ESI-MS for C20H12F5NO4S: [M-H]- calculated 456.0, found 456.2
5-bromo-2-(4'-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-87). The
reaction of 4’-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonyl chloride according to General
Procedure I afforded JMT-87 as a white powder. ESI-MS for C20H13BrF3NO4S: [M-H]calculated 498.0, found 498.1, 500.2
4-methyl-2-(4'-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-88). The
reaction of 4’-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonyl chloride according to General
Procedure I afforded JMT-88 as an off-white powder. ESI-MS for C21H16F3NO4S: [M-H]calculated 434.1, found 434.2
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5-methyl-2-(4'-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-89). The
reaction of 4’-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonyl chloride according to General
Procedure I afforded JMT-89 as an off-white powder. ESI-MS for C21H16F3NO4S: [M-H]calculated 434.1, found 434.2
4-(trifluoromethyl)-2-(4'-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT90). The reaction of 4’-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonyl chloride according to
General Procedure I afforded JMT-90 as a white powder. ESI-MS for C21H13F6NO4S: [MH]- calculated 488.0, found 488.2
5-(trifluoromethyl)-2-(4'-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT91). The reaction of 4’-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonyl chloride according to
General Procedure I afforded JMT-91 as a white powder. ESI-MS for C21H13F6NO4S: [MH]- calculated 488.0, found 488.2
4-methoxy-2-(4'-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-92).
The reaction of 4’-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonyl chloride according to General
Procedure I afforded JMT-92 as an off-white powder. ESI-MS for C21H16F3NO5S: [M-H]calculated 450.1, found 450.2
5-methoxy-2-(4'-trifluoromethyl)-[1,1'-biphenyl]-4-sulfonamido)benzoic acid (JMT-93).
The reaction of 4’-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonyl chloride according to General
Procedure I afforded JMT-93 as a white powder. ESI-MS for C21H16F3NO5S: [M-H]calculated 450.1, found 450.2
N-(2-(1H-tetrazol-5-yl)-5-fluorophenyl)-4'-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonamide
(JMT-94). The reaction of 4’-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonyl chloride according
to General Procedure II afforded JMT-94 as a white powder. ESI-MS for C20H13F4N5O2S:
[M-H]- calculated 462.1, found 462.2
N-(2-(1H-tetrazol-5-yl)-4-fluorophenyl)-4'-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonamide
(JMT-95). The reaction of 4’-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonyl chloride according
to General Procedure II afforded JMT-95 as a white powder. ESI-MS for C20H13F4N5O2S:
[M-H]- calculated 462.1, found 462.2
N-(2-(1H-tetrazol-5-yl)-4-bromophenyl)-4'-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonamide
(JMT-96). The reaction of 4’-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonyl chloride according
to General Procedure II afforded JMT-96 as a white powder. ESI-MS for C20H13BrF3N5O2S:
[M-H]- calculated 522.0, found 522.1, 524.2
N-(2-(1H-tetrazol-5-yl)-5-methylphenyl)-4'-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonamide
(JMT-97). The reaction of 4’-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonyl chloride according
to General Procedure II afforded JMT-97 as an off-white powder. ESI-MS for
C21H16F3N5O2S: [M-H]- calculated 458.1, found 458.2
N-(2-(1H-tetrazol-5-yl)-4-methylphenyl)-4'-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonamide
(JMT-98). The reaction of 4’-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonyl chloride according
to General Procedure II afforded JMT-94 as a white powder. ESI-MS for C21H16F3N5O2S:
[M-H]- calculated 458.1, found 458.2
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N-(2-(1H-tetrazol-5-yl)-5-methoxyphenyl)-4'-(trifluoromethyl)-[1,1'-biphenyl]-4sulfonamide (JMT-99). The reaction of 4’-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonyl
chloride according to General Procedure II afforded JMT-99 as a beige powder. ESI-MS
for C21H16F3N5O3S: [M-H]- calculated 474.1, found 474.3
N-(2-(1H-tetrazol-5-yl)-4-methoxyphenyl)-4'-(trifluoromethyl)-[1,1'-biphenyl]-4sulfonamide (JMT-100). The reaction of 4’-(trifluoromethyl)-[1,1'-biphenyl]-4-sulfonyl
chloride according to General Procedure II afforded JMT-100 as a white powder. ESI-MS
for C21H16F3N5O3S: [M-H]- calculated 474.1, found 474.3
2-((4-cyclohexylphenyl)sulfonamido)-4-fluorobenzoic acid (JMT-101). The reaction of 4cyclohexylbenzenesulfonyl chloride according to General Procedure I afforded JMT-101
as a beige powder. ESI-MS for C19H20FNO4S: [M-H]- calculated 376.1, found 376.2
2-((4-cyclohexylphenyl)sulfonamido)-5-fluorobenzoic acid (JMT-102). The reaction of 4cyclohexylbenzenesulfonyl chloride according to General Procedure I afforded JMT-102
as an off-white powder. ESI-MS for C19H20FNO4S: [M-H]- calculated 376.1, found 376.2
2-((4-cyclohexylphenyl)sulfonamido)-4,5-difluorobenzoic acid (JMT-103). The reaction of
4-cyclohexylbenzenesulfonyl chloride according to General Procedure I afforded JMT103 as a beige powder. ESI-MS for C19H19F2NO4S: [M-H]- calculated 394.1, found 394.2
2-((4-cyclohexylphenyl)sulfonamido)-5-bromobenzoic acid (JMT-104). The reaction of 4cyclohexylbenzenesulfonyl chloride according to General Procedure I afforded JMT-104
as a white powder. ESI-MS for C19H20BrNO4S: [M-H]- calculated 436.0, found 436.1,
438.1
2-((4-cyclohexylphenyl)sulfonamido)-4-methylbenzoic acid (JMT-105). The reaction of 4cyclohexylbenzenesulfonyl chloride according to General Procedure I afforded JMT-105
as a white powder. ESI-MS for C20H23NO4S: [M-H]- calculated 372.1, found 372.3
2-((4-cyclohexylphenyl)sulfonamido)-5-methylbenzoic acid (JMT-106). The reaction of 4cyclohexylbenzenesulfonyl chloride according to General Procedure I afforded JMT-106
as a white powder. ESI-MS for C20H23NO4S: [M-H]- calculated 372.1, found 372.3
2-((4-cyclohexylphenyl)sulfonamido)-4-(trifluoromethyl)benzoic acid (JMT-107). The
reaction of 4-cyclohexylbenzenesulfonyl chloride according to General Procedure I
afforded JMT-107 as a white powder. ESI-MS for C20H20F3NO4S: [M-H]- calculated 426.1,
found 426.2
2-((4-cyclohexylphenyl)sulfonamido)-5-(trifluoromethyl)benzoic acid (JMT-108). The
reaction of 4-cyclohexylbenzenesulfonyl chloride according to General Procedure I
afforded JMT-108 as a white powder. 1H NMR (600 MHz, D3COCD3): δ = 11.27 (s, 1H),
8.28 (s, 1H), 7.87 (m, 4H), 2.60 (tt, J = 2.8, 11.5 Hz, 1H), 1.79 (dt, J = 2.8, 12.2 Hz, 4H),
1.70 (dtt, J = 1.5, 3.0, 12.9 Hz, 1H), 1.40 (ddt, J = 1.7, 12.7, 24.0 Hz, 4H), 1.25 (ddt, J =
3.1, 12.7, 23.9 Hz, 1H). ESI-MS for C20H20F3NO4S: [M-H]- calculated 426.1, found 426.3
2-((4-cyclohexylphenyl)sulfonamido)-4-methoxybenzoic acid (JMT-109). The reaction of
4-cyclohexylbenzenesulfonyl chloride according to General Procedure I afforded JMT-109
as an off-white powder. ESI-MS for C20H23NO5S: [M-H]- calculated 388.1, found 388.3
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2-((4-cyclohexylphenyl)sulfonamido)-5-methoxybenzoic acid (JMT-110). The reaction of
4-cyclohexylbenzenesulfonyl chloride according to General Procedure I afforded JMT-110
as an off-white powder. ESI-MS for C20H23NO5S: [M-H]- calculated 388.1, found 388.3
N-(2-(1H-tetrazol-5-yl)-5-fluorophenyl)-4-cyclohexylbenzenesulfonamide (JMT-111). The
reaction of 4-cyclohexylbenzenesulfonyl chloride according to General Procedure II
afforded JMT-111 as a white powder. ESI-MS for C19H20FN5O2S: [M-H]- calculated 400.1,
found 400.3
N-(2-(1H-tetrazol-5-yl)-4-fluorophenyl)-4-cyclohexylbenzenesulfonamide (JMT-112). The
reaction of 4-cyclohexylbenzenesulfonyl chloride according to General Procedure II
afforded JMT-112 as a white powder. ESI-MS for C19H20FN5O2S: [M-H]- calculated 400.1,
found 400.2
N-(2-(1H-tetrazol-5-yl)-4-bromophenyl)-4-cyclohexylbenzenesulfonamide (JMT-113). The
reaction of 4-cyclohexylbenzenesulfonyl chloride according to General Procedure II
afforded JMT-113 as a white powder. 1H NMR (600 MHz, D3COCD3): δ = 10.63 (s, 1H),
8.14 (d, J = 2.2, 1H), 7.75 (d, J = 8.9, 1H), 7.71 (m, 1H), 7.67 (d, J = 8.4 Hz, 2H), 7.31 (d,
J = 8.3 Hz, 2H), 2.53 (d, J = 8.3 Hz, 2H), 2.53 (tt, J = 2.9, 11.6 Hz, 1H), 1.76 (dt, J = 4.2,
22.3 Hz, 4H), 1.69 (dtt, J = 1.5, 2.9, 12.8 Hz, 4H), 1.36 (ddt, J = 2.0, 12.8, 23.0 Hz, 1H)
1.24 (ddt, J = 3.5, 12.7, 22.9 Hz, 1H). ESI-MS for C19H20BrN5O2S: [M-H]- calculated 460.0,
found 460.2, 462.2
N-(2-(1H-tetrazol-5-yl)-5-methylphenyl)-4-cyclohexylbenzenesulfonamide
(JMT-114).
The reaction of 4-cyclohexylbenzenesulfonyl chloride according to General Procedure II
afforded JMT-114 as a white powder. ESI-MS for C20H23N5O2S: [M-H]- calculated 396.2,
found 396.3
N-(2-(1H-tetrazol-5-yl)-4-methylphenyl)-4-cyclohexylbenzenesulfonamide
(JMT-115).
The reaction of 4-cyclohexylbenzenesulfonyl chloride according to General Procedure II
afforded JMT-115 as a white powder. ESI-MS for C20H23N5O2S: [M-H]- calculated 396.2,
found 396.3
N-(2-(1H-tetrazol-5-yl)-5-(trifluoromethyl)phenyl)-4-cyclohexylbenzenesulfonamide (JMT116). The reaction of 4-cyclohexylbenzenesulfonyl chloride according to General
Procedure II afforded JMT-116 as a white powder. ESI-MS for C20H20F3N5O2S: [M-H]calculated 450.1, found 450.2
N-(2-(1H-tetrazol-5-yl)-5-methoxyphenyl)-4-cyclohexylbenzenesulfonamide (JMT-117).
The reaction of 4-cyclohexylbenzenesulfonyl chloride according to General Procedure II
afforded JMT-117 as an off-white powder. ESI-MS for C20H23N5O3S: [M-H]- calculated
412.1, found 412.3
N-(2-(1H-tetrazol-5-yl)-4-methoxyphenyl)-4-cyclohexylbenzenesulfonamide (JMT-118).
The reaction of 4-cyclohexylbenzenesulfonyl chloride according to General Procedure II
afforded JMT-118 as a white powder. ESI-MS for C20H23N5O3S: [M-H]- calculated 412.1,
found 412.3
4-fluoro-2-(naphthalene-2-sulfonamido)benzoic acid (JMT-119). The reaction of
naphthalene-2-sulfonyl chloride according to General Procedure I afforded JMT-119 as a
beige powder. ESI-MS for C17H12FNO4S: [M-H]- calculated 344.0, found 344.2
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5-fluoro-2-(naphthalene-2-sulfonamido)benzoic acid (JMT-120). The reaction of
naphthalene-2-sulfonyl chloride according to General Procedure I afforded JMT-120 as
an off-white powder. ESI-MS for C17H12FNO4S: [M-H]- calculated 344.0, found 344.1
5-methyl-2-(naphthalene-2-sulfonamido)benzoic acid (JMT-121). The reaction of
naphthalene-2-sulfonyl chloride according to General Procedure I afforded JMT-121 as
an off-white powder. ESI-MS for C18H15NO4S: [M-H]- calculated 340.1, found 340.2
4-fluoro-2-((5,6,7,8-tetrahydronaphthalene)-2-sulfonamido)benzoic acid (JMT-122). The
reaction of 5,6,7,8-tetrahydronaphthalene-2-sulfonyl chloride according to General
Procedure I afforded JMT-122 as a beige powder. ESI-MS for C17H16FNO4S: [M-H]calculated 348.1, found 348.2
5-fluoro-2-((5,6,7,8-tetrahydronaphthalene)-2-sulfonamido)benzoic acid (JMT-123). The
reaction of 5,6,7,8-tetrahydronaphthalene-2-sulfonyl chloride according to General
Procedure I afforded JMT-123 as an off-white powder. ESI-MS for C17H16FNO4S: [M-H]calculated 348.1, found 348.2
5-methyl-2-((5,6,7,8-tetrahydronaphthalene)-2-sulfonamido)benzoic acid (JMT-124). The
reaction of 5,6,7,8-tetrahydronaphthalene-2-sulfonyl chloride according to General
Procedure I afforded JMT-124 as an off-white powder. ESI-MS for C18H19NO4S: [M-H]calculated 344.1, found 344.2
2-((2,3-dihydrobenzo[b][1,4]dioxine)-6-sulfonamido)benzoic acid (JMT-125). The reaction
of 2,3-dihydrobenzo[b][1,4]dioxine)-6-sulfonyl chloride according to General Procedure I
afforded JMT-125 as an off-white powder. ESI-MS for C15H13NO6S: [M-H]- calculated
334.0, found 334.1
2-((2,3-dihydrobenzo[b][1,4]dioxine)-6-sulfonamido)-4-fluorobenzoic acid (JMT-126). The
reaction of 2,3-dihydrobenzo[b][1,4]dioxine)-6-sulfonyl chloride according to General
Procedure I afforded JMT-126 as a beige powder. ESI-MS for C15H12FNO6S: [M-H]calculated 352.0, found 352.1
2-((2,3-dihydrobenzo[b][1,4]dioxine)-6-sulfonamido)-5-fluorobenzoic acid (JMT-127). The
reaction of 2,3-dihydrobenzo[b][1,4]dioxine)-6-sulfonyl chloride according to General
Procedure I afforded JMT-127 as an off-white powder. ESI-MS for C15H12FNO6S: [M-H]calculated 352.0, found 352.1
2-((2,3-dihydrobenzo[b][1,4]dioxine)-6-sulfonamido)-5-methylbenzoic acid (JMT-128).
The reaction of 2,3-dihydrobenzo[b][1,4]dioxine)-6-sulfonyl chloride according to General
Procedure I afforded JMT-128 as an off-white powder. ESI-MS for C16H15NO6S: [M-H]calculated 348.1, found 348.2

312

Appendix E. Pharmacophore screening of FDA-approved therapies for putative PBP
inhibitors

Figure E.1: Pharmacophore search of a virtualized library of FDA-approved drugs. A. A three-point
pharmacophore consisting of one anionic feature (radius = 0.7 Å), one hydrophobic/aromatic
feature (radius = 0.9 Å), and one hydrogen bond accepting feature (radius = 1.0 Å) was used to
search a virtual library of FDA-approved drug structures, yielding 1,862 matching conformations.
B. Enalapril shown in a pharmacophore-matching conformation (rmsd = 0.6 Å).
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Figure E.2: Example structures of ACE inhibitors matching the three-point pharmacophore model.
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Figure E.4: Example structures of additional miscellaneous drugs matching the three-point
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.

Figure E.5: Modeled binding modes of example FDA-approved pharamacophore matches with
tPBP2WT. A. Enalapril (ENP, green). B. Lifitegrast (LFG, green). C. Argatroban (AGB, green). Polar
contacts are indicated by black dashed lines.
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Appendix F: High-throughput virtual screen for inhibitors of Pseudomonas
aeruginosa PBP3

Figure F.1: In silico screen performance characteristics. A. Physicochemical properties of ligands (βlactams) and matched decoys, C. Comparison of ligand and decoy energy scores (***p < 0.001). D,
E. Receiver-operator curves for true ligand detection. F, G. Enrichment curves for true ligands versus
the full rank-ordered dataset (AUC 0.682 and 0.684, respectively).
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Figure F.2: High-throughput virtual screen against P. aeruginosa PBP3. A. Rigid-receptor dock
rank-ordered energy scores. B. Rigid-receptor dock energy score distribution. C. Induced fit
consensus dock rank-ordered energy scores. D. Induced fit consensus dock energy score
distribution. E. Inhibition of P. aeruginosa PBP3 by 1 mM of purchased compounds exhibiting
favorable scores from the high-throughput virtual screen. F. Least energy conformer for
NSC605657, a mid-micromolar, dose-dependent inhibitor of PBP3 identified from the highthroughput virtual screen.
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Figure F.3: NSC605657 (norbadione A) inhibition of P. aeruginosa PBP3. A. NSC605657 is a 2oxatricyclo[6.3.1.0⁴,¹²]dodeca-1(11),4,6,8(12),9-pentaen-3-one comprising two pulvinic acid
moieties. B. NSC605657 exhibits dose-dependent inhibition of PBP3 with half-maximal activity at
78.1 ± 1.4 μM (n = 3 replicates per concentration, r2 = 0.967).

Figure F.4: Screening of 2H-chromene (A) and cinnamic acid (B) compounds against PBP3.
Values were determined in a purified protein assay in which PBP3 was preincubated with
compound, followed by addition of 1 µM Bocillin-FL. Data are presented as a fraction of DMSO
control.
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Figure F.5: 2H-chromene inhibition of P. aeruginosa PBP3. A. NSC119893, NSC122391, and
Z19713177 are 2H-chromenes with carboxylate or phenolate moieties. B. NSC119893,
NSC122391, and Z19713177 exhibit dose-dependent inhibition of PBP3 with half-maximal
inhibitory activities at 41.1 ± 2.5 µM (n = 3 replicates per concentration, r2 = 0.982), 75.0 ± 14.1 μM
(n = 4 replicates per concentration, r2 = 0.924), and 83.5 ± 17.2 μM (n = 3 replicates per
concentration, r2 = 0.910), respectively.

Figure F.6: Proposed mode of PBP3 inhibition by 2H-chromenes. A) Flexible alignment to show
common features of most potent inhibitors from the class (hydrogen bond donors, magenta;
hydrogen bond acceptors, cyan; interchangeable donors/acceptors, rose; anionic atoms, red;
aromatic centers, orange; hydrophobic atoms, green). B) Least energy conformer for 2H-chromene
NSC119893 docked against P. aeruginosa PBP3, polar contacts shown in black.
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Figure F.7: Screening of 3-hydroxy-1,5-dihydro-2H-pyrrol-2-ones against PBP3. Values were
determined in a purified protein assay in which PBP3 was preincubated with compound, followed
by addition of 1 µM Bocillin-FL. Data are presented as a fraction of DMSO control.

Figure F.8: STK577136 and STK704344 inhibition of P. aeruginosa PBP3. A. STK57716 and
STK704344 are 3-hydroxy-1,5-dihydro-2H-pyrrol-2-ones with aromatic substitutions at their 1-, 4-,
and 5-positions. B. STK577136 and STK704344 exhibit dose-dependent inhibition of PBP3 with
half-maximal activities at 25.8 ± 1.9 μM (n = 3 replicates per concentration, r2 = 0.980) and 24.9 ±
2.7 μM (n = 3 replicates per concentration, r2 = 0.983), respectively.
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Figure F.9: Proposed mode of PBP3 inhibition by 3-hydroxy-1,5-dihydro-2H-pyrrol-2-ones. A)
Flexible alignment to show common features of most potent inhibitors from the class (hydrogen
bond donors, magenta; hydrogen bond acceptors, cyan; interchangeable donors/acceptors, rose;
anionic atoms, red; aromatic centers, orange; hydrophobic atoms, green). B) Least energy
conformer for 3-hydroxy-1,5-dihydro-2H-pyrrol-2-one STK704344 docked against P. aeruginosa
PBP3, polar contacts shown in black.
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Figure F.10: Structures of additional PBP3-inhibitory chemotypes. Other non-β-lactam PBP
inhibitors found in the course of this work include quinolines and quinoline analogues Q,
arylsulfonamides S, triazoles and tetrazoles T, 4-thiazolidinones (rhodanines) R, and 2thioxodihydropyrimidine-4,6(1H,5H)-diones (barbituric acids) B.
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Figure A.11: Screening of quinolones, quinazolines, and quinoxalines Q against PBP3. Values
were determined in a purified protein assay in which PBP3 was preincubated with compound,
followed by addition of 1 µM Bocillin-FL. Data are presented as a fraction of DMSO control.

Figure F.12: Proposed mode of PBP3 inhibition by quinoxalines Q. A. Flexible alignment to show
common features of most potent quinolines (hydrogen bond donors, magenta; hydrogen bond
acceptors, cyan; interchangeable donors/acceptors, rose; anionic atoms, red; aromatic centers,
orange; hydrophobic atoms, green). B) Least energy conformer for quinoline STK549604 docked
against P. aeruginosa PBP3, polar contacts shown in black.
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Figure F.13: Screening of sulfonamides S against PBP3. Values were determined in a purified
protein assay in which PBP3 was preincubated with compound, followed by addition of 1 µM
Bocillin-FL. Data are presented as a fraction of DMSO control.

Figure F.14: Proposed mode of PBP3 inhibition by sulfonamides S. A. Flexible alignment to show
common features of most potent arylsulfonamides (hydrogen bond donors, magenta; hydrogen
bond acceptors, cyan; interchangeable donors/acceptors, rose; anionic atoms, red; aromatic
centers, orange; hydrophobic atoms, green). B. Least energy conformer for arylsulfonamide
CB7453894 docked against P. aeruginosa PBP3, polar contacts shown in black.
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Figure F.15: Screening of azoles (A), 4-thiazolidinones (B), and pyrimidine-4,6(1H,5H)-diones (C)
against PBP3. Values were determined in a purified protein assay in which PBP3 was preincubated
with compound, followed by addition of 1 µM Bocillin-FL. Data are presented as a fraction of DMSO
control.
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Figure F.16: Proposed modes of PBP3 inhibition by azoles, 4-thiazolidinones, and pyrimidine4,6(1H,5H)-diones. A-C. Flexible alignment to show common features of most potent azoles (A),
4-thiazolidinones (B), and pyrimidine-4,6(1H,5H)-diones (C) (hydrogen bond donors, magenta;
hydrogen bond acceptors, cyan; interchangeable donors/acceptors, rose; anionic atoms, red;
aromatic centers, orange; hydrophobic atoms, green). D-F. Least energy conformers for
aryltetrazole Z26552032 (D), 4-thiazolidinone CB6126765 (E), and pyrimidine-4,6(1H,5H)-dione
CB5376753 (F) docked against P. aeruginosa PBP3, polar contacts shown in black.
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Table F.1: PBP3 inhibition data for NSC605657 analogues identified through substructure and
similarity searches of the PubChem database. Most potent hits (defined as >50% inhibition at 100
µM) are highlighted in green.

Compound
NSC5897
NSC167376
NSC311454
NSC338986
NSC621468
NSC81924
NSC631509
NSC155504
NSC32899
NSC347512
NSC3483
NSC720435
NSC119893
NSC157
NSC19027
NSC19801
NSC101137
NSC155476
NSC215568
NSC720435
EN300-41020
Z90122589
Z1946684614
Z905065810
Z95232844
Z223849600
Z19713177
EN300-305263
NSC122391
NSC622475
STL099530
STL099536
STK007398
STK034285
STK447520
STK791461
STK837716
STK987640
STL058314
STL061985
STL295948

Inhibition at 1 mM (%)
13.7 ± 6.8
NS
NS
46.9 ± 12.9
57.5 ± 17.5
NS
22.8 ± 20.9
28.1 ± 5.8
79.8 ± 5.3
NS
81.3 ± 15.8
NS
92.3 ± 4.3
98.5 ± 1.9
NS
38.1 ± 29.7
NS
9.1 ± 4.4
11.0 ± 9.9
NS
NS
NS
NS
50.7 ± 18.9
22.6 ± 11.7
51.3 ± 6.8
66.1 ± 12.8
10.0 ± 2.7
74.8 ± 19.5
NS
NS
NS
26.2 ± 10.6
47.3 ± 17.6
13.9 ± 6.5
NS
NS
NS
NS
NS
NS

Inhibition at 100 μM (%)
ND
ND
ND
NS
NS
ND
ND
ND
NS
ND
8.5 ± 3.1
ND
72.9 ± 3.6
NS
ND
ND
ND
ND
ND
ND
ND
ND
ND
8.9 ± 2.5
ND
NS
53.1 ± 28.4
ND
58.9 ± 3.9
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
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Table F.2: PBP3 inhibition data for compounds predicted to have activity from structure-activity
relationships of noncovalent inhibitors against PBP3.

Compound
STK369807
STK888755
STK270718
STK522653
STK549572
STK522651
STK522656
STL048854
STK541644
STK328887
STK887542
STK994187
STK191801
STK718016
STK577136
STL031938
STK460513
CB6140541
CB6126765
CB6130015
STL031936
STK704344
STK818923
Z26552032
STK192475
STK197617
STK197649
STK197654
STK542406
STK549604
STL336609
STK059577
STK572022
STK576161
STK589175
STK596018
STK626827
STK631838
STK818556
STK818561
STK819418
STK098795
STL361235
STK095131
STK052461

Inhibition at 1 mM (%)
95.2 ± 2.4
41.4 ± 10.7
24.8 ± 19.6
82.8 ± 16.4
88.4 ± 4.7
48.8 ± 14.2
85.8 ± 7.8
67.7 ± 23.1
98.1 ± 1.4
NS
NS
51.2 ± 9.8
80.6 ± 11.3
NS
88.3 ± 7.2
55.5± 17.6
NS
NS
80.9 ± 14.1
44.3 ± 8.1
39.0 ± 27.9
97.5 ± 2.2
85.0 ± 7.8
95.9 ± 1.7
97.2 ± 2.8
97.3 ± 1.6
95.1 ± 8.4
96.0 ± 2.6
66.3 ± 20.1
90.7 ± 4.9
75.9 ± 13.9
90.3 ± 4.7
94.3 ± 3.2
96.1 ± 2.7
NS
95.6 ± 4.7
91.8 ± 4.4
98.8 ± 2.4
87.9 ± 7.1
89.6 ± 5.6
48.7 ±5.1
NS
55.7 ± 12.4
28.4 ± 14.4
13.2 ± 4.5

Inhibition at 100 μM (%)
21.5 ± 7.1
ND
ND
31.4 ± 4.2
39.8 ± 4.8
ND
NS
43.4 ± 0.3
44.5 ± 8.9
ND
ND
NS
NS
ND
86.5 ± 0.7
23.2 ± 10.3
ND
ND
95.8 ± 3.8
ND
ND
96.2 ± 2.4
10.3 ± 5.7
54.8 ± 14.6
35.4 ± 9.3
29.1 ± 1.4
15.3 ± 3.0
38.2 ± 1.9
42.2 ± 8.0
66.1 ± 5.9
31.7 ± 3.0
76.8 ± 7.0
NS
NS
ND
NS
NS
NS
NS
NS
ND
ND
9.8 ± 5.5
ND
ND
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STK129507
STK071540
STK634916
STK029374
STK871156
STK871000
STK202948
STK070625
STK084156
STK010482
STK057971
STL040105
STK041773
CB5477031
CB5530695
CB6624338
CB7647715
CB5151615
CB5730506
CB5729373
CB5737652
CB7630081
CB5214931
CB5218577
CB5247550
CB5238280
CB5376753
CB5376658
CB5175181
CB5228302
CB5228304
CB6155033
CB7453894
CB5940861

20.6 ± 15.0
8.6 ± 6.3
NS
NS
NS
NS
30.6 ± 2.7
NS
44.4 ± 23.3
NS
NS
NS
NS
96.2 ± 2.4
91.8 ± 6.1
51.9 ± 7.6
NS
87.8 ± 6.9
96.4 ± 1.7
67.0 ± 10.5
88.2 ± 6.7
85.1 ± 3.6
66.9 ± 7.0
97.9 ± 1.2
39.5 ± 21.8
53.9 ± 28.0
83.7 ± 10.5
83.7 ± 5.9
66.4 ± 11.8
64.7 ± 5.5
64.0 ± 8.8
82.3 ± 8.0
76.1 ± 7.8
80.4 ± 3.2

ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
68.5 ± 7.9
NS
NS
ND
NS
56.7 ± 7.3
NS
50.5 ± 17.4
66.8 ± 11.2
43.2 ± 7.1
61.0 ± 9.1
ND
ND
46.0 ± 5.5
NS
NS
4.3 ± 2.4
NS
36.8 ± 21.4
76.8 ± 4.5
33.1 ± 2.2

329

